[{"id":"a1cf","symbol":"A1CF","href":"/targets/a1cf/","tldr":"A1CF (APOBEC1 complementation factor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"abcb1","symbol":"ABCB1","href":"/targets/abcb1/","tldr":"ABCB1 (ATP-dependent translocase ABCB1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Non-small-cell lung cancer and 1 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"abcc1","symbol":"ABCC1","href":"/targets/abcc1/","tldr":"ABCC1 (ATP-binding cassette sub-family C member 1) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"abcc10","symbol":"ABCC10","href":"/targets/abcc10/","tldr":"ABCC10 (ATP-binding cassette sub-family C member 10) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"abcc3","symbol":"ABCC3","href":"/targets/abcc3/","tldr":"ABCC3 (ATP-binding cassette sub-family C member 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"abcc4","symbol":"ABCC4","href":"/targets/abcc4/","tldr":"ABCC4 (ATP-binding cassette sub-family C member 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Angiosarcoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"abcg2","symbol":"ABCG2","href":"/targets/abcg2/","tldr":"ABCG2 (Broad substrate specificity ATP-binding cassette transporter ABCG2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"abi1","symbol":"ABI1","href":"/targets/abi1/","tldr":"ABI1 (Abl interactor 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"abl2","symbol":"ABL2","href":"/targets/abl2/","tldr":"ABL2 (Tyrosine-protein kinase ABL2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Endometrial cancer, Lung cancer and 2 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"abo","symbol":"ABO","href":"/targets/abo/","tldr":"ABO (Histo-blood group ABO system transferase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ackr3","symbol":"ACKR3","href":"/targets/ackr3/","tldr":"ACKR3 (Atypical chemokine receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Colorectal cancer, Skin cancer and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"acoxl","symbol":"ACOXL","href":"/targets/acoxl/","tldr":"ACOXL (Acyl-coenzyme A oxidase-like protein) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"acsl3","symbol":"ACSL3","href":"/targets/acsl3/","tldr":"ACSL3 (Fatty acid CoA ligase Acsl3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"acsl6","symbol":"ACSL6","href":"/targets/acsl6/","tldr":"ACSL6 (Long-chain-fatty-acid--CoA ligase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas and Liposarcoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"acsm3","symbol":"ACSM3","href":"/targets/acsm3/","tldr":"ACSM3 (Acyl-coenzyme A synthetase ACSM3, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"acta1","symbol":"ACTA1","href":"/targets/acta1/","tldr":"ACTA1 (Actin, alpha skeletal muscle) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"acta2","symbol":"ACTA2","href":"/targets/acta2/","tldr":"ACTA2 (Actin, aortic smooth muscle) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"actb","symbol":"ACTB","href":"/targets/actb/","tldr":"ACTB (Actin, cytoplasmic 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"actg1","symbol":"ACTG1","href":"/targets/actg1/","tldr":"ACTG1 (Actin, cytoplasmic 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"actl6a","symbol":"ACTL6A","href":"/targets/actl6a/","tldr":"ACTL6A (Actin-like protein 6A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"acvr1b","symbol":"ACVR1B","href":"/targets/acvr1b/","tldr":"ACVR1B (Activin receptor type-1B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Breast cancer and 4 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"acvr2a","symbol":"ACVR2A","href":"/targets/acvr2a/","tldr":"ACVR2A (Activin receptor type-2A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"adam29","symbol":"ADAM29","href":"/targets/adam29/","tldr":"ADAM29 (Disintegrin and metalloproteinase domain-containing protein 29) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"adamts9","symbol":"ADAMTS9","href":"/targets/adamts9/","tldr":"ADAMTS9 (A disintegrin and metalloproteinase with thrombospondin motifs 9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"adh1b","symbol":"ADH1B","href":"/targets/adh1b/","tldr":"ADH1B (All-trans-retinol dehydrogenase [NAD(+)] ADH1B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oesophageal cancer.","roles":[],"tier":"association-only"},{"id":"adora2a","symbol":"ADORA2A","href":"/targets/adora2a/","tldr":"The A2A receptor is where adenosine lands on a T cell and tells it to rest. Oral antagonists, cousins of caffeine, are in phase 2 combinations with PD-1 blockade and chemotherapy.","roles":["immune-checkpoint"]},{"id":"adra1a","symbol":"ADRA1A","href":"/targets/adra1a/","tldr":"ADRA1A (Alpha-1A adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra1b","symbol":"ADRA1B","href":"/targets/adra1b/","tldr":"ADRA1B (Alpha-1B adrenergic receptor) is a receptor that reads hormone signals inside the cell nucleus. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra1d","symbol":"ADRA1D","href":"/targets/adra1d/","tldr":"ADRA1D (Alpha-1D adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra2a","symbol":"ADRA2A","href":"/targets/adra2a/","tldr":"ADRA2A (Alpha-2A adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adra2b","symbol":"ADRA2B","href":"/targets/adra2b/","tldr":"ADRA2B (Alpha-2B adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"adra2c","symbol":"ADRA2C","href":"/targets/adra2c/","tldr":"ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"adrm1","symbol":"ADRM1","href":"/targets/adrm1/","tldr":"ADRM1 (Proteasomal ubiquitin receptor ADRM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"aebp1","symbol":"AEBP1","href":"/targets/aebp1/","tldr":"AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"afdn","symbol":"AFDN","href":"/targets/afdn/","tldr":"AFDN (Afadin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"aff1","symbol":"AFF1","href":"/targets/aff1/","tldr":"AFF1 (AF4/FMR2 family member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Melanoma and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"aff3","symbol":"AFF3","href":"/targets/aff3/","tldr":"AFF3 (AF4/FMR2 family member 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Thyroid cancer, Skin cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"aff4","symbol":"AFF4","href":"/targets/aff4/","tldr":"AFF4 (AF4/FMR2 family member 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Skin cancer, Colorectal cancer and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"aggf1","symbol":"AGGF1","href":"/targets/aggf1/","tldr":"AGGF1 (Angiogenic factor with G patch and FHA domains 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"agk","symbol":"AGK","href":"/targets/agk/","tldr":"AGK (Acylglycerol kinase, mitochondrial) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"agr2","symbol":"AGR2","href":"/targets/agr2/","tldr":"AGR2 (Anterior gradient protein 2 homolog) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"agtrap","symbol":"AGTRAP","href":"/targets/agtrap/","tldr":"AGTRAP (Type-1 angiotensin II receptor-associated protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"aimp2","symbol":"AIMP2","href":"/targets/aimp2/","tldr":"AIMP2 (Aminoacyl tRNA synthase complex-interacting multifunctional protein 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ajuba","symbol":"AJUBA","href":"/targets/ajuba/","tldr":"AJUBA (LIM domain-containing protein ajuba) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"akap9","symbol":"AKAP9","href":"/targets/akap9/","tldr":"AKAP9 (A-kinase anchor protein 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"alcam","symbol":"ALCAM","href":"/targets/alcam/","tldr":"ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aldh1a2","symbol":"ALDH1A2","href":"/targets/aldh1a2/","tldr":"ALDH1A2 (Retinal dehydrogenase 2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aldh2","symbol":"ALDH2","href":"/targets/aldh2/","tldr":"ALDH2 (Aldehyde dehydrogenase, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Osteosarcoma.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"alpk1","symbol":"ALPK1","href":"/targets/alpk1/","tldr":"ALPK1 (Alpha-protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"amer1","symbol":"AMER1","href":"/targets/amer1/","tldr":"AMER1 (APC membrane recruitment protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Leukaemia and 3 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"angpt1","symbol":"ANGPT1","href":"/targets/angpt1/","tldr":"ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"ank1","symbol":"ANK1","href":"/targets/ank1/","tldr":"ANK1 (Ankyrin-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Angiosarcoma and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ankrd11","symbol":"ANKRD11","href":"/targets/ankrd11/","tldr":"ANKRD11 (Ankyrin repeat domain-containing protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ano7","symbol":"ANO7","href":"/targets/ano7/","tldr":"ANO7 (Anoctamin-7) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"ap3b1","symbol":"AP3B1","href":"/targets/ap3b1/","tldr":"AP3B1 (AP-3 complex subunit beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"apbb1ip","symbol":"APBB1IP","href":"/targets/apbb1ip/","tldr":"APBB1IP (Amyloid beta A4 precursor protein-binding family B member 1-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"apc","symbol":"APC","href":"/targets/apc/","tldr":"APC (Adenomatous polyposis coli protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Hepatocellular carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"aph1a","symbol":"APH1A","href":"/targets/aph1a/","tldr":"APH1A (Gamma-secretase subunit APH-1A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"aph1b","symbol":"APH1B","href":"/targets/aph1b/","tldr":"APH1B (Gamma-secretase subunit APH-1B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"apobec3b","symbol":"APOBEC3B","href":"/targets/apobec3b/","tldr":"APOBEC3B (DNA dC->dU-editing enzyme APOBEC-3B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"apoe","symbol":"APOE","href":"/targets/apoe/","tldr":"APOE (Apolipoprotein E) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"araf","symbol":"ARAF","href":"/targets/araf/","tldr":"ARAF (Serine/threonine-protein kinase A-Raf) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Langerhans cell histiocytosis and 4 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"areg","symbol":"AREG","href":"/targets/areg/","tldr":"AREG (Amphiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Head and neck squamous cell carcinoma and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"arhgap26","symbol":"ARHGAP26","href":"/targets/arhgap26/","tldr":"ARHGAP26 (Rho GTPase-activating protein 26) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Leukaemia and 2 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"arhgap35","symbol":"ARHGAP35","href":"/targets/arhgap35/","tldr":"ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Bladder & urothelial cancer, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"arhgap5","symbol":"ARHGAP5","href":"/targets/arhgap5/","tldr":"ARHGAP5 (Rho GTPase-activating protein 5) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Multiple myeloma, Pancreatic ductal adenocarcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"arhgef10","symbol":"ARHGEF10","href":"/targets/arhgef10/","tldr":"ARHGEF10 (Rho guanine nucleotide exchange factor 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Cutaneous squamous cell carcinoma, Non-small-cell lung cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"arhgef10l","symbol":"ARHGEF10L","href":"/targets/arhgef10l/","tldr":"ARHGEF10L (Rho guanine nucleotide exchange factor 10-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Basal cell carcinoma and Clear cell renal cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"arhgef12","symbol":"ARHGEF12","href":"/targets/arhgef12/","tldr":"ARHGEF12 (Rho guanine nucleotide exchange factor 12) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"arhgef5","symbol":"ARHGEF5","href":"/targets/arhgef5/","tldr":"ARHGEF5 (Rho guanine nucleotide exchange factor 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"arid1a","symbol":"ARID1A","href":"/targets/arid1a/","tldr":"ARID1A (AT-rich interactive domain-containing protein 1A) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Colorectal cancer, Endometrial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"arid1b","symbol":"ARID1B","href":"/targets/arid1b/","tldr":"ARID1B (AT-rich interactive domain-containing protein 1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"arid2","symbol":"ARID2","href":"/targets/arid2/","tldr":"ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"arid5b","symbol":"ARID5B","href":"/targets/arid5b/","tldr":"ARID5B (AT-rich interactive domain-containing protein 5B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":[],"tier":"association-only"},{"id":"arnt","symbol":"ARNT","href":"/targets/arnt/","tldr":"ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Breast cancer, Small-cell lung cancer and 1 more.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"arrb1","symbol":"ARRB1","href":"/targets/arrb1/","tldr":"ARRB1 (Beta-arrestin-1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"arrb2","symbol":"ARRB2","href":"/targets/arrb2/","tldr":"ARRB2 (Beta-arrestin-2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ascl1","symbol":"ASCL1","href":"/targets/ascl1/","tldr":"ASCL1 (Achaete-scute homolog 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Atypical teratoid/rhabdoid tumour.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"asns","symbol":"ASNS","href":"/targets/asns/","tldr":"ASNS (Asparagine synthetase [glutamine-hydrolysing]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"aspscr1","symbol":"ASPSCR1","href":"/targets/aspscr1/","tldr":"ASPSCR1 (Tether containing UBX domain for GLUT4) is a gene. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas.","roles":["drug-target","fusion-partner"],"tier":"association-only","specificity":"tumour-specific"},{"id":"ass1","symbol":"ASS1","href":"/targets/ass1/","tldr":"ASS1 (Argininosuccinate synthase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Sarcomas.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"asxl1","symbol":"ASXL1","href":"/targets/asxl1/","tldr":"ASXL1 (Polycomb group protein ASXL1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"asxl2","symbol":"ASXL2","href":"/targets/asxl2/","tldr":"ASXL2 (Putative Polycomb group protein ASXL2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer and Acute myeloid leukaemia.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"atf1","symbol":"ATF1","href":"/targets/atf1/","tldr":"ATF1 (Cyclic AMP-dependent transcription factor ATF-1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas, Colorectal cancer and Melanoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"atf7ip","symbol":"ATF7IP","href":"/targets/atf7ip/","tldr":"ATF7IP (Activating transcription factor 7-interacting protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer and Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"atg12","symbol":"ATG12","href":"/targets/atg12/","tldr":"ATG12 (Ubiquitin-like protein ATG12) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"atg7","symbol":"ATG7","href":"/targets/atg7/","tldr":"ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"atic","symbol":"ATIC","href":"/targets/atic/","tldr":"ATIC (Bifunctional purine biosynthesis protein ATIC) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":[],"tier":"association-only"},{"id":"atm","symbol":"ATM","href":"/targets/atm/","tldr":"ATM is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"atp1a1","symbol":"ATP1A1","href":"/targets/atp1a1/","tldr":"ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Colorectal cancer.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"atp2b3","symbol":"ATP2B3","href":"/targets/atp2b3/","tldr":"ATP2B3 (Plasma membrane calcium-transporting ATPase 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Lung cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"atp4a","symbol":"ATP4A","href":"/targets/atp4a/","tldr":"ATP4A (Potassium-transporting ATPase alpha chain 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"atp4b","symbol":"ATP4B","href":"/targets/atp4b/","tldr":"ATP4B (Potassium-transporting ATPase subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"atp7b","symbol":"ATP7B","href":"/targets/atp7b/","tldr":"ATP7B (Copper-transporting ATPase 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"atrx","symbol":"ATRX","href":"/targets/atrx/","tldr":"ATRX (Chromatin remodeler ATRX) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Neuroendocrine tumours, Adrenocortical carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"atxn1l","symbol":"ATXN1L","href":"/targets/atxn1l/","tldr":"ATXN1L (Ataxin-1-like) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"atxn7","symbol":"ATXN7","href":"/targets/atxn7/","tldr":"ATXN7 (Ataxin-7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"aurka","symbol":"AURKA","href":"/targets/aurka/","tldr":"AURKA (Aurora kinase A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Ovarian cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"aurkb","symbol":"AURKB","href":"/targets/aurkb/","tldr":"AURKB (Aurora kinase B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"axin1","symbol":"AXIN1","href":"/targets/axin1/","tldr":"AXIN1 (Axin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Oesophageal cancer, Skin cancer and 5 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"axin2","symbol":"AXIN2","href":"/targets/axin2/","tldr":"AXIN2 (Axin-2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer, Lung cancer and 2 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"b2m","symbol":"B2M","href":"/targets/b2m/","tldr":"B2M (Beta-2-microglobulin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Colorectal cancer, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"b4galt1","symbol":"B4GALT1","href":"/targets/b4galt1/","tldr":"B4GALT1 (Beta-1,4-galactosyltransferase 1) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"bach2","symbol":"BACH2","href":"/targets/bach2/","tldr":"BACH2 (Transcription regulator protein BACH2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer and Basal cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"bag4","symbol":"BAG4","href":"/targets/bag4/","tldr":"BAG4 (BAG family molecular chaperone regulator 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"bak1","symbol":"BAK1","href":"/targets/bak1/","tldr":"BAK1 (Bcl-2 homologous antagonist/killer) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":[],"tier":"association-only"},{"id":"bap1","symbol":"BAP1","href":"/targets/bap1/","tldr":"BAP1 (Ubiquitin carboxyl-terminal hydrolase BAP1) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Mesothelioma, Biliary tract cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"bard1","symbol":"BARD1","href":"/targets/bard1/","tldr":"BARD1 (BRCA1-associated RING domain protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"baz1a","symbol":"BAZ1A","href":"/targets/baz1a/","tldr":"BAZ1A (Bromodomain adjacent to zinc finger domain protein 1A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bcl10","symbol":"BCL10","href":"/targets/bcl10/","tldr":"BCL10 (B-cell lymphoma/leukaemia 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"bcl11a","symbol":"BCL11A","href":"/targets/bcl11a/","tldr":"BCL11A (BCL11 transcription factor A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Breast cancer and 2 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"bcl11b","symbol":"BCL11B","href":"/targets/bcl11b/","tldr":"BCL11B (B-cell lymphoma/leukaemia 11B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer, Non-Hodgkin lymphoma, Skin cancer and 5 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"bcl3","symbol":"BCL3","href":"/targets/bcl3/","tldr":"BCL3 (B-cell lymphoma 3 protein) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"bcl6","symbol":"BCL6","href":"/targets/bcl6/","tldr":"BCL6 (B-cell lymphoma 6 protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Myeloproliferative neoplasms and 3 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"bcl7a","symbol":"BCL7A","href":"/targets/bcl7a/","tldr":"BCL7A (B-cell CLL/lymphoma 7 protein family member A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"bcl9","symbol":"BCL9","href":"/targets/bcl9/","tldr":"BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"bcl9l","symbol":"BCL9L","href":"/targets/bcl9l/","tldr":"BCL9L (B-cell CLL/lymphoma 9-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bclaf1","symbol":"BCLAF1","href":"/targets/bclaf1/","tldr":"BCLAF1 (Bcl-2-associated transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Gastric & gastro-oesophageal junction cancer, Acute myeloid leukaemia and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"bcor","symbol":"BCOR","href":"/targets/bcor/","tldr":"BCOR (BCL-6 corepressor) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"bcorl1","symbol":"BCORL1","href":"/targets/bcorl1/","tldr":"BCORL1 (BCL-6 corepressor-like protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Skin cancer and 4 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bik","symbol":"BIK","href":"/targets/bik/","tldr":"BIK (Bcl-2-interacting killer) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"birc3","symbol":"BIRC3","href":"/targets/birc3/","tldr":"BIRC3 (Baculoviral IAP repeat-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 4 more.","roles":["drug-target","oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"birc5","symbol":"BIRC5","href":"/targets/birc5/","tldr":"BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"birc6","symbol":"BIRC6","href":"/targets/birc6/","tldr":"BIRC6 (Dual E2 ubiquitin-conjugating enzyme/E3 ubiquitin-protein ligase BIRC6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Breast cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"birc7","symbol":"BIRC7","href":"/targets/birc7/","tldr":"BIRC7 (Baculoviral IAP repeat-containing protein 7) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"blk","symbol":"BLK","href":"/targets/blk/","tldr":"BLK (Tyrosine-protein kinase Blk) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"blm","symbol":"BLM","href":"/targets/blm/","tldr":"BLM (RecQ-like DNA helicase BLM) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Colorectal cancer, Breast cancer and 4 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"bmp2","symbol":"BMP2","href":"/targets/bmp2/","tldr":"BMP2 (Bone morphogenetic protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"bmp4","symbol":"BMP4","href":"/targets/bmp4/","tldr":"BMP4 (Bone morphogenetic protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"bmp5","symbol":"BMP5","href":"/targets/bmp5/","tldr":"BMP5 (Bone morphogenetic protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"bmp6","symbol":"BMP6","href":"/targets/bmp6/","tldr":"BMP6 (Bone morphogenetic protein 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"bmp7","symbol":"BMP7","href":"/targets/bmp7/","tldr":"BMP7 (Bone morphogenetic protein 7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"bmpr1a","symbol":"BMPR1A","href":"/targets/bmpr1a/","tldr":"BMPR1A (Bone morphogenetic protein receptor type-1A) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Breast cancer and 1 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"bnc2","symbol":"BNC2","href":"/targets/bnc2/","tldr":"BNC2 (Zinc finger protein basonuclin-2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"brd7","symbol":"BRD7","href":"/targets/brd7/","tldr":"BRD7 (Bromodomain-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"brip1","symbol":"BRIP1","href":"/targets/brip1/","tldr":"BRIP1 (Fanconi anaemia group J protein) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Gastric & gastro-oesophageal junction cancer and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"btc","symbol":"BTC","href":"/targets/btc/","tldr":"BTC (Probetacellulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"btg1","symbol":"BTG1","href":"/targets/btg1/","tldr":"BTG1 (BTG anti-proliferation factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"btg2","symbol":"BTG2","href":"/targets/btg2/","tldr":"BTG2 (BTG anti-proliferation factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"btla","symbol":"BTLA","href":"/targets/btla/","tldr":"BTLA is a brake on T and B cells that is pressed by HVEM, a molecule many tumours carry. An antibody that blocks it is being tested with PD-1 blockade in small-cell lung cancer.","roles":["immune-checkpoint"]},{"id":"bub1b","symbol":"BUB1B","href":"/targets/bub1b/","tldr":"BUB1B (Mitotic checkpoint serine/threonine-protein kinase BUB1 beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Skin cancer, Breast cancer and 3 more.","roles":[],"tier":"association-only"},{"id":"c11orf65","symbol":"C11orf65","href":"/targets/c11orf65/","tldr":"C11orf65 (chromosome 11 open reading frame 65) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Colorectal cancer, Ovarian cancer and 4 more.","roles":[],"tier":"association-only"},{"id":"cacna1d","symbol":"CACNA1D","href":"/targets/cacna1d/","tldr":"CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cacna1g","symbol":"CACNA1G","href":"/targets/cacna1g/","tldr":"CACNA1G (Voltage-dependent T-type calcium channel subunit alpha-1G) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cacna1h","symbol":"CACNA1H","href":"/targets/cacna1h/","tldr":"CACNA1H (Voltage-dependent T-type calcium channel subunit alpha-1H) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cacna1i","symbol":"CACNA1I","href":"/targets/cacna1i/","tldr":"CACNA1I (Voltage-dependent T-type calcium channel subunit alpha-1I) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cadm2","symbol":"CADM2","href":"/targets/cadm2/","tldr":"CADM2 (Cell adhesion molecule 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"calr","symbol":"CALR","href":"/targets/calr/","tldr":"CALR (Calreticulin) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Essential thrombocythaemia and Primary myelofibrosis.","roles":["drug-target","biomarker","fusion-partner"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"camta1","symbol":"CAMTA1","href":"/targets/camta1/","tldr":"CAMTA1 (Calmodulin-binding transcription activator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Prostate cancer, Breast cancer and 3 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cant1","symbol":"CANT1","href":"/targets/cant1/","tldr":"CANT1 (Soluble calcium-activated nucleotidase 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"card11","symbol":"CARD11","href":"/targets/card11/","tldr":"CARD11 (Caspase recruitment domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Hepatocellular carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cars1","symbol":"CARS1","href":"/targets/cars1/","tldr":"CARS1 (Cysteine--tRNA ligase, cytoplasmic) is an enzyme. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Lung cancer and Melanoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"casp10","symbol":"CASP10","href":"/targets/casp10/","tldr":"CASP10 (Caspase-10) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Gastric & gastro-oesophageal junction cancer and Non-Hodgkin lymphoma.","roles":[],"tier":"association-only"},{"id":"casp8","symbol":"CASP8","href":"/targets/casp8/","tldr":"CASP8 (Caspase-8) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Cervical cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"casr","symbol":"CASR","href":"/targets/casr/","tldr":"CASR (Extracellular calcium-sensing receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"casz1","symbol":"CASZ1","href":"/targets/casz1/","tldr":"CASZ1 (Zinc finger protein castor homolog 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cbfa2t3","symbol":"CBFA2T3","href":"/targets/cbfa2t3/","tldr":"CBFA2T3 (Transcriptional corepressor CBFA2T3) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Breast cancer, Lung cancer and 2 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"cbfb","symbol":"CBFB","href":"/targets/cbfb/","tldr":"CBFB (Core-binding factor subunit beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"cbl","symbol":"CBL","href":"/targets/cbl/","tldr":"CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cblb","symbol":"CBLB","href":"/targets/cblb/","tldr":"CBLB (E3 ubiquitin-protein ligase CBL-B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Skin cancer, Breast cancer and 2 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cblc","symbol":"CBLC","href":"/targets/cblc/","tldr":"CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ccar1","symbol":"CCAR1","href":"/targets/ccar1/","tldr":"CCAR1 (Cell division cycle and apoptosis regulator protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ccdc170","symbol":"CCDC170","href":"/targets/ccdc170/","tldr":"CCDC170 (Coiled-coil domain-containing protein 170) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"ccdc6","symbol":"CCDC6","href":"/targets/ccdc6/","tldr":"CCDC6 (Coiled-coil domain-containing protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"ccdc88c","symbol":"CCDC88C","href":"/targets/ccdc88c/","tldr":"CCDC88C (coiled-coil and HOOK domain protein 88C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ccn2","symbol":"CCN2","href":"/targets/ccn2/","tldr":"CCN2 (CCN family member 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ccnb1ip1","symbol":"CCNB1IP1","href":"/targets/ccnb1ip1/","tldr":"CCNB1IP1 (E3 ubiquitin-protein ligase CCNB1IP1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"ccnd1","symbol":"CCND1","href":"/targets/ccnd1/","tldr":"CCND1 (G1/S-specific cyclin-D1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Skin cancer, Multiple myeloma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner","dna-repair"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"ccnd2","symbol":"CCND2","href":"/targets/ccnd2/","tldr":"CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ccnd3","symbol":"CCND3","href":"/targets/ccnd3/","tldr":"CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ccne1","symbol":"CCNE1","href":"/targets/ccne1/","tldr":"CCNE1 (G1/S-specific cyclin-E1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"ccne2","symbol":"CCNE2","href":"/targets/ccne2/","tldr":"CCNE2 (G1/S-specific cyclin-E2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ccnh","symbol":"CCNH","href":"/targets/ccnh/","tldr":"CCNH (Cyclin-H) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ccnt1","symbol":"CCNT1","href":"/targets/ccnt1/","tldr":"CCNT1 (Cyclin-T1) is a protein that switches other genes on and off. In the public catalogues it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":[],"tier":"cohort-driver"},{"id":"ccr7","symbol":"CCR7","href":"/targets/ccr7/","tldr":"CCR7 (C-C chemokine receptor type 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cd200","symbol":"CD200","href":"/targets/cd200/","tldr":"CD200 (OX-2 membrane glycoprotein) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"immune-microenvironment"},{"id":"cd209","symbol":"CD209","href":"/targets/cd209/","tldr":"CD209 (CD209 antigen) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cd24","symbol":"CD24","href":"/targets/cd24/","tldr":"CD24 is a second 'don't eat me' badge after CD47: tumours show it to Siglec-10 on macrophages, which then leave them alone. Blocking antibodies are in first-in-human trials.","roles":["immune-checkpoint"]},{"id":"cd27","symbol":"CD27","href":"/targets/cd27/","tldr":"CD27 is an accelerator on most T cells that is pressed by CD70. Agonist antibodies against it reached phase 2 in lymphoma; its partner CD70 is a separate target for antibodies and CAR-T cells.","roles":["immune-checkpoint"]},{"id":"pdl1","symbol":"CD274","href":"/targets/pdl1/","tldr":"PD-L1 is the tumour's side of the PD-1 brake, and also the biomarker that decides who gets immunotherapy.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"b7h3","symbol":"CD276","href":"/targets/b7h3/","tldr":"B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.","roles":["immune-checkpoint"],"specificity":"tumour-associated"},{"id":"cd28","symbol":"CD28","href":"/targets/cd28/","tldr":"CD28 is the second signal a T cell needs before it attacks. Many CAR-T cells carry a piece of CD28 inside them to fire harder, ipilimumab works by stopping CTLA-4 from hogging CD28's partners, and a new bispecific antibody presses CD28 directly on T cells that are already bound to prostate cancer cells.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"cd3d","symbol":"CD3D","href":"/targets/cd3d/","tldr":"CD3D (T-cell surface glycoprotein CD3 delta chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cd3g","symbol":"CD3G","href":"/targets/cd3g/","tldr":"CD3G (T-cell surface glycoprotein CD3 gamma chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cd40","symbol":"CD40","href":"/targets/cd40/","tldr":"CD40 sits on the cells that teach T cells what to attack. Agonist antibodies press it to turn cold tumours hot; the strongest signals so far are in pancreatic cancer with chemotherapy.","roles":["immune-checkpoint"]},{"id":"cd44","symbol":"CD44","href":"/targets/cd44/","tldr":"CD44 (CD44 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Colorectal cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"cd47","symbol":"CD47","href":"/targets/cd47/","tldr":"CD47 is the 'don't eat me' signal: it binds SIRP-alpha on macrophages to stop them engulfing the cell, and over 90% of AML blasts and large B-cell lymphoma cells display it. Blocking it should let macrophages eat tumour cells, but red cells carry CD47 too, so anaemia is built in, and the lead antibody magrolimab was dropped after failed trials.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"cd58","symbol":"CD58","href":"/targets/cd58/","tldr":"CD58 (Lymphocyte function-associated antigen 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cd74","symbol":"CD74","href":"/targets/cd74/","tldr":"CD74 (HLA class II histocompatibility antigen gamma chain) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Lung cancer and Non-small-cell lung cancer.","roles":["drug-target","fusion-partner"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"cd79a","symbol":"CD79A","href":"/targets/cd79a/","tldr":"CD79A (B-cell antigen receptor complex-associated protein alpha chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Non-Hodgkin lymphoma and Skin cancer.","roles":[],"tier":"association-only"},{"id":"cd80","symbol":"CD80","href":"/targets/cd80/","tldr":"B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.","roles":["immune-checkpoint"]},{"id":"cd83","symbol":"CD83","href":"/targets/cd83/","tldr":"CD83 (CD83 antigen) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cd86","symbol":"CD86","href":"/targets/cd86/","tldr":"CD86 is one of the two B7 molecules on antigen-presenting cells that either wake a T cell up (through CD28) or calm it down (through CTLA-4). Ipilimumab works by stopping CTLA-4 from hogging CD86 and CD80.","roles":["immune-checkpoint"]},{"id":"cd96","symbol":"CD96","href":"/targets/cd96/","tldr":"CD96 sits on T and NK cells and binds CD155, the same molecule TIGIT reads on tumour cells. It is the least tested of that family; one blocking antibody is in phase 2 platform trials in lung cancer.","roles":["immune-checkpoint"]},{"id":"cda","symbol":"CDA","href":"/targets/cda/","tldr":"CDA (Cytidine deaminase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms and Myelodysplastic syndromes / neoplasms.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cdc37","symbol":"CDC37","href":"/targets/cdc37/","tldr":"CDC37 (Hsp90 co-chaperone Cdc37) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cdc50a","symbol":"CDC50A","href":"/targets/cdc50a/","tldr":"CDC50A (Cell cycle control protein 50A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"cdc73","symbol":"CDC73","href":"/targets/cdc73/","tldr":"CDC73 (Parafibromin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Endometrial cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cdca7","symbol":"CDCA7","href":"/targets/cdca7/","tldr":"CDCA7 (Cell division cycle-associated protein 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"cdh1","symbol":"CDH1","href":"/targets/cdh1/","tldr":"CDH1 (Cadherin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cdh10","symbol":"CDH10","href":"/targets/cdh10/","tldr":"CDH10 (Cadherin-10) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Endometrial cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cdh11","symbol":"CDH11","href":"/targets/cdh11/","tldr":"CDH11 (Cadherin-11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"cdk12","symbol":"CDK12","href":"/targets/cdk12/","tldr":"CDK12 (Cyclin-dependent kinase 12) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Ovarian cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cdk2","symbol":"CDK2","href":"/targets/cdk2/","tldr":"CDK2 (Cyclin-dependent kinase 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"cdk5","symbol":"CDK5","href":"/targets/cdk5/","tldr":"CDK5 (Cyclin-dependent kinase 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cdk9","symbol":"CDK9","href":"/targets/cdk9/","tldr":"CDK9 (Cyclin-dependent kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Oesophageal cancer and Neuroblastoma.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"cdkal1","symbol":"CDKAL1","href":"/targets/cdkal1/","tldr":"CDKAL1 (Threonylcarbamoyladenosine tRNA methylthiotransferase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cdkn1a","symbol":"CDKN1A","href":"/targets/cdkn1a/","tldr":"CDKN1A (Cyclin-dependent kinase inhibitor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Colorectal cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cdkn1b","symbol":"CDKN1B","href":"/targets/cdkn1b/","tldr":"CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cdkn2a","symbol":"CDKN2A","href":"/targets/cdkn2a/","tldr":"CDKN2A (Cyclin-dependent kinase inhibitor 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"lineage-antigen"},{"id":"cdkn2b","symbol":"CDKN2B","href":"/targets/cdkn2b/","tldr":"CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"cdkn2c","symbol":"CDKN2C","href":"/targets/cdkn2c/","tldr":"CDKN2C (Cyclin-dependent kinase 4 inhibitor C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Brain and spinal cord tumours and Burkitt lymphoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cdx2","symbol":"CDX2","href":"/targets/cdx2/","tldr":"CDX2 (Homeobox protein CDX-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Skin cancer and 3 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ceacam1","symbol":"CEACAM1","href":"/targets/ceacam1/","tldr":"CEACAM1 (Cell adhesion molecule CEACAM1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Hepatocellular carcinoma.","roles":["biomarker","immune-checkpoint"],"tier":"clinical-evidence"},{"id":"cebpa","symbol":"CEBPA","href":"/targets/cebpa/","tldr":"CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"celf2","symbol":"CELF2","href":"/targets/celf2/","tldr":"CELF2 (CUGBP Elav-like family member 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cep43","symbol":"CEP43","href":"/targets/cep43/","tldr":"CEP43 (Centrosomal protein 43) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":["fusion-partner"],"tier":"association-only"},{"id":"cep89","symbol":"CEP89","href":"/targets/cep89/","tldr":"CEP89 (Centrosomal protein of 89 kDa) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cflar","symbol":"CFLAR","href":"/targets/cflar/","tldr":"CFLAR (CASP8 and FADD-like apoptosis regulator) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"chchd7","symbol":"CHCHD7","href":"/targets/chchd7/","tldr":"CHCHD7 (Coiled-coil-helix-coiled-coil-helix domain-containing protein 7) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"chd2","symbol":"CHD2","href":"/targets/chd2/","tldr":"CHD2 (ATP-dependent chromatin remodeler CHD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"chd4","symbol":"CHD4","href":"/targets/chd4/","tldr":"CHD4 (ATP-dependent chromatin remodeler CHD4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer, Colorectal cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"chd7","symbol":"CHD7","href":"/targets/chd7/","tldr":"CHD7 (ATP-dependent chromatin remodeler CHD7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"chd8","symbol":"CHD8","href":"/targets/chd8/","tldr":"CHD8 (ATP-dependent chromatin remodeler CHD8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"chek1","symbol":"CHEK1","href":"/targets/chek1/","tldr":"CHEK1 (Serine/threonine-protein kinase Chk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"chek2","symbol":"CHEK2","href":"/targets/chek2/","tldr":"CHEK2 (Serine/threonine-protein kinase Chk2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Sarcomas and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"chmp4c","symbol":"CHMP4C","href":"/targets/chmp4c/","tldr":"CHMP4C (Charged multivesicular body protein 4c) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"chrdl1","symbol":"CHRDL1","href":"/targets/chrdl1/","tldr":"CHRDL1 (Chordin-like protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"chrna3","symbol":"CHRNA3","href":"/targets/chrna3/","tldr":"CHRNA3 (Neuronal acetylcholine receptor subunit alpha-3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"chrna4","symbol":"CHRNA4","href":"/targets/chrna4/","tldr":"CHRNA4 (Neuronal acetylcholine receptor subunit alpha-4) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"chrna5","symbol":"CHRNA5","href":"/targets/chrna5/","tldr":"CHRNA5 (Neuronal acetylcholine receptor subunit alpha-5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":[],"tier":"association-only"},{"id":"cic","symbol":"CIC","href":"/targets/cic/","tldr":"CIC (Protein capicua homolog) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ciita","symbol":"CIITA","href":"/targets/ciita/","tldr":"CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cip2a","symbol":"CIP2A","href":"/targets/cip2a/","tldr":"CIP2A (cellular inhibitor of PP2A) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"clcn6","symbol":"CLCN6","href":"/targets/clcn6/","tldr":"CLCN6 (H(+)/Cl(-) exchange transporter 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"clip1","symbol":"CLIP1","href":"/targets/clip1/","tldr":"CLIP1 (CAP-Gly domain-containing linker protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Cervical cancer, Oesophageal cancer and 2 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"clptm1l","symbol":"CLPTM1L","href":"/targets/clptm1l/","tldr":"CLPTM1L (Lipid scramblase CLPTM1L) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cltc","symbol":"CLTC","href":"/targets/cltc/","tldr":"CLTC (Clathrin heavy chain 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cltcl1","symbol":"CLTCL1","href":"/targets/cltcl1/","tldr":"CLTCL1 (Clathrin heavy chain 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Skin cancer and 2 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cmtr2","symbol":"CMTR2","href":"/targets/cmtr2/","tldr":"CMTR2 (Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cnbp","symbol":"CNBP","href":"/targets/cnbp/","tldr":"CNBP (CCHC-type zinc finger nucleic acid binding protein) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cnksr1","symbol":"CNKSR1","href":"/targets/cnksr1/","tldr":"CNKSR1 (Connector enhancer of kinase suppressor of ras 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cnksr2","symbol":"CNKSR2","href":"/targets/cnksr2/","tldr":"CNKSR2 (Connector enhancer of kinase suppressor of ras 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cnot3","symbol":"CNOT3","href":"/targets/cnot3/","tldr":"CNOT3 (CCR4-NOT transcription complex subunit 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Leukaemia, Non-Hodgkin lymphoma and 4 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cnot9","symbol":"CNOT9","href":"/targets/cnot9/","tldr":"CNOT9 (CCR4-NOT transcription complex subunit 9) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cntrl","symbol":"CNTRL","href":"/targets/cntrl/","tldr":"CNTRL (Centriolin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Nasopharyngeal carcinoma, Cutaneous squamous cell carcinoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"col1a1","symbol":"COL1A1","href":"/targets/col1a1/","tldr":"COL1A1 (Collagen alpha-1(I) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Anal cancer, Pancreatic ductal adenocarcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"col2a1","symbol":"COL2A1","href":"/targets/col2a1/","tldr":"COL2A1 (Collagen alpha-1(II) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer and Papillary thyroid cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"col6a3","symbol":"COL6A3","href":"/targets/col6a3/","tldr":"COL6A3 (Collagen alpha-3(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Melanoma.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"col6a6","symbol":"COL6A6","href":"/targets/col6a6/","tldr":"COL6A6 (Collagen alpha-6(VI) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"cpeb3","symbol":"CPEB3","href":"/targets/cpeb3/","tldr":"CPEB3 (Cytoplasmic polyadenylation element-binding protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Basal cell carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cpsf6","symbol":"CPSF6","href":"/targets/cpsf6/","tldr":"CPSF6 (Cleavage and polyadenylation specificity factor subunit 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"cpvl","symbol":"CPVL","href":"/targets/cpvl/","tldr":"CPVL (Probable serine carboxypeptidase CPVL) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"creb1","symbol":"CREB1","href":"/targets/creb1/","tldr":"CREB1 (Cyclic AMP-responsive element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Sarcomas, Skin cancer and 1 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"creb3l1","symbol":"CREB3L1","href":"/targets/creb3l1/","tldr":"CREB3L1 (Cyclic AMP-responsive element-binding protein 3-like protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas, Lung cancer and Breast cancer.","roles":[],"tier":"association-only"},{"id":"creb3l2","symbol":"CREB3L2","href":"/targets/creb3l2/","tldr":"CREB3L2 (Cyclic AMP-responsive element-binding protein 3-like protein 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas, Breast cancer and Lung cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"crebbp","symbol":"CREBBP","href":"/targets/crebbp/","tldr":"CREBBP (CREB-binding protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Bladder & urothelial cancer, Leukaemia and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"crkl","symbol":"CRKL","href":"/targets/crkl/","tldr":"CRKL (Crk-like protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"crlf2","symbol":"CRLF2","href":"/targets/crlf2/","tldr":"CRLF2 (Cytokine receptor-like factor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Acute lymphoblastic leukaemia and 2 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"crtc1","symbol":"CRTC1","href":"/targets/crtc1/","tldr":"CRTC1 (CREB-regulated transcription coactivator 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers, Lung cancer, Skin cancer and 5 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"crtc3","symbol":"CRTC3","href":"/targets/crtc3/","tldr":"CRTC3 (CREB-regulated transcription coactivator 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.","roles":[],"tier":"association-only"},{"id":"csf1","symbol":"CSF1","href":"/targets/csf1/","tldr":"CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"csf2rb","symbol":"CSF2RB","href":"/targets/csf2rb/","tldr":"CSF2RB (Cytokine receptor common subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Leukaemia, Myeloproliferative neoplasms and 1 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"csk","symbol":"CSK","href":"/targets/csk/","tldr":"CSK (Tyrosine-protein kinase CSK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"csmd3","symbol":"CSMD3","href":"/targets/csmd3/","tldr":"CSMD3 (CUB and sushi domain-containing protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"csnk1a1","symbol":"CSNK1A1","href":"/targets/csnk1a1/","tldr":"CSNK1A1 (Casein kinase I isoform alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"csnk1e","symbol":"CSNK1E","href":"/targets/csnk1e/","tldr":"CSNK1E (Casein kinase I isoform epsilon) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Follicular lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"cspg4","symbol":"CSPG4","href":"/targets/cspg4/","tldr":"CSPG4 (Chondroitin sulfate proteoglycan 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ctag1b","symbol":"CTAG1B","href":"/targets/ctag1b/","tldr":"CTAG1B (Cancer/testis antigen 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"ctag2","symbol":"CTAG2","href":"/targets/ctag2/","tldr":"CTAG2 (Cancer/testis antigen 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ctcf","symbol":"CTCF","href":"/targets/ctcf/","tldr":"CTCF (Transcriptional repressor CTCF) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ctla4","symbol":"CTLA4","href":"/targets/ctla4/","tldr":"The first immune brake ever targeted for cancer; releasing it won a Nobel Prize and cures a fraction of melanomas.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"ctnna1","symbol":"CTNNA1","href":"/targets/ctnna1/","tldr":"CTNNA1 (Catenin alpha-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer and Cervical cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ctnna2","symbol":"CTNNA2","href":"/targets/ctnna2/","tldr":"CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ctnnb1","symbol":"CTNNB1","href":"/targets/ctnnb1/","tldr":"CTNNB1 (Catenin beta-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Colorectal cancer, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"ctnnd2","symbol":"CTNND2","href":"/targets/ctnnd2/","tldr":"CTNND2 (Catenin delta-2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ctr9","symbol":"CTR9","href":"/targets/ctr9/","tldr":"CTR9 (RNA polymerase-associated protein CTR9 homolog) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Wilms tumour.","roles":[],"tier":"association-only"},{"id":"ctsh","symbol":"CTSH","href":"/targets/ctsh/","tldr":"CTSH (Pro-cathepsin H) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ctss","symbol":"CTSS","href":"/targets/ctss/","tldr":"CTSS (Cathepsin S) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"cul1","symbol":"CUL1","href":"/targets/cul1/","tldr":"CUL1 (Cullin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"cul3","symbol":"CUL3","href":"/targets/cul3/","tldr":"CUL3 (Cullin-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Non-small-cell lung cancer and Papillary renal cell carcinoma.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"cul4a","symbol":"CUL4A","href":"/targets/cul4a/","tldr":"CUL4A (Cullin-4A) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"cul7","symbol":"CUL7","href":"/targets/cul7/","tldr":"CUL7 (Cullin-7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"cux1","symbol":"CUX1","href":"/targets/cux1/","tldr":"CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cx3cl1","symbol":"CX3CL1","href":"/targets/cx3cl1/","tldr":"CX3CL1 (Fractalkine) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"cxcl10","symbol":"CXCL10","href":"/targets/cxcl10/","tldr":"CXCL10 (C-X-C motif chemokine 10) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Osteosarcoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cyld","symbol":"CYLD","href":"/targets/cyld/","tldr":"CYLD (Ubiquitin carboxyl-terminal hydrolase CYLD) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"cyp11b1","symbol":"CYP11B1","href":"/targets/cyp11b1/","tldr":"CYP11B1 (Cytochrome P450 11B1, mitochondrial) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"cyp1b1","symbol":"CYP1B1","href":"/targets/cyp1b1/","tldr":"CYP1B1 (Cytochrome P450 1B1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"cyp2c8","symbol":"CYP2C8","href":"/targets/cyp2c8/","tldr":"CYP2C8 (Cytochrome P450 2C8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Melanoma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cyp2d6","symbol":"CYP2D6","href":"/targets/cyp2d6/","tldr":"CYP2D6 (Cytochrome P450 2D6) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"cysltr2","symbol":"CYSLTR2","href":"/targets/cysltr2/","tldr":"CYSLTR2 (Cysteinyl leukotriene receptor 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Uveal melanoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"daxx","symbol":"DAXX","href":"/targets/daxx/","tldr":"DAXX (Death domain-associated protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Adrenocortical carcinoma, Pancreatic ductal adenocarcinoma and 2 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dazap1","symbol":"DAZAP1","href":"/targets/dazap1/","tldr":"DAZAP1 (DAZ-associated protein 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"dcaf12l2","symbol":"DCAF12L2","href":"/targets/dcaf12l2/","tldr":"DCAF12L2 (DDB1- and CUL4-associated factor 12-like protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Glioma & glioblastoma and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"dcc","symbol":"DCC","href":"/targets/dcc/","tldr":"DCC (Netrin receptor DCC) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Oesophageal cancer, Hepatocellular carcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"dclk1","symbol":"DCLK1","href":"/targets/dclk1/","tldr":"DCLK1 is a kinase gene from neuronal development that also marks a rare stem-like cell population in the gut, studied as a colorectal and pancreatic cancer stem-cell marker.","roles":["biomarker"],"tier":"association-only"},{"id":"dclre1b","symbol":"DCLRE1B","href":"/targets/dclre1b/","tldr":"DCLRE1B (5' exonuclease Apollo) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"dctn1","symbol":"DCTN1","href":"/targets/dctn1/","tldr":"DCTN1 (Dynactin subunit 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ddb1","symbol":"DDB1","href":"/targets/ddb1/","tldr":"DDB1 (DNA damage-binding protein 1) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"ddb2","symbol":"DDB2","href":"/targets/ddb2/","tldr":"DDB2 (DNA damage-binding protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Skin cancer and Acute myeloid leukaemia.","roles":["oncogene-driver","tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"ddit3","symbol":"DDIT3","href":"/targets/ddit3/","tldr":"DDIT3 (DDIT3 upstream open reading frame protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas and Liposarcoma.","roles":[],"tier":"association-only"},{"id":"ddx10","symbol":"DDX10","href":"/targets/ddx10/","tldr":"DDX10 (Probable ATP-dependent RNA helicase DDX10) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer and Skin cancer.","roles":[],"tier":"association-only"},{"id":"ddx3x","symbol":"DDX3X","href":"/targets/ddx3x/","tldr":"DDX3X (ATP-dependent RNA helicase DDX3X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ddx41","symbol":"DDX41","href":"/targets/ddx41/","tldr":"DDX41 (Probable ATP-dependent RNA helicase DDX41) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 1 more.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ddx43","symbol":"DDX43","href":"/targets/ddx43/","tldr":"DDX43 (Probable ATP-dependent RNA helicase DDX43) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Uveal melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ddx5","symbol":"DDX5","href":"/targets/ddx5/","tldr":"DDX5 (Probable ATP-dependent RNA helicase DDX5) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Skin cancer.","roles":[],"tier":"association-only"},{"id":"ddx6","symbol":"DDX6","href":"/targets/ddx6/","tldr":"DDX6 (Probable ATP-dependent RNA helicase DDX6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Lung cancer, Leiomyosarcoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"defa1","symbol":"DEFA1","href":"/targets/defa1/","tldr":"DEFA1 (Neutrophil defensin 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"dek","symbol":"DEK","href":"/targets/dek/","tldr":"DEK (DEK proto-oncogene) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Gastric & gastro-oesophageal junction cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"dgcr8","symbol":"DGCR8","href":"/targets/dgcr8/","tldr":"DGCR8 (Microprocessor complex subunit DGCR8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Thyroid cancer, Diffuse large B-cell lymphoma and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"dhx9","symbol":"DHX9","href":"/targets/dhx9/","tldr":"DHX9 (ATP-dependent RNA helicase A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"dicer1","symbol":"DICER1","href":"/targets/dicer1/","tldr":"DICER1 (Endoribonuclease Dicer) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Sarcomas, Brain and spinal cord tumours and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"dis3","symbol":"DIS3","href":"/targets/dis3/","tldr":"DIS3 (Exosome complex exonuclease RRP44) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"dkk1","symbol":"DKK1","href":"/targets/dkk1/","tldr":"DKK1 (Dickkopf-related protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"dlc1","symbol":"DLC1","href":"/targets/dlc1/","tldr":"DLC1 (Rho GTPase-activating protein 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dll1","symbol":"DLL1","href":"/targets/dll1/","tldr":"DLL1 (Delta-like protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dll4","symbol":"DLL4","href":"/targets/dll4/","tldr":"DLL4 (Delta-like protein 4) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","antigen"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"dlst","symbol":"DLST","href":"/targets/dlst/","tldr":"DLST (Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.","roles":[],"tier":"association-only"},{"id":"dna2","symbol":"DNA2","href":"/targets/dna2/","tldr":"DNA2 (DNA replication ATP-dependent helicase/nuclease DNA2) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"dnah11","symbol":"DNAH11","href":"/targets/dnah11/","tldr":"DNAH11 (Dynein axonemal heavy chain 11) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dnajb1","symbol":"DNAJB1","href":"/targets/dnajb1/","tldr":"DNAJB1 (DnaJ homolog subfamily B member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dnajc1","symbol":"DNAJC1","href":"/targets/dnajc1/","tldr":"DNAJC1 (DnaJ homolog subfamily C member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dnajc12","symbol":"DNAJC12","href":"/targets/dnajc12/","tldr":"DNAJC12 is a co-chaperone gene that is strongly expressed in oestrogen receptor-positive (luminal) breast cancers and is used as a luminal marker.","roles":["biomarker"],"tier":"association-only"},{"id":"dnm2","symbol":"DNM2","href":"/targets/dnm2/","tldr":"DNM2 (Dynamin-2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma, Colorectal cancer and 3 more.","roles":[],"tier":"association-only"},{"id":"dnmt3b","symbol":"DNMT3B","href":"/targets/dnmt3b/","tldr":"DNMT3B (DNA (cytosine-5)-methyltransferase 3B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dock8","symbol":"DOCK8","href":"/targets/dock8/","tldr":"DOCK8 (Dedicator of cytokinesis protein 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"dot1l","symbol":"DOT1L","href":"/targets/dot1l/","tldr":"DOT1L (Histone-lysine N-methyltransferase, H3 lysine-79 specific) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma and Neuroblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dpyd","symbol":"DPYD","href":"/targets/dpyd/","tldr":"DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"drd5","symbol":"DRD5","href":"/targets/drd5/","tldr":"DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"drosha","symbol":"DROSHA","href":"/targets/drosha/","tldr":"DROSHA (Ribonuclease 3) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Brain and spinal cord tumours, Pancreatic ductal adenocarcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"dsp","symbol":"DSP","href":"/targets/dsp/","tldr":"DSP (Desmoplakin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dtx1","symbol":"DTX1","href":"/targets/dtx1/","tldr":"DTX1 (E3 ubiquitin-protein ligase DTX1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma and Chronic lymphocytic leukaemia.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"dusp16","symbol":"DUSP16","href":"/targets/dusp16/","tldr":"DUSP16 (Dual specificity protein phosphatase 16) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"dusp2","symbol":"DUSP2","href":"/targets/dusp2/","tldr":"DUSP2 (Dual specificity protein phosphatase 2) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"dusp6","symbol":"DUSP6","href":"/targets/dusp6/","tldr":"DUSP6 (Dual specificity protein phosphatase 6) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"e2f7","symbol":"E2F7","href":"/targets/e2f7/","tldr":"E2F7 is an unusual member of the E2F family that represses genes rather than activating them, helping cells pause after DNA damage.","roles":["biomarker"],"tier":"association-only"},{"id":"ebf1","symbol":"EBF1","href":"/targets/ebf1/","tldr":"EBF1 (Transcription factor COE1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Neuroendocrine tumours and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ebf2","symbol":"EBF2","href":"/targets/ebf2/","tldr":"EBF2 (Transcription factor COE2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ecscr","symbol":"ECSCR","href":"/targets/ecscr/","tldr":"ECSCR (Endothelial cell-specific chemotaxis regulator) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ednra","symbol":"EDNRA","href":"/targets/ednra/","tldr":"EDNRA (Endothelin-1 receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"eed","symbol":"EED","href":"/targets/eed/","tldr":"EED (Polycomb protein EED) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and the evidence so far is association rather than a proven role.","roles":["drug-target"],"tier":"association-only","specificity":"broadly-expressed"},{"id":"eftud2","symbol":"EFTUD2","href":"/targets/eftud2/","tldr":"EFTUD2 (116 kDa U5 small nuclear ribonucleoprotein component) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"egf","symbol":"EGF","href":"/targets/egf/","tldr":"EGF (Pro-epidermal growth factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"egr2","symbol":"EGR2","href":"/targets/egr2/","tldr":"EGR2 (E3 SUMO-protein ligase EGR2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ehbp1","symbol":"EHBP1","href":"/targets/ehbp1/","tldr":"EHBP1 (EH domain-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"eif1ax","symbol":"EIF1AX","href":"/targets/eif1ax/","tldr":"EIF1AX (Eukaryotic translation initiation factor 1A, X-chromosomal) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Lung cancer, Prostate cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"eif2ak3","symbol":"EIF2AK3","href":"/targets/eif2ak3/","tldr":"EIF2AK3 (Eukaryotic translation initiation factor 2-alpha kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"eif3e","symbol":"EIF3E","href":"/targets/eif3e/","tldr":"EIF3E (Eukaryotic translation initiation factor 3 subunit E) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer and Lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"eif4a1","symbol":"EIF4A1","href":"/targets/eif4a1/","tldr":"EIF4A1 (Eukaryotic initiation factor 4A-I) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"eif4a2","symbol":"EIF4A2","href":"/targets/eif4a2/","tldr":"EIF4A2 (Eukaryotic initiation factor 4A-II) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"eif4ebp1","symbol":"EIF4EBP1","href":"/targets/eif4ebp1/","tldr":"EIF4EBP1 (Eukaryotic translation initiation factor 4E-binding protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"elac2","symbol":"ELAC2","href":"/targets/elac2/","tldr":"ELAC2 (Zinc phosphodiesterase ELAC protein 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"elf3","symbol":"ELF3","href":"/targets/elf3/","tldr":"ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"elf4","symbol":"ELF4","href":"/targets/elf4/","tldr":"ELF4 (ETS-related transcription factor Elf-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Acute myeloid leukaemia.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"elk4","symbol":"ELK4","href":"/targets/elk4/","tldr":"ELK4 (ETS domain-containing protein Elk-4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma and Skin cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ell","symbol":"ELL","href":"/targets/ell/","tldr":"ELL (RNA polymerase II elongation factor ELL) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Breast cancer, Skin cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"eln","symbol":"ELN","href":"/targets/eln/","tldr":"ELN (Elastin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Cutaneous squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"elp1","symbol":"ELP1","href":"/targets/elp1/","tldr":"ELP1 (Elongator complex protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Medulloblastoma.","roles":[],"tier":"association-only"},{"id":"elp4","symbol":"ELP4","href":"/targets/elp4/","tldr":"ELP4 (Elongator complex protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"eml4","symbol":"EML4","href":"/targets/eml4/","tldr":"EML4 (Echinoderm microtubule-associated protein-like 4) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer and Non-small-cell lung cancer.","roles":["drug-target","fusion-partner"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"emsy","symbol":"EMSY","href":"/targets/emsy/","tldr":"EMSY (BRCA2-interacting transcriptional repressor EMSY) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"entpd1","symbol":"ENTPD1","href":"/targets/entpd1/","tldr":"CD39 is the first of two enzymes that turn the ATP spilt by dying tumour cells into adenosine, which sedates T cells. Blocking it keeps the ATP alarm ringing; one antibody has completed phase 2 in pancreatic cancer.","roles":["immune-checkpoint"]},{"id":"eomes","symbol":"EOMES","href":"/targets/eomes/","tldr":"EOMES (Eomesodermin homolog) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"ep300","symbol":"EP300","href":"/targets/ep300/","tldr":"EP300 (Histone acetyltransferase p300) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Bladder & urothelial cancer, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"epha1","symbol":"EPHA1","href":"/targets/epha1/","tldr":"EPHA1 (Ephrin type-A receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha10","symbol":"EPHA10","href":"/targets/epha10/","tldr":"EPHA10 (Ephrin type-A receptor 10) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha3","symbol":"EPHA3","href":"/targets/epha3/","tldr":"EPHA3 (Ephrin type-A receptor 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours, Thyroid cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"epha4","symbol":"EPHA4","href":"/targets/epha4/","tldr":"EPHA4 (Ephrin type-A receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha5","symbol":"EPHA5","href":"/targets/epha5/","tldr":"EPHA5 (Ephrin type-A receptor 5) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha6","symbol":"EPHA6","href":"/targets/epha6/","tldr":"EPHA6 (Ephrin type-A receptor 6) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"epha7","symbol":"EPHA7","href":"/targets/epha7/","tldr":"EPHA7 (Ephrin type-A receptor 7) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer, Neuroendocrine tumours, Colorectal cancer and 2 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"epha8","symbol":"EPHA8","href":"/targets/epha8/","tldr":"EPHA8 (Ephrin type-A receptor 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours and Thyroid cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ephb1","symbol":"EPHB1","href":"/targets/ephb1/","tldr":"EPHB1 (Ephrin type-B receptor 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ephb2","symbol":"EPHB2","href":"/targets/ephb2/","tldr":"EPHB2 (Ephrin type-B receptor 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"ephb3","symbol":"EPHB3","href":"/targets/ephb3/","tldr":"EPHB3 (Ephrin type-B receptor 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ephb4","symbol":"EPHB4","href":"/targets/ephb4/","tldr":"EPHB4 (Ephrin type-B receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Thyroid cancer and Neuroendocrine tumours.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"eps15","symbol":"EPS15","href":"/targets/eps15/","tldr":"EPS15 (Epidermal growth factor receptor substrate 15) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Non-Hodgkin lymphoma and 2 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"erbin","symbol":"ERBIN","href":"/targets/erbin/","tldr":"ERBIN (Erbin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"erc1","symbol":"ERC1","href":"/targets/erc1/","tldr":"ERC1 (ELKS/Rab6-interacting/CAST family member 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"ercc1","symbol":"ERCC1","href":"/targets/ercc1/","tldr":"ERCC1 (DNA excision repair protein ERCC-1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Mesothelioma, Ovarian cancer and 1 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ercc2","symbol":"ERCC2","href":"/targets/ercc2/","tldr":"ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Skin cancer, Colorectal cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ercc3","symbol":"ERCC3","href":"/targets/ercc3/","tldr":"ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Skin cancer, Ovarian cancer and 3 more.","roles":["drug-target","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"ercc4","symbol":"ERCC4","href":"/targets/ercc4/","tldr":"ERCC4 (DNA repair endonuclease XPF) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Myeloproliferative neoplasms and 4 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"ercc5","symbol":"ERCC5","href":"/targets/ercc5/","tldr":"ERCC5 (DNA excision repair protein ERCC-5) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Skin cancer, Neuroendocrine tumours and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"ercc6","symbol":"ERCC6","href":"/targets/ercc6/","tldr":"ERCC6 (Chimeric ERCC6-PGBD3 protein) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Lung cancer.","roles":["drug-target","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ereg","symbol":"EREG","href":"/targets/ereg/","tldr":"EREG (Proepiregulin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"erg","symbol":"ERG","href":"/targets/erg/","tldr":"ERG (Transcriptional regulator ERG) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Prostate cancer, Non-Hodgkin lymphoma and 4 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"erlin2","symbol":"ERLIN2","href":"/targets/erlin2/","tldr":"ERLIN2 (Erlin-2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"errfi1","symbol":"ERRFI1","href":"/targets/errfi1/","tldr":"ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"esr2","symbol":"ESR2","href":"/targets/esr2/","tldr":"ESR2 (Oestrogen receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer and Prostate cancer.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"esrp1","symbol":"ESRP1","href":"/targets/esrp1/","tldr":"ESRP1 (Epithelial splicing regulatory protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"esrra","symbol":"ESRRA","href":"/targets/esrra/","tldr":"ESRRA (Steroid hormone receptor ERR1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers and Adenoid cystic carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"etnk1","symbol":"ETNK1","href":"/targets/etnk1/","tldr":"ETNK1 (Ethanolamine kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Breast cancer and Myeloproliferative neoplasms.","roles":[],"tier":"association-only"},{"id":"ets1","symbol":"ETS1","href":"/targets/ets1/","tldr":"ETS1 (ETS proto-oncogene 1, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"ets2","symbol":"ETS2","href":"/targets/ets2/","tldr":"ETS2 (ETS proto-oncogene 2, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"etv1","symbol":"ETV1","href":"/targets/etv1/","tldr":"ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"etv4","symbol":"ETV4","href":"/targets/etv4/","tldr":"ETV4 (ETS translocation variant 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Lung cancer, Pancreatic ductal adenocarcinoma and 1 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"etv5","symbol":"ETV5","href":"/targets/etv5/","tldr":"ETV5 (ETS translocation variant 5) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Neuroendocrine tumours and 4 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"etv6","symbol":"ETV6","href":"/targets/etv6/","tldr":"ETV6 (Transcription factor ETV6) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"exo1","symbol":"EXO1","href":"/targets/exo1/","tldr":"EXO1 (Exonuclease 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"ext1","symbol":"EXT1","href":"/targets/ext1/","tldr":"EXT1 (Exostosin-1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas, Breast cancer, Ovarian cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"ext2","symbol":"EXT2","href":"/targets/ext2/","tldr":"EXT2 (Exostosin-2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Ovarian cancer, Skin cancer and Breast cancer.","roles":[],"tier":"association-only"},{"id":"ezr","symbol":"EZR","href":"/targets/ezr/","tldr":"EZR (Ezrin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":[],"tier":"association-only"},{"id":"faap20","symbol":"FAAP20","href":"/targets/faap20/","tldr":"FAAP20 (Fanconi anaemia core complex-associated protein 20) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fam114a2","symbol":"FAM114A2","href":"/targets/fam114a2/","tldr":"FAM114A2 (family with sequence similarity 114 member A2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fam131b","symbol":"FAM131B","href":"/targets/fam131b/","tldr":"FAM131B (family with sequence similarity 131 member B) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fam135b","symbol":"FAM135B","href":"/targets/fam135b/","tldr":"FAM135B (family with sequence similarity 135 member B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Endometrial cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fam174b","symbol":"FAM174B","href":"/targets/fam174b/","tldr":"FAM174B (Membrane protein FAM174B) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Medulloblastoma and Paediatric low-grade glioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"fanca","symbol":"FANCA","href":"/targets/fanca/","tldr":"FANCA (Fanconi anaemia group A protein) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Skin cancer, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fancb","symbol":"FANCB","href":"/targets/fancb/","tldr":"FANCB (Fanconi anaemia group B protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancc","symbol":"FANCC","href":"/targets/fancc/","tldr":"FANCC (Fanconi anaemia group C protein) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Leukaemia, Pancreatic ductal adenocarcinoma and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"fancd2","symbol":"FANCD2","href":"/targets/fancd2/","tldr":"FANCD2 (Fanconi anaemia group D2 protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms, Breast cancer and 5 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"fance","symbol":"FANCE","href":"/targets/fance/","tldr":"FANCE (Fanconi anaemia group E protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Colorectal cancer, Myeloproliferative neoplasms and 2 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancf","symbol":"FANCF","href":"/targets/fancf/","tldr":"FANCF (Fanconi anaemia group F protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Skin cancer and Melanoma.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancg","symbol":"FANCG","href":"/targets/fancg/","tldr":"FANCG (Fanconi anaemia group G protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms, Colorectal cancer and 2 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"fanci","symbol":"FANCI","href":"/targets/fanci/","tldr":"FANCI (Fanconi anaemia group I protein) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"fancl","symbol":"FANCL","href":"/targets/fancl/","tldr":"FANCL (E3 ubiquitin-protein ligase FANCL) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"fancm","symbol":"FANCM","href":"/targets/fancm/","tldr":"FANCM (Fanconi anaemia group M protein) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Ovarian cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"fas","symbol":"FAS","href":"/targets/fas/","tldr":"FAS (Tumour necrosis factor receptor superfamily member 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Cervical cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fat1","symbol":"FAT1","href":"/targets/fat1/","tldr":"FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fat2","symbol":"FAT2","href":"/targets/fat2/","tldr":"FAT2 (Protocadherin Fat 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Vulvar cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"fat3","symbol":"FAT3","href":"/targets/fat3/","tldr":"FAT3 (Protocadherin Fat 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Pancreatic ductal adenocarcinoma, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fat4","symbol":"FAT4","href":"/targets/fat4/","tldr":"FAT4 (Protocadherin Fat 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fbln2","symbol":"FBLN2","href":"/targets/fbln2/","tldr":"FBLN2 (Fibulin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Bladder & urothelial cancer, Hepatocellular carcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"fbn2","symbol":"FBN2","href":"/targets/fbn2/","tldr":"FBN2 (Fibrillin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"fbxo11","symbol":"FBXO11","href":"/targets/fbxo11/","tldr":"FBXO11 (F-box only protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fbxw11","symbol":"FBXW11","href":"/targets/fbxw11/","tldr":"FBXW11 (F-box/WD repeat-containing protein 11) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fbxw7","symbol":"FBXW7","href":"/targets/fbxw7/","tldr":"FBXW7 (F-box/WD repeat-containing protein 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Non-Hodgkin lymphoma, Endometrial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fcgr2a","symbol":"FCGR2A","href":"/targets/fcgr2a/","tldr":"FCGR2A (Low affinity immunoglobulin gamma Fc region receptor II-a) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fcgr2b","symbol":"FCGR2B","href":"/targets/fcgr2b/","tldr":"FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Non-Hodgkin lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fcgr3a","symbol":"FCGR3A","href":"/targets/fcgr3a/","tldr":"FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fcrl4","symbol":"FCRL4","href":"/targets/fcrl4/","tldr":"FCRL4 (Fc receptor-like protein 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Skin cancer, Lung cancer and 2 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"fdps","symbol":"FDPS","href":"/targets/fdps/","tldr":"FDPS (Farnesyl pyrophosphate synthase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Multiple myeloma and Breast cancer.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"fermt2","symbol":"FERMT2","href":"/targets/fermt2/","tldr":"FERMT2 (Fermitin family homolog 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fes","symbol":"FES","href":"/targets/fes/","tldr":"FES (Tyrosine-protein kinase Fes/Fps) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Leukaemia and Colorectal cancer.","roles":[],"tier":"association-only","specificity":"lineage-antigen"},{"id":"fev","symbol":"FEV","href":"/targets/fev/","tldr":"FEV (FEV transcription factor, ETS family member) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"fga","symbol":"FGA","href":"/targets/fga/","tldr":"FGA (Fibrinogen alpha chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgb","symbol":"FGB","href":"/targets/fgb/","tldr":"FGB (Fibrinogen beta chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgd1","symbol":"FGD1","href":"/targets/fgd1/","tldr":"FGD1 (FYVE, RhoGEF and PH domain-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"fgd5","symbol":"FGD5","href":"/targets/fgd5/","tldr":"FGD5 (FYVE, RhoGEF and PH domain-containing protein 5) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"fgf1","symbol":"FGF1","href":"/targets/fgf1/","tldr":"FGF1 (Fibroblast growth factor 1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgf10","symbol":"FGF10","href":"/targets/fgf10/","tldr":"FGF10 (Fibroblast growth factor 10) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf13","symbol":"FGF13","href":"/targets/fgf13/","tldr":"FGF13 (Fibroblast growth factor 13) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"fgf16","symbol":"FGF16","href":"/targets/fgf16/","tldr":"FGF16 (Fibroblast growth factor 16) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf17","symbol":"FGF17","href":"/targets/fgf17/","tldr":"FGF17 (Fibroblast growth factor 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf18","symbol":"FGF18","href":"/targets/fgf18/","tldr":"FGF18 (Fibroblast growth factor 18) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf19","symbol":"FGF19","href":"/targets/fgf19/","tldr":"FGF19 (Fibroblast growth factor 19) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma and Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf2","symbol":"FGF2","href":"/targets/fgf2/","tldr":"FGF2 (Fibroblast growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fgf20","symbol":"FGF20","href":"/targets/fgf20/","tldr":"FGF20 (Fibroblast growth factor 20) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf22","symbol":"FGF22","href":"/targets/fgf22/","tldr":"FGF22 (Fibroblast growth factor 22) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf23","symbol":"FGF23","href":"/targets/fgf23/","tldr":"FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.","roles":["drug-target","antigen"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"fgf3","symbol":"FGF3","href":"/targets/fgf3/","tldr":"FGF3 (Fibroblast growth factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf4","symbol":"FGF4","href":"/targets/fgf4/","tldr":"FGF4 (Fibroblast growth factor 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fgf5","symbol":"FGF5","href":"/targets/fgf5/","tldr":"FGF5 (Fibroblast growth factor 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf6","symbol":"FGF6","href":"/targets/fgf6/","tldr":"FGF6 (Fibroblast growth factor 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf7","symbol":"FGF7","href":"/targets/fgf7/","tldr":"FGF7 (Fibroblast growth factor 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"fgf8","symbol":"FGF8","href":"/targets/fgf8/","tldr":"FGF8 (Fibroblast growth factor 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgf9","symbol":"FGF9","href":"/targets/fgf9/","tldr":"FGF9 (Fibroblast growth factor 9) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fgfr1op2","symbol":"FGFR1OP2","href":"/targets/fgfr1op2/","tldr":"FGFR1OP2 (FGFR1 oncogene partner 2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":["fusion-partner"],"tier":"association-only"},{"id":"fgfr4","symbol":"FGFR4","href":"/targets/fgfr4/","tldr":"FGFR4 (Fibroblast growth factor receptor 4) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Sarcomas, Biliary tract cancer, Colorectal cancer and 5 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"fgg","symbol":"FGG","href":"/targets/fgg/","tldr":"FGG (Fibrinogen gamma chain) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"fgl1","symbol":"FGL1","href":"/targets/fgl1/","tldr":"FGL1 is a liver protein that some tumours secrete; it binds LAG-3 on T cells and switches them off, separately from the MHC class II route. It explains part of how LAG-3 blockade works.","roles":["immune-checkpoint"]},{"id":"fgr","symbol":"FGR","href":"/targets/fgr/","tldr":"FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"fh","symbol":"FH","href":"/targets/fh/","tldr":"FH (Fumarate hydratase, mitochondrial) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Skin cancer, Papillary renal cell carcinoma and 1 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"fhit","symbol":"FHIT","href":"/targets/fhit/","tldr":"FHIT (Bis(5'-adenosyl)-triphosphatase) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Skin cancer and 1 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fip1l1","symbol":"FIP1L1","href":"/targets/fip1l1/","tldr":"FIP1L1 (Pre-mRNA 3'-end-processing factor FIP1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"flcn","symbol":"FLCN","href":"/targets/flcn/","tldr":"FLCN (Folliculin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 3 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"flg","symbol":"FLG","href":"/targets/flg/","tldr":"FLG (Filaggrin) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Mesothelioma, Acute myeloid leukaemia and 2 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"flt3lg","symbol":"FLT3LG","href":"/targets/flt3lg/","tldr":"FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fmn1","symbol":"FMN1","href":"/targets/fmn1/","tldr":"FMN1 (Formin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fmn2","symbol":"FMN2","href":"/targets/fmn2/","tldr":"FMN2 (Formin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"fn1","symbol":"FN1","href":"/targets/fn1/","tldr":"FN1 (Fibronectin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"fndc3b","symbol":"FNDC3B","href":"/targets/fndc3b/","tldr":"FNDC3B (Fibronectin type III domain-containing protein 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"fntb","symbol":"FNTB","href":"/targets/fntb/","tldr":"FNTB (Protein farnesyltransferase subunit beta) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fos","symbol":"FOS","href":"/targets/fos/","tldr":"FOS (Fos proto-oncogene, AP-1 transcription factor subunit) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fosb","symbol":"FOSB","href":"/targets/fosb/","tldr":"FOSB (FosB proto-oncogene, AP-1 transcription factor subunit) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"foxa1","symbol":"FOXA1","href":"/targets/foxa1/","tldr":"FOXA1 (Hepatocyte nuclear factor 3-alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Breast cancer, Neuroendocrine tumours and 1 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"foxa2","symbol":"FOXA2","href":"/targets/foxa2/","tldr":"FOXA2 (Hepatocyte nuclear factor 3-beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"foxc2","symbol":"FOXC2","href":"/targets/foxc2/","tldr":"FOXC2 (Forkhead box protein C2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"foxe1","symbol":"FOXE1","href":"/targets/foxe1/","tldr":"FOXE1 (Forkhead box protein E1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"foxf1","symbol":"FOXF1","href":"/targets/foxf1/","tldr":"FOXF1 (Forkhead box protein F1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"foxl2","symbol":"FOXL2","href":"/targets/foxl2/","tldr":"FOXL2 (Forkhead box protein L2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"foxo1","symbol":"FOXO1","href":"/targets/foxo1/","tldr":"FOXO1 (Forkhead box protein O1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Non-Hodgkin lymphoma, Ovarian cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"foxo3","symbol":"FOXO3","href":"/targets/foxo3/","tldr":"FOXO3 (Forkhead box protein O3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Acute myeloid leukaemia and 1 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"foxo4","symbol":"FOXO4","href":"/targets/foxo4/","tldr":"FOXO4 (Forkhead box protein O4) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"foxp1","symbol":"FOXP1","href":"/targets/foxp1/","tldr":"FOXP1 (Forkhead box protein P1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 5 more.","roles":["tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"foxp3","symbol":"FOXP3","href":"/targets/foxp3/","tldr":"FOXP3 (Forkhead box protein P3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"foxp4","symbol":"FOXP4","href":"/targets/foxp4/","tldr":"FOXP4 (Forkhead box protein P4) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"foxr2","symbol":"FOXR2","href":"/targets/foxr2/","tldr":"FOXR2 (Forkhead box protein R2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"frs2","symbol":"FRS2","href":"/targets/frs2/","tldr":"FRS2 (Fibroblast growth factor receptor substrate 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"frs3","symbol":"FRS3","href":"/targets/frs3/","tldr":"FRS3 (Fibroblast growth factor receptor substrate 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fto","symbol":"FTO","href":"/targets/fto/","tldr":"FTO (Alpha-ketoglutarate-dependent dioxygenase FTO) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"fubp1","symbol":"FUBP1","href":"/targets/fubp1/","tldr":"FUBP1 (Far upstream element-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"fus","symbol":"FUS","href":"/targets/fus/","tldr":"FUS (RNA-binding protein FUS) is a gene. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Hepatocellular carcinoma and Liposarcoma.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"fxr1","symbol":"FXR1","href":"/targets/fxr1/","tldr":"FXR1 (RNA-binding protein FXR1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"fyn","symbol":"FYN","href":"/targets/fyn/","tldr":"FYN (Tyrosine-protein kinase Fyn) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Myeloproliferative neoplasms and 2 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"gab1","symbol":"GAB1","href":"/targets/gab1/","tldr":"GAB1 (GRB2-associated-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"gab2","symbol":"GAB2","href":"/targets/gab2/","tldr":"GAB2 (GRB2-associated-binding protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.","roles":[],"tier":"association-only"},{"id":"gabrg3","symbol":"GABRG3","href":"/targets/gabrg3/","tldr":"GABRG3 (Gamma-aminobutyric acid receptor subunit gamma-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"gadd45a","symbol":"GADD45A","href":"/targets/gadd45a/","tldr":"GADD45A (Growth arrest and DNA damage-inducible protein GADD45 alpha) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"galnt14","symbol":"GALNT14","href":"/targets/galnt14/","tldr":"GALNT14 (Polypeptide N-acetylgalactosaminyltransferase 14) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"gas6","symbol":"GAS6","href":"/targets/gas6/","tldr":"GAS6 (Growth arrest-specific protein 6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"gata1","symbol":"GATA1","href":"/targets/gata1/","tldr":"GATA1 (Erythroid transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 1 more.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"gata2","symbol":"GATA2","href":"/targets/gata2/","tldr":"GATA2 (Endothelial transcription factor GATA-2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Myelodysplastic syndromes / neoplasms and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gata3","symbol":"GATA3","href":"/targets/gata3/","tldr":"GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gdf7","symbol":"GDF7","href":"/targets/gdf7/","tldr":"GDF7 (Growth/differentiation factor 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ghsr","symbol":"GHSR","href":"/targets/ghsr/","tldr":"GHSR (Growth hormone secretagogue receptor type 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"gli1","symbol":"GLI1","href":"/targets/gli1/","tldr":"GLI1 (Transcription activator GLI1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas and Leiomyosarcoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"gmps","symbol":"GMPS","href":"/targets/gmps/","tldr":"GMPS (GMP synthase [glutamine-hydrolysing]) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"gna11","symbol":"GNA11","href":"/targets/gna11/","tldr":"GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gna13","symbol":"GNA13","href":"/targets/gna13/","tldr":"GNA13 (Guanine nucleotide-binding protein subunit alpha-13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gnai2","symbol":"GNAI2","href":"/targets/gnai2/","tldr":"GNAI2 (Guanine nucleotide-binding protein G(i) subunit alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gnaq","symbol":"GNAQ","href":"/targets/gnaq/","tldr":"GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Breast cancer and 3 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gnas","symbol":"GNAS","href":"/targets/gnas/","tldr":"GNAS (Neuroendocrine secretory protein 55) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gnb1","symbol":"GNB1","href":"/targets/gnb1/","tldr":"GNB1 (Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":[],"tier":"association-only"},{"id":"golga4","symbol":"GOLGA4","href":"/targets/golga4/","tldr":"GOLGA4 (Golgin subfamily A member 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"golga5","symbol":"GOLGA5","href":"/targets/golga5/","tldr":"GOLGA5 (Golgin subfamily A member 5) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"golgb1","symbol":"GOLGB1","href":"/targets/golgb1/","tldr":"GOLGB1 (Golgin subfamily B member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"gopc","symbol":"GOPC","href":"/targets/gopc/","tldr":"GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"gpaa1","symbol":"GPAA1","href":"/targets/gpaa1/","tldr":"GPAA1 (GPI-anchor transamidase component GPAA1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"gpc5","symbol":"GPC5","href":"/targets/gpc5/","tldr":"GPC5 (Glypican-5) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer and Biliary tract cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"gpr161","symbol":"GPR161","href":"/targets/gpr161/","tldr":"GPR161 (G protein-coupled receptor 161) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Medulloblastoma.","roles":[],"tier":"association-only"},{"id":"grb2","symbol":"GRB2","href":"/targets/grb2/","tldr":"GRB2 (Growth factor receptor-bound protein 2) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Chronic myeloid leukaemia.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"grb7","symbol":"GRB7","href":"/targets/grb7/","tldr":"GRB7 is an adaptor protein gene that sits next to HER2 on chromosome 17 and is copied along with it in HER2-positive cancers.","roles":["biomarker"],"tier":"association-only"},{"id":"grem1","symbol":"GREM1","href":"/targets/grem1/","tldr":"GREM1 (Gremlin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"grhl2","symbol":"GRHL2","href":"/targets/grhl2/","tldr":"GRHL2 (Grainyhead-like protein 2 homolog) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"grhpr","symbol":"GRHPR","href":"/targets/grhpr/","tldr":"GRHPR (Glyoxylate reductase/hydroxypyruvate reductase) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"grin2a","symbol":"GRIN2A","href":"/targets/grin2a/","tldr":"GRIN2A (Glutamate receptor ionotropic, NMDA 2A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Lung cancer, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"grm3","symbol":"GRM3","href":"/targets/grm3/","tldr":"GRM3 (Metabotropic glutamate receptor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Chromophobe renal cell carcinoma and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"gsk3b","symbol":"GSK3B","href":"/targets/gsk3b/","tldr":"GSK3B (Glycogen synthase kinase-3 beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"gstp1","symbol":"GSTP1","href":"/targets/gstp1/","tldr":"GSTP1 (Glutathione S-transferase P) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"gtf2i","symbol":"GTF2I","href":"/targets/gtf2i/","tldr":"GTF2I (General transcription factor II-I) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thymoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"h1-2","symbol":"H1-2","href":"/targets/h1-2/","tldr":"H1-2 (Histone H1.2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"h1-3","symbol":"H1-3","href":"/targets/h1-3/","tldr":"H1-3 (Histone H1.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h1-5","symbol":"H1-5","href":"/targets/h1-5/","tldr":"H1-5 (Histone H1.5) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h2ac17","symbol":"H2AC17","href":"/targets/h2ac17/","tldr":"H2AC17 (Histone H2A type 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"h2ac6","symbol":"H2AC6","href":"/targets/h2ac6/","tldr":"H2AC6 (Histone H2A type 1-C) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"h2bc12","symbol":"H2BC12","href":"/targets/h2bc12/","tldr":"H2BC12 (Histone H2B type 1-K) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"h2bc5","symbol":"H2BC5","href":"/targets/h2bc5/","tldr":"H2BC5 (Histone H2B type 1-D) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"h3-3a","symbol":"H3-3A","href":"/targets/h3-3a/","tldr":"H3.3 is one of the histone proteins DNA wraps around; a single change at position 27 (K27M) locks brain-stem and midline gliomas in an immature state and defines the diagnosis.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"h3-3b","symbol":"H3-3B","href":"/targets/h3-3b/","tldr":"H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h3c14","symbol":"H3C14","href":"/targets/h3c14/","tldr":"H3C14 (Histone H3.2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse midline glioma, H3 K27-altered.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"h3c2","symbol":"H3C2","href":"/targets/h3c2/","tldr":"H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"h3c4","symbol":"H3C4","href":"/targets/h3c4/","tldr":"H3C4 (Histone H3.1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"h4c9","symbol":"H4C9","href":"/targets/h4c9/","tldr":"H4C9 (Histone H4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"habp2","symbol":"HABP2","href":"/targets/habp2/","tldr":"HABP2 (Factor VII-activating protease) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"tim3","symbol":"HAVCR2","href":"/targets/tim3/","tldr":"An immune checkpoint on exhausted T cells and on leukaemic stem cells; antibodies against it failed in lung cancer and MDS after strong preclinical promise.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"hbb","symbol":"HBB","href":"/targets/hbb/","tldr":"HBB (Haemoglobin subunit beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"hbegf","symbol":"HBEGF","href":"/targets/hbegf/","tldr":"HBEGF (Proheparin-binding EGF-like growth factor) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"hcar3","symbol":"HCAR3","href":"/targets/hcar3/","tldr":"HCAR3 (Hydroxycarboxylic acid receptor 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hdac10","symbol":"HDAC10","href":"/targets/hdac10/","tldr":"HDAC10 (Polyamine deacetylase HDAC10) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"hdac11","symbol":"HDAC11","href":"/targets/hdac11/","tldr":"HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"hdac4","symbol":"HDAC4","href":"/targets/hdac4/","tldr":"HDAC4 (Histone deacetylase 4) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Non-Hodgkin lymphoma, Multiple myeloma and 1 more.","roles":["drug-target","oncogene-driver"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"hdac5","symbol":"HDAC5","href":"/targets/hdac5/","tldr":"HDAC5 (Histone deacetylase 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"hdac7","symbol":"HDAC7","href":"/targets/hdac7/","tldr":"HDAC7 (Histone deacetylase 7) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"hdac8","symbol":"HDAC8","href":"/targets/hdac8/","tldr":"HDAC8 (Histone deacetylase 8) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Multiple myeloma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"hdac9","symbol":"HDAC9","href":"/targets/hdac9/","tldr":"HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.","roles":["drug-target","biomarker","fusion-partner"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"herpud1","symbol":"HERPUD1","href":"/targets/herpud1/","tldr":"HERPUD1 (Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hey1","symbol":"HEY1","href":"/targets/hey1/","tldr":"HEY1 (Hairy/enhancer-of-split related with YRPW motif protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas and Chondrosarcoma.","roles":[],"tier":"association-only"},{"id":"hgf","symbol":"HGF","href":"/targets/hgf/","tldr":"HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"lineage-antigen"},{"id":"hhip","symbol":"HHIP","href":"/targets/hhip/","tldr":"HHIP (Hedgehog-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"hhla2","symbol":"HHLA2","href":"/targets/hhla2/","tldr":"HHLA2 is a B7 relative found on gut, kidney and lung tissue and on many tumours; it can both encourage and restrain T cells depending on the receptor. No drug against it is in the corpus yet.","roles":["immune-checkpoint"]},{"id":"hip1","symbol":"HIP1","href":"/targets/hip1/","tldr":"HIP1 (Huntingtin-interacting protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Breast cancer, Lung cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"hla-b","symbol":"HLA-B","href":"/targets/hla-b/","tldr":"HLA-B (HLA class I histocompatibility antigen, B alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Oesophageal cancer, Head and neck squamous cell carcinoma and 3 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"hla-c","symbol":"HLA-C","href":"/targets/hla-c/","tldr":"HLA-C (HLA class I histocompatibility antigen, C alpha chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Diffuse large B-cell lymphoma.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"hla-dqa1","symbol":"HLA-DQA1","href":"/targets/hla-dqa1/","tldr":"HLA-DQA1 (HLA class II histocompatibility antigen, DQ alpha 1 chain) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hla-dra","symbol":"HLA-DRA","href":"/targets/hla-dra/","tldr":"HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker","immune-checkpoint"],"tier":"clinical-evidence"},{"id":"hla-e","symbol":"HLA-E","href":"/targets/hla-e/","tldr":"HLA-E is the self badge that NKG2A on NK cells reads. Tumours raise it to escape NK cells; monalizumab blocks the reader rather than the badge.","roles":["immune-checkpoint"]},{"id":"hlf","symbol":"HLF","href":"/targets/hlf/","tldr":"HLF (Transcription factor HLF) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"hmga1","symbol":"HMGA1","href":"/targets/hmga1/","tldr":"HMGA1 (High mobility group protein HMG-I/HMG-Y) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"hmga2","symbol":"HMGA2","href":"/targets/hmga2/","tldr":"HMGA2 (High mobility group protein HMGI-C) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer and Oral cavity cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"hmgcr","symbol":"HMGCR","href":"/targets/hmgcr/","tldr":"HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"hmox1","symbol":"HMOX1","href":"/targets/hmox1/","tldr":"HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hnf1a","symbol":"HNF1A","href":"/targets/hnf1a/","tldr":"HNF1A (Hepatocyte nuclear factor 1-alpha) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Hepatocellular carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"hnf1b","symbol":"HNF1B","href":"/targets/hnf1b/","tldr":"HNF1B (Hepatocyte nuclear factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma and Ovarian cancer.","roles":[],"tier":"association-only"},{"id":"hnf4g","symbol":"HNF4G","href":"/targets/hnf4g/","tldr":"HNF4G (Hepatocyte nuclear factor 4-gamma) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hnrnpa2b1","symbol":"HNRNPA2B1","href":"/targets/hnrnpa2b1/","tldr":"HNRNPA2B1 (Heterogeneous nuclear ribonucleoproteins A2/B1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Leukaemia and Non-Hodgkin lymphoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hnrnph1","symbol":"HNRNPH1","href":"/targets/hnrnph1/","tldr":"HNRNPH1 (Heterogeneous nuclear ribonucleoprotein H) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"hnrnpu","symbol":"HNRNPU","href":"/targets/hnrnpu/","tldr":"HNRNPU (Heterogeneous nuclear ribonucleoprotein U) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"hook3","symbol":"HOOK3","href":"/targets/hook3/","tldr":"HOOK3 (Protein Hook homolog 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxa11","symbol":"HOXA11","href":"/targets/hoxa11/","tldr":"HOXA11 (Homeobox protein Hox-A11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxa13","symbol":"HOXA13","href":"/targets/hoxa13/","tldr":"HOXA13 (Homeobox protein Hox-A13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only","specificity":"tumour-associated"},{"id":"hoxb13","symbol":"HOXB13","href":"/targets/hoxb13/","tldr":"HOXB13 (Homeobox protein Hox-B13) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Gastric & gastro-oesophageal junction cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"hoxc10","symbol":"HOXC10","href":"/targets/hoxc10/","tldr":"HOXC10 (Homeobox protein Hox-C10) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hoxc11","symbol":"HOXC11","href":"/targets/hoxc11/","tldr":"HOXC11 (Homeobox protein Hox-C11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"hoxc13","symbol":"HOXC13","href":"/targets/hoxc13/","tldr":"HOXC13 (Homeobox protein Hox-C13) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"hoxd11","symbol":"HOXD11","href":"/targets/hoxd11/","tldr":"HOXD11 (Homeobox protein Hox-D11) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"hoxd13","symbol":"HOXD13","href":"/targets/hoxd13/","tldr":"HOXD13 (Homeobox protein Hox-D13) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"hoxd8","symbol":"HOXD8","href":"/targets/hoxd8/","tldr":"HOXD8 (Homeobox protein Hox-D8) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hras","symbol":"HRAS","href":"/targets/hras/","tldr":"HRAS (GTPase HRas) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Thyroid cancer, Sarcomas and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"hsp90aa1","symbol":"HSP90AA1","href":"/targets/hsp90aa1/","tldr":"HSP90AA1 (Heat shock protein HSP 90-alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"hsp90ab1","symbol":"HSP90AB1","href":"/targets/hsp90ab1/","tldr":"HSP90AB1 (Heat shock protein HSP 90-beta) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"hsp90b1","symbol":"HSP90B1","href":"/targets/hsp90b1/","tldr":"HSP90B1 (Endoplasmin) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"hspa5","symbol":"HSPA5","href":"/targets/hspa5/","tldr":"HSPA5 (Endoplasmic reticulum chaperone BiP) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"hspb1","symbol":"HSPB1","href":"/targets/hspb1/","tldr":"HSPB1 (Heat shock protein beta-1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"hspg2","symbol":"HSPG2","href":"/targets/hspg2/","tldr":"HSPG2 (Basement membrane-specific heparan sulfate proteoglycan core protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"hsph1","symbol":"HSPH1","href":"/targets/hsph1/","tldr":"HSPH1 (Heat shock protein 105 kDa) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"hvcn1","symbol":"HVCN1","href":"/targets/hvcn1/","tldr":"HVCN1 (Voltage-gated hydrogen channel 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"icos","symbol":"ICOS","href":"/targets/icos/","tldr":"ICOS (Inducible T-cell costimulator) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","immune-checkpoint"],"tier":"clinical-evidence","specificity":"immune-microenvironment"},{"id":"id3","symbol":"ID3","href":"/targets/id3/","tldr":"ID3 (DNA-binding protein inhibitor ID-3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Burkitt lymphoma and Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ido1","symbol":"IDO1","href":"/targets/ido1/","tldr":"IDO1 is an enzyme tumours use to burn up tryptophan, starving T cells and producing by-products that switch them off. Epacadostat blocked it but its programme ended in failure; the IO102-IO103 vaccine instead teaches T cells to attack the IDO1-expressing cells themselves.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"ifna2","symbol":"IFNA2","href":"/targets/ifna2/","tldr":"IFNA2 (Interferon alpha-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ifnar2","symbol":"IFNAR2","href":"/targets/ifnar2/","tldr":"IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"ifngr1","symbol":"IFNGR1","href":"/targets/ifngr1/","tldr":"IFNGR1 (Interferon gamma receptor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"igf2","symbol":"IGF2","href":"/targets/igf2/","tldr":"IGF2 (Insulin-like growth factor 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Ovarian cancer and Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"igf2r","symbol":"IGF2R","href":"/targets/igf2r/","tldr":"IGF2R (Cation-independent mannose-6-phosphate receptor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ikbkb","symbol":"IKBKB","href":"/targets/ikbkb/","tldr":"IKBKB (Inhibitor of nuclear factor kappa-B kinase subunit beta) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer, Breast cancer and 2 more.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"il10","symbol":"IL10","href":"/targets/il10/","tldr":"IL-10 is a calming signal that many immune cells release; tumours and the viruses behind them raise it to keep the immune system quiet. Oddly, the main cancer drug built on it gave more IL-10 rather than less, and failed.","roles":["immune-checkpoint"]},{"id":"il2rb","symbol":"IL2RB","href":"/targets/il2rb/","tldr":"IL2RB (Interleukin-2 receptor subunit beta) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Leukaemia, Renal cell carcinoma and 3 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"lineage-antigen"},{"id":"il2rg","symbol":"IL2RG","href":"/targets/il2rg/","tldr":"IL2RG (Cytokine receptor common subunit gamma) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Renal cell carcinoma, Leukaemia and 3 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"il33","symbol":"IL33","href":"/targets/il33/","tldr":"IL33 (Interleukin-33) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"il4r","symbol":"IL4R","href":"/targets/il4r/","tldr":"IL4R (Interleukin-4 receptor subunit alpha) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"il6st","symbol":"IL6ST","href":"/targets/il6st/","tldr":"IL6ST (Interleukin-6 receptor subunit beta) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Prostate cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"il7r","symbol":"IL7R","href":"/targets/il7r/","tldr":"IL7R (Interleukin-7 receptor subunit alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"impdh1","symbol":"IMPDH1","href":"/targets/impdh1/","tldr":"IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"incenp","symbol":"INCENP","href":"/targets/incenp/","tldr":"INCENP (Inner centromere protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ing1","symbol":"ING1","href":"/targets/ing1/","tldr":"ING1 (Inhibitor of growth protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Colorectal cancer and Endometrial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"inhbb","symbol":"INHBB","href":"/targets/inhbb/","tldr":"INHBB (Inhibin beta B chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"inppl1","symbol":"INPPL1","href":"/targets/inppl1/","tldr":"INPPL1 (Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"iqgap1","symbol":"IQGAP1","href":"/targets/iqgap1/","tldr":"IQGAP1 (Ras GTPase-activating-like protein IQGAP1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"irak1","symbol":"IRAK1","href":"/targets/irak1/","tldr":"IRAK1 (Interleukin-1 receptor-associated kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Multiple myeloma.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"irf1","symbol":"IRF1","href":"/targets/irf1/","tldr":"IRF1 (Interferon regulatory factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer and Multiple myeloma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"irf5","symbol":"IRF5","href":"/targets/irf5/","tldr":"IRF5 (Interferon regulatory factor 5) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"irf8","symbol":"IRF8","href":"/targets/irf8/","tldr":"IRF8 (Interferon regulatory factor 8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"irs1","symbol":"IRS1","href":"/targets/irs1/","tldr":"IRS1 (Insulin receptor substrate 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"irs2","symbol":"IRS2","href":"/targets/irs2/","tldr":"IRS2 (Insulin receptor substrate 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"irs4","symbol":"IRS4","href":"/targets/irs4/","tldr":"IRS4 (Insulin receptor substrate 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"irx4","symbol":"IRX4","href":"/targets/irx4/","tldr":"IRX4 (Iroquois-class homeodomain protein IRX-4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"itga2b","symbol":"ITGA2B","href":"/targets/itga2b/","tldr":"ITGA2B (Integrin alpha-IIb) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"itga6","symbol":"ITGA6","href":"/targets/itga6/","tldr":"ITGA6 (Integrin alpha-6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"itgav","symbol":"ITGAV","href":"/targets/itgav/","tldr":"ITGAV (Integrin alpha-V) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"itgb3","symbol":"ITGB3","href":"/targets/itgb3/","tldr":"ITGB3 (Integrin beta-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"itk","symbol":"ITK","href":"/targets/itk/","tldr":"ITK (Tyrosine-protein kinase ITK/TSK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma and Sarcomas.","roles":["drug-target"],"tier":"approved-drug","specificity":"lineage-antigen"},{"id":"itpkb","symbol":"ITPKB","href":"/targets/itpkb/","tldr":"ITPKB (Inositol-trisphosphate 3-kinase B) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"itpr1","symbol":"ITPR1","href":"/targets/itpr1/","tldr":"ITPR1 (Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"jag1","symbol":"JAG1","href":"/targets/jag1/","tldr":"JAG1 (jagged canonical Notch ligand 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"jag2","symbol":"JAG2","href":"/targets/jag2/","tldr":"JAG2 (jagged canonical Notch ligand 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"jak3","symbol":"JAK3","href":"/targets/jak3/","tldr":"JAK3 (Tyrosine-protein kinase JAK3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"jazf1","symbol":"JAZF1","href":"/targets/jazf1/","tldr":"JAZF1 (Juxtaposed with another zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer and Prostate cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"jun","symbol":"JUN","href":"/targets/jun/","tldr":"JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"kank1","symbol":"KANK1","href":"/targets/kank1/","tldr":"KANK1 (KN motif and ankyrin repeat domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"kat2a","symbol":"KAT2A","href":"/targets/kat2a/","tldr":"KAT2A (Histone acetyltransferase KAT2A) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"kat2b","symbol":"KAT2B","href":"/targets/kat2b/","tldr":"KAT2B (Histone acetyltransferase KAT2B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"kat5","symbol":"KAT5","href":"/targets/kat5/","tldr":"KAT5 (Histone acetyltransferase KAT5) is a protein that switches other genes on and off. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"kat6a","symbol":"KAT6A","href":"/targets/kat6a/","tldr":"KAT6A (Histone acetyltransferase KAT6A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Skin cancer, Breast cancer and 5 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"kat6b","symbol":"KAT6B","href":"/targets/kat6b/","tldr":"KAT6B (Histone acetyltransferase KAT6B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Nasopharyngeal carcinoma, Prostate cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"kat7","symbol":"KAT7","href":"/targets/kat7/","tldr":"KAT7 (Histone acetyltransferase KAT7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"kcna3","symbol":"KCNA3","href":"/targets/kcna3/","tldr":"KCNA3 (Potassium voltage-gated channel subfamily A member 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcna4","symbol":"KCNA4","href":"/targets/kcna4/","tldr":"KCNA4 (Potassium voltage-gated channel subfamily A member 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnb2","symbol":"KCNB2","href":"/targets/kcnb2/","tldr":"KCNB2 (Potassium voltage-gated channel subfamily B member 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnc2","symbol":"KCNC2","href":"/targets/kcnc2/","tldr":"KCNC2 (Voltage-gated potassium channel KCNC2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnd2","symbol":"KCND2","href":"/targets/kcnd2/","tldr":"KCND2 (A-type voltage-gated potassium channel KCND2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnd3","symbol":"KCND3","href":"/targets/kcnd3/","tldr":"KCND3 (A-type voltage-gated potassium channel KCND3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnf1","symbol":"KCNF1","href":"/targets/kcnf1/","tldr":"KCNF1 (Voltage-gated potassium channel regulatory subunit KCNF1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnh1","symbol":"KCNH1","href":"/targets/kcnh1/","tldr":"KCNH1 (Voltage-gated delayed rectifier potassium channel KCNH1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnh7","symbol":"KCNH7","href":"/targets/kcnh7/","tldr":"KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnh8","symbol":"KCNH8","href":"/targets/kcnh8/","tldr":"KCNH8 (Voltage-gated delayed rectifier potassium channel KCNH8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnq1","symbol":"KCNQ1","href":"/targets/kcnq1/","tldr":"KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnq3","symbol":"KCNQ3","href":"/targets/kcnq3/","tldr":"KCNQ3 (Potassium voltage-gated channel subfamily KQT member 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kcnq5","symbol":"KCNQ5","href":"/targets/kcnq5/","tldr":"KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"kdm3b","symbol":"KDM3B","href":"/targets/kdm3b/","tldr":"KDM3B (Lysine-specific demethylase 3B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"kdm5a","symbol":"KDM5A","href":"/targets/kdm5a/","tldr":"KDM5A (Lysine-specific demethylase 5A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Lung cancer and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"kdm5c","symbol":"KDM5C","href":"/targets/kdm5c/","tldr":"KDM5C (Lysine-specific demethylase 5C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"kdm5d","symbol":"KDM5D","href":"/targets/kdm5d/","tldr":"KDM5D (Lysine-specific demethylase 5D) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"kdm6a","symbol":"KDM6A","href":"/targets/kdm6a/","tldr":"KDM6A (Lysine-specific demethylase 6A) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"kdm7a","symbol":"KDM7A","href":"/targets/kdm7a/","tldr":"KDM7A (Lysine-specific demethylase 7A) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"keap1","symbol":"KEAP1","href":"/targets/keap1/","tldr":"KEAP1 (Kelch-like ECH-associated protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Hepatocellular carcinoma, Nasopharyngeal carcinoma and 3 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"kiaa1549","symbol":"KIAA1549","href":"/targets/kiaa1549/","tldr":"KIAA1549 (UPF0606 protein KIAA1549) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"kif23","symbol":"KIF23","href":"/targets/kif23/","tldr":"KIF23 (Kinesin-like protein KIF23) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"kif5b","symbol":"KIF5B","href":"/targets/kif5b/","tldr":"KIF5B (Kinesin-1 heavy chain) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Neuroendocrine tumours and 2 more.","roles":["drug-target","oncogene-driver"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"kir2dl1","symbol":"KIR2DL1","href":"/targets/kir2dl1/","tldr":"Inhibitory KIRs are the receptors NK cells use to recognise a person's own HLA-C and stand down. Lirilumab, an antibody that blocks three of them, reached phase 2 but was dropped for blood cancers.","roles":["immune-checkpoint"]},{"id":"kitlg","symbol":"KITLG","href":"/targets/kitlg/","tldr":"KITLG (Kit ligand) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Testicular germ cell tumours.","roles":[],"tier":"association-only"},{"id":"klc1","symbol":"KLC1","href":"/targets/klc1/","tldr":"KLC1 (Kinesin light chain 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"klf2","symbol":"KLF2","href":"/targets/klf2/","tldr":"KLF2 (Krueppel-like factor 2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"klf4","symbol":"KLF4","href":"/targets/klf4/","tldr":"KLF4 (Krueppel-like factor 4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Hepatocellular carcinoma, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"klf5","symbol":"KLF5","href":"/targets/klf5/","tldr":"KLF5 (Krueppel-like factor 5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Cervical cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"klf6","symbol":"KLF6","href":"/targets/klf6/","tldr":"KLF6 (Krueppel-like factor 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Skin cancer and Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"klhdc8b","symbol":"KLHDC8B","href":"/targets/klhdc8b/","tldr":"KLHDC8B (Kelch domain-containing protein 8B) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Hodgkin lymphoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"klhl14","symbol":"KLHL14","href":"/targets/klhl14/","tldr":"KLHL14 (Kelch-like protein 14) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"klhl6","symbol":"KLHL6","href":"/targets/klhl6/","tldr":"KLHL6 (Kelch-like protein 6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"klk3","symbol":"KLK3","href":"/targets/klk3/","tldr":"KLK3 (Prostate-specific antigen) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"klln","symbol":"KLLN","href":"/targets/klln/","tldr":"KLLN (Killin) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Renal cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"klrc1","symbol":"KLRC1","href":"/targets/klrc1/","tldr":"NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer.","roles":["immune-checkpoint"]},{"id":"kmt2b","symbol":"KMT2B","href":"/targets/kmt2b/","tldr":"KMT2B (Histone-lysine N-methyltransferase 2B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Vulvar cancer, Melanoma and 1 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"kmt2c","symbol":"KMT2C","href":"/targets/kmt2c/","tldr":"KMT2C (Histone-lysine N-methyltransferase 2C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"kmt2d","symbol":"KMT2D","href":"/targets/kmt2d/","tldr":"KMT2D (Histone-lysine N-methyltransferase 2D) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Non-Hodgkin lymphoma, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"kmt5a","symbol":"KMT5A","href":"/targets/kmt5a/","tldr":"KMT5A (N-lysine methyltransferase KMT5A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"knl1","symbol":"KNL1","href":"/targets/knl1/","tldr":"KNL1 (Outer kinetochore KNL1 complex subunit KNL1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Skin cancer, Colorectal cancer and 4 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"knstrn","symbol":"KNSTRN","href":"/targets/knstrn/","tldr":"KNSTRN (Small kinetochore-associated protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"krt18","symbol":"KRT18","href":"/targets/krt18/","tldr":"KRT18 (Keratin, type I cytoskeletal 18) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"krt5","symbol":"KRT5","href":"/targets/krt5/","tldr":"KRT5 (Keratin, type II cytoskeletal 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"ksr1","symbol":"KSR1","href":"/targets/ksr1/","tldr":"KSR1 (Kinase suppressor of Ras 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ksr2","symbol":"KSR2","href":"/targets/ksr2/","tldr":"KSR2 (Kinase suppressor of Ras 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ktn1","symbol":"KTN1","href":"/targets/ktn1/","tldr":"KTN1 (Kinectin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"l3mbtl3","symbol":"L3MBTL3","href":"/targets/l3mbtl3/","tldr":"L3MBTL3 (Lethal(3)malignant brain tumour-like protein 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"lag3","symbol":"LAG3","href":"/targets/lag3/","tldr":"LAG-3 is the third immune brake to reach approval, combined with PD-1 blockade in melanoma.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"lama5","symbol":"LAMA5","href":"/targets/lama5/","tldr":"LAMA5 (Laminin subunit alpha-5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lamc1","symbol":"LAMC1","href":"/targets/lamc1/","tldr":"LAMC1 (Laminin subunit gamma-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lats1","symbol":"LATS1","href":"/targets/lats1/","tldr":"LATS1 (Serine/threonine-protein kinase LATS1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer, Ovarian cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"lats2","symbol":"LATS2","href":"/targets/lats2/","tldr":"LATS2 (Serine/threonine-protein kinase LATS2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"lck","symbol":"LCK","href":"/targets/lck/","tldr":"LCK (Tyrosine-protein kinase Lck) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Renal cell carcinoma, Myeloproliferative neoplasms and 5 more.","roles":["drug-target","fusion-partner"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"ldb1","symbol":"LDB1","href":"/targets/ldb1/","tldr":"LDB1 (LIM domain-binding protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lef1","symbol":"LEF1","href":"/targets/lef1/","tldr":"LEF1 (Lymphoid enhancer-binding factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Hepatocellular carcinoma and 3 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lepr","symbol":"LEPR","href":"/targets/lepr/","tldr":"LEPR (Leptin receptor) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"lgals9","symbol":"LGALS9","href":"/targets/lgals9/","tldr":"Galectin-9 is a sugar-binding protein that presses TIM-3 on T cells and can kill the helper T cells that carry it. Tumour blood vessels make more of it than normal ones.","roles":["immune-checkpoint"]},{"id":"lgr5-gene","symbol":"LGR5","href":"/targets/lgr5-gene/","tldr":"LGR5 (Leucine-rich repeat-containing G protein-coupled receptor 5) is a protein on the cell surface. The public catalogues list it as a drug target, a biomarker and an antigen, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Sarcomas.","roles":["drug-target","biomarker","antigen"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"lifr","symbol":"LIFR","href":"/targets/lifr/","tldr":"LIFR (Leukaemia inhibitory factor receptor) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma and Small-cell lung cancer.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"lig4","symbol":"LIG4","href":"/targets/lig4/","tldr":"LIG4 (DNA ligase 4) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"lilrb1","symbol":"LILRB1","href":"/targets/lilrb1/","tldr":"LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials.","roles":["immune-checkpoint"]},{"id":"lilrb2","symbol":"LILRB2","href":"/targets/lilrb2/","tldr":"LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab.","roles":["immune-checkpoint"]},{"id":"lmna","symbol":"LMNA","href":"/targets/lmna/","tldr":"LMNA (Prelamin-A/C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lmo1","symbol":"LMO1","href":"/targets/lmo1/","tldr":"LMO1 (Rhombotin-1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lmo2","symbol":"LMO2","href":"/targets/lmo2/","tldr":"LMO2 (Rhombotin-2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lmo7","symbol":"LMO7","href":"/targets/lmo7/","tldr":"LMO7 (LIM domain only protein 7) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lmx1b","symbol":"LMX1B","href":"/targets/lmx1b/","tldr":"LMX1B (LIM homeobox transcription factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lpa","symbol":"LPA","href":"/targets/lpa/","tldr":"LPA (Apolipoprotein(a)) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lpp","symbol":"LPP","href":"/targets/lpp/","tldr":"LPP (Lipoma-preferred partner) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Non-Hodgkin lymphoma and 4 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lratd2","symbol":"LRATD2","href":"/targets/lratd2/","tldr":"LRATD2 (LRAT domain containing 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lrfn2","symbol":"LRFN2","href":"/targets/lrfn2/","tldr":"LRFN2 (Leucine-rich repeat and fibronectin type-III domain-containing protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lrig3","symbol":"LRIG3","href":"/targets/lrig3/","tldr":"LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"lrp1b","symbol":"LRP1B","href":"/targets/lrp1b/","tldr":"LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"lrp5","symbol":"LRP5","href":"/targets/lrp5/","tldr":"LRP5 (Low-density lipoprotein receptor-related protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"lrrfip1","symbol":"LRRFIP1","href":"/targets/lrrfip1/","tldr":"LRRFIP1 (Leucine-rich repeat flightless-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"lsm14a","symbol":"LSM14A","href":"/targets/lsm14a/","tldr":"LSM14A (Protein LSM14 homolog A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"lsp1","symbol":"LSP1","href":"/targets/lsp1/","tldr":"LSP1 (Lymphocyte-specific protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"ltb","symbol":"LTB","href":"/targets/ltb/","tldr":"LTB (Lymphotoxin-beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"lyl1","symbol":"LYL1","href":"/targets/lyl1/","tldr":"LYL1 (LYL1 basic helix-loop-helix family member) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"lztr1","symbol":"LZTR1","href":"/targets/lztr1/","tldr":"LZTR1 (Leucine-zipper-like transcriptional regulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Prostate cancer, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"macc1","symbol":"MACC1","href":"/targets/macc1/","tldr":"MACC1 (Metastasis-associated in colon cancer protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"maf","symbol":"MAF","href":"/targets/maf/","tldr":"MAF (Transcription factor Maf) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Multiple myeloma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"mafb","symbol":"MAFB","href":"/targets/mafb/","tldr":"MAFB (Transcription factor MafB) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"mageh1","symbol":"MAGEH1","href":"/targets/mageh1/","tldr":"MAGEH1 (Melanoma-associated antigen H1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"malt1","symbol":"MALT1","href":"/targets/malt1/","tldr":"MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"maml1","symbol":"MAML1","href":"/targets/maml1/","tldr":"MAML1 (Mastermind-like protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"maml2","symbol":"MAML2","href":"/targets/maml2/","tldr":"MAML2 (Mastermind-like protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Vulvar cancer, Breast cancer and 5 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"maml3","symbol":"MAML3","href":"/targets/maml3/","tldr":"MAML3 (Mastermind-like protein 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mamld1","symbol":"MAMLD1","href":"/targets/mamld1/","tldr":"MAMLD1 (Mastermind-like domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"map2k4","symbol":"MAP2K4","href":"/targets/map2k4/","tldr":"MAP2K4 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"map2k7","symbol":"MAP2K7","href":"/targets/map2k7/","tldr":"MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"map3k1","symbol":"MAP3K1","href":"/targets/map3k1/","tldr":"MAP3K1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"map3k13","symbol":"MAP3K13","href":"/targets/map3k13/","tldr":"MAP3K13 (Mitogen-activated protein kinase kinase kinase 13) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Breast cancer, Lung cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"mapk1","symbol":"MAPK1","href":"/targets/mapk1/","tldr":"MAPK1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"mapk11","symbol":"MAPK11","href":"/targets/mapk11/","tldr":"MAPK11 (Mitogen-activated protein kinase 11) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"mapk3","symbol":"MAPK3","href":"/targets/mapk3/","tldr":"MAPK3 (Mitogen-activated protein kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mapk8","symbol":"MAPK8","href":"/targets/mapk8/","tldr":"MAPK8 (Mitogen-activated protein kinase 8) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mapk9","symbol":"MAPK9","href":"/targets/mapk9/","tldr":"MAPK9 (Mitogen-activated protein kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mark2","symbol":"MARK2","href":"/targets/mark2/","tldr":"MARK2 (Serine/threonine-protein kinase MARK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mark3","symbol":"MARK3","href":"/targets/mark3/","tldr":"MARK3 (MAP/microtubule affinity-regulating kinase 3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"max","symbol":"MAX","href":"/targets/max/","tldr":"MAX (MYC associated transcriptional regulator X) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroendocrine tumours, Multiple myeloma, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"mb21d2","symbol":"MB21D2","href":"/targets/mb21d2/","tldr":"MB21D2 (Nucleotidyltransferase MB21D2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Sarcomas, Bladder & urothelial cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"mbd4","symbol":"MBD4","href":"/targets/mbd4/","tldr":"MBD4 (Methyl-CpG-binding domain protein 4) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Leukaemia, Myeloproliferative neoplasms and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"mc1r","symbol":"MC1R","href":"/targets/mc1r/","tldr":"MC1R (Melanocyte-stimulating hormone receptor) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"mcl1","symbol":"MCL1","href":"/targets/mcl1/","tldr":"MCL1 (Induced myeloid leukaemia cell differentiation protein Mcl-1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"mcm7","symbol":"MCM7","href":"/targets/mcm7/","tldr":"MCM7 (DNA replication licensing factor MCM7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mcm8","symbol":"MCM8","href":"/targets/mcm8/","tldr":"MCM8 (DNA helicase MCM8) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"mdga2","symbol":"MDGA2","href":"/targets/mdga2/","tldr":"MDGA2 (MAM domain-containing glycosylphosphatidylinositol anchor protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"mdm4","symbol":"MDM4","href":"/targets/mdm4/","tldr":"MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mecom","symbol":"MECOM","href":"/targets/mecom/","tldr":"MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"med12","symbol":"MED12","href":"/targets/med12/","tldr":"MED12 (Mediator of RNA polymerase II transcription subunit 12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Cervical cancer, Endometrial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"med23","symbol":"MED23","href":"/targets/med23/","tldr":"MED23 (Mediator of RNA polymerase II transcription subunit 23) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mef2b","symbol":"MEF2B","href":"/targets/mef2b/","tldr":"MEF2B (Myocyte-specific enhancer factor 2B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Mantle cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"mef2c","symbol":"MEF2C","href":"/targets/mef2c/","tldr":"MEF2C (Myocyte-specific enhancer factor 2C) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mef2d","symbol":"MEF2D","href":"/targets/mef2d/","tldr":"MEF2D (Myocyte-specific enhancer factor 2D) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mertk","symbol":"MERTK","href":"/targets/mertk/","tldr":"MERTK (Tyrosine-protein kinase Mer) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mga","symbol":"MGA","href":"/targets/mga/","tldr":"MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"mgmt-protein","symbol":"MGMT","href":"/targets/mgmt-protein/","tldr":"MGMT is a DNA repair enzyme that removes the damage temozolomide causes; when the gene is switched off by methylation the tumour cannot repair itself and the drug works better.","roles":["drug-target","biomarker","dna-repair"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"mib2","symbol":"MIB2","href":"/targets/mib2/","tldr":"MIB2 (E3 ubiquitin-protein ligase MIB2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"mien1","symbol":"MIEN1","href":"/targets/mien1/","tldr":"MIEN1 is a small HER2-amplicon gene whose protein promotes cell migration and is strongly raised in breast and prostate cancers.","roles":["biomarker"],"tier":"association-only"},{"id":"minpp1","symbol":"MINPP1","href":"/targets/minpp1/","tldr":"MINPP1 (Multiple inositol polyphosphate phosphatase 1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"mir21","symbol":"MIR21","href":"/targets/mir21/","tldr":"MIR21 (microRNA 21) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mir218-1","symbol":"MIR218-1","href":"/targets/mir218-1/","tldr":"MIR218-1 (microRNA 218-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Pancreatic ductal adenocarcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mitf","symbol":"MITF","href":"/targets/mitf/","tldr":"MITF (Microphthalmia-associated transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Ovarian cancer and 2 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mki67","symbol":"MKI67","href":"/targets/mki67/","tldr":"Ki-67 is a protein present only in cells that are dividing, so the share of tumour cells that stain for it is a direct read of how fast the cancer is growing.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mlf1","symbol":"MLF1","href":"/targets/mlf1/","tldr":"MLF1 (Myeloid leukaemia factor 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Lung cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"mlh1","symbol":"MLH1","href":"/targets/mlh1/","tldr":"MLH1 (DNA mismatch repair protein Mlh1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ovarian cancer, Endometrial cancer and 4 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"mlh3","symbol":"MLH3","href":"/targets/mlh3/","tldr":"MLH3 (DNA mismatch repair protein Mlh3) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Endometrial cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"mllt1","symbol":"MLLT1","href":"/targets/mllt1/","tldr":"MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"mllt10","symbol":"MLLT10","href":"/targets/mllt10/","tldr":"MLLT10 (MLLT10 histone lysine methyltransferase DOT1L cofactor) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Ovarian cancer, Leukaemia and 2 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"mllt3","symbol":"MLLT3","href":"/targets/mllt3/","tldr":"MLLT3 (MLLT3 super elongation complex subunit) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma and Melanoma.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"mllt6","symbol":"MLLT6","href":"/targets/mllt6/","tldr":"MLLT6 (MLLT6, PHD finger containing) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pheochromocytoma and paraganglioma and Bladder & urothelial cancer.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"mlph","symbol":"MLPH","href":"/targets/mlph/","tldr":"MLPH (Melanophilin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mmp1","symbol":"MMP1","href":"/targets/mmp1/","tldr":"MMP1 (Interstitial collagenase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to HR-positive / HER2-negative breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mmp2","symbol":"MMP2","href":"/targets/mmp2/","tldr":"MMP2 (72 kDa type IV collagenase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mmp7","symbol":"MMP7","href":"/targets/mmp7/","tldr":"MMP7 (Matrilysin) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mmp9","symbol":"MMP9","href":"/targets/mmp9/","tldr":"MMP9 (Matrix metalloproteinase-9) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mn1","symbol":"MN1","href":"/targets/mn1/","tldr":"MN1 (Transcriptional activator MN1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Colorectal cancer, Skin cancer and 1 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"mov10","symbol":"MOV10","href":"/targets/mov10/","tldr":"MOV10 (RNA helicase MOV-10) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mpeg1","symbol":"MPEG1","href":"/targets/mpeg1/","tldr":"MPEG1 (Macrophage-expressed gene 1 protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mprip","symbol":"MPRIP","href":"/targets/mprip/","tldr":"MPRIP (Myosin phosphatase Rho-interacting protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer and Renal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"mre11","symbol":"MRE11","href":"/targets/mre11/","tldr":"MRE11 (Double-strand break repair protein MRE11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 1 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mrtfa","symbol":"MRTFA","href":"/targets/mrtfa/","tldr":"MRTFA (Myocardin-related transcription factor A) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer, Skin cancer, Lung cancer and 1 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"msh2","symbol":"MSH2","href":"/targets/msh2/","tldr":"MSH2 (DNA mismatch repair protein Msh2) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"msh3","symbol":"MSH3","href":"/targets/msh3/","tldr":"MSH3 (DNA mismatch repair protein Msh3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Colorectal cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"msh6","symbol":"MSH6","href":"/targets/msh6/","tldr":"MSH6 (DNA mismatch repair protein Msh6) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"msi2","symbol":"MSI2","href":"/targets/msi2/","tldr":"MSI2 (RNA-binding protein Musashi homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer and Neuroblastoma.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"msmb","symbol":"MSMB","href":"/targets/msmb/","tldr":"MSMB (Beta-microseminoprotein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"msn","symbol":"MSN","href":"/targets/msn/","tldr":"MSN (Moesin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Renal cell carcinoma, Basal cell carcinoma and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"msr1","symbol":"MSR1","href":"/targets/msr1/","tldr":"MSR1 (Macrophage scavenger receptor types I and II) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mt-co1","symbol":"MT-CO1","href":"/targets/mt-co1/","tldr":"MT-CO1 (Cytochrome c oxidase subunit 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"mt-cyb","symbol":"MT-CYB","href":"/targets/mt-cyb/","tldr":"MT-CYB (Cytochrome b) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"mt-nd1","symbol":"MT-ND1","href":"/targets/mt-nd1/","tldr":"MT-ND1 (NADH-ubiquinone oxidoreductase chain 1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mt-nd6","symbol":"MT-ND6","href":"/targets/mt-nd6/","tldr":"MT-ND6 (NADH-ubiquinone oxidoreductase chain 6) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"mtcp1","symbol":"MTCP1","href":"/targets/mtcp1/","tldr":"MTCP1 (Protein p13 MTCP-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"mthfr","symbol":"MTHFR","href":"/targets/mthfr/","tldr":"MTHFR (Methylenetetrahydrofolate reductase (NADPH)) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"muc6","symbol":"MUC6","href":"/targets/muc6/","tldr":"MUC6 (Mucin-6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Acute myeloid leukaemia and Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"mus81","symbol":"MUS81","href":"/targets/mus81/","tldr":"MUS81 (Structure-specific endonuclease subunit MUS81) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"mutyh","symbol":"MUTYH","href":"/targets/mutyh/","tldr":"MUTYH (Adenine DNA glycosylase) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Breast cancer and 5 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"mx2","symbol":"MX2","href":"/targets/mx2/","tldr":"MX2 (Interferon-induced GTP-binding protein Mx2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Melanoma.","roles":[],"tier":"association-only"},{"id":"mxi1","symbol":"MXI1","href":"/targets/mxi1/","tldr":"MXI1 (Max-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"myb","symbol":"MYB","href":"/targets/myb/","tldr":"MYB (Transcriptional activator Myb) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Colorectal cancer and 5 more.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mybl1","symbol":"MYBL1","href":"/targets/mybl1/","tldr":"MYBL1 (Myb-related protein A) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"myc-gene","symbol":"MYC","href":"/targets/myc-gene/","tldr":"MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Multiple myeloma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"mycl","symbol":"MYCL","href":"/targets/mycl/","tldr":"MYCL (MYCL proto-oncogene, bHLH transcription factor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Skin cancer and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"mycn","symbol":"MYCN","href":"/targets/mycn/","tldr":"MYCN is a growth-driving gene that some neuroblastomas copy many times over; that amplification is one of the strongest signs the tumour is aggressive and sets the intensity of treatment.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"myd88","symbol":"MYD88","href":"/targets/myd88/","tldr":"MYD88 (Myeloid differentiation primary response protein MyD88) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"myeov","symbol":"MYEOV","href":"/targets/myeov/","tldr":"MYEOV (Myeloma-overexpressed gene protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"myh11","symbol":"MYH11","href":"/targets/myh11/","tldr":"MYH11 (Myosin-11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"myh9","symbol":"MYH9","href":"/targets/myh9/","tldr":"MYH9 (Myosin-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma, Breast cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"myo18a","symbol":"MYO18A","href":"/targets/myo18a/","tldr":"MYO18A (Putative TGFB1-induced anti-apoptotic factor 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia.","roles":[],"tier":"association-only"},{"id":"myo5a","symbol":"MYO5A","href":"/targets/myo5a/","tldr":"MYO5A (Unconventional myosin-Va) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Hepatocellular carcinoma, Lung cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"myod1","symbol":"MYOD1","href":"/targets/myod1/","tldr":"MYOD1 (Myoblast determination protein 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer and Rhabdomyosarcoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"mysm1","symbol":"MYSM1","href":"/targets/mysm1/","tldr":"MYSM1 (Deubiquitinase MYSM1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.","roles":[],"tier":"association-only"},{"id":"n4bp2","symbol":"N4BP2","href":"/targets/n4bp2/","tldr":"N4BP2 (NEDD4-binding protein 2) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Bladder & urothelial cancer and Biliary tract cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nab2","symbol":"NAB2","href":"/targets/nab2/","tldr":"NAB2 (NGFI-A-binding protein 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"naca","symbol":"NACA","href":"/targets/naca/","tldr":"NACA (Nascent polypeptide-associated complex subunit alpha, muscle-specific form) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Melanoma and Basal cell carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"naf1","symbol":"NAF1","href":"/targets/naf1/","tldr":"NAF1 (H/ACA ribonucleoprotein complex non-core subunit NAF1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"naprt","symbol":"NAPRT","href":"/targets/naprt/","tldr":"NAPRT (Nicotinate phosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nbea","symbol":"NBEA","href":"/targets/nbea/","tldr":"NBEA (Neurobeachin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Breast cancer, Colorectal cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nbn","symbol":"NBN","href":"/targets/nbn/","tldr":"NBN (Nibrin) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"ncaph","symbol":"NCAPH","href":"/targets/ncaph/","tldr":"NCAPH (Condensin complex subunit 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nckipsd","symbol":"NCKIPSD","href":"/targets/nckipsd/","tldr":"NCKIPSD (NCK-interacting protein with SH3 domain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"ncoa1","symbol":"NCOA1","href":"/targets/ncoa1/","tldr":"NCOA1 (Nuclear receptor coactivator 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"ncoa2","symbol":"NCOA2","href":"/targets/ncoa2/","tldr":"NCOA2 (Nuclear receptor coactivator 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ncoa3","symbol":"NCOA3","href":"/targets/ncoa3/","tldr":"NCOA3 (Nuclear receptor coactivator 3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ncoa4","symbol":"NCOA4","href":"/targets/ncoa4/","tldr":"NCOA4 (Nuclear receptor coactivator 4) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"ncor1","symbol":"NCOR1","href":"/targets/ncor1/","tldr":"NCOR1 (Nuclear receptor corepressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Prostate cancer, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ncor2","symbol":"NCOR2","href":"/targets/ncor2/","tldr":"NCOR2 (Nuclear receptor corepressor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Hepatocellular carcinoma, Prostate cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ncstn","symbol":"NCSTN","href":"/targets/ncstn/","tldr":"NCSTN (Nicastrin) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"ndrg1","symbol":"NDRG1","href":"/targets/ndrg1/","tldr":"NDRG1 (N-myc downstream regulated 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Lung cancer, Colorectal cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"ndufa13","symbol":"NDUFA13","href":"/targets/ndufa13/","tldr":"NDUFA13 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"nectin2","symbol":"NECTIN2","href":"/targets/nectin2/","tldr":"CD112 is a widespread cell-adhesion molecule that can either encourage a T cell (through CD226) or hold it back (through PVRIG and TIGIT), depending on which receptor grabs it first.","roles":["immune-checkpoint"]},{"id":"nedd9","symbol":"NEDD9","href":"/targets/nedd9/","tldr":"NEDD9 (Enhancer of filamentation 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"neil1","symbol":"NEIL1","href":"/targets/neil1/","tldr":"NEIL1 (Endonuclease 8-like 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"nek10","symbol":"NEK10","href":"/targets/nek10/","tldr":"NEK10 (Serine/threonine-protein kinase Nek10) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"nf2","symbol":"NF2","href":"/targets/nf2/","tldr":"NF2 (Merlin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Renal cell carcinoma, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"nfatc2","symbol":"NFATC2","href":"/targets/nfatc2/","tldr":"NFATC2 (Nuclear factor of activated T-cells, cytoplasmic 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Breast cancer, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nfe2l2","symbol":"NFE2L2","href":"/targets/nfe2l2/","tldr":"NFE2L2 (Nuclear factor erythroid 2-related factor 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"nfib","symbol":"NFIB","href":"/targets/nfib/","tldr":"NFIB (Nuclear factor 1 B-type) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Oral cavity cancer and Adenoid cystic carcinoma.","roles":[],"tier":"association-only"},{"id":"nfkb2","symbol":"NFKB2","href":"/targets/nfkb2/","tldr":"NFKB2 (Nuclear factor NF-kappa-B p100 subunit) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Colorectal cancer, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nfkbia","symbol":"NFKBIA","href":"/targets/nfkbia/","tldr":"NFKBIA (NF-kappa-B inhibitor alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma and Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"nfkbie","symbol":"NFKBIE","href":"/targets/nfkbie/","tldr":"NFKBIE (NF-kappa-B inhibitor epsilon) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"nfkbiz","symbol":"NFKBIZ","href":"/targets/nfkbiz/","tldr":"NFKBIZ (NF-kappa-B inhibitor zeta) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"nin","symbol":"NIN","href":"/targets/nin/","tldr":"NIN (Ninein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Mesothelioma, Gastric & gastro-oesophageal junction cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"nipbl","symbol":"NIPBL","href":"/targets/nipbl/","tldr":"NIPBL (Nipped-B-like protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nktr","symbol":"NKTR","href":"/targets/nktr/","tldr":"NKTR (NK-tumour recognition protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nkx2-1","symbol":"NKX2-1","href":"/targets/nkx2-1/","tldr":"NKX2-1 (Homeobox protein Nkx-2.1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Lung cancer, Skin cancer and 1 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nkx3-1","symbol":"NKX3-1","href":"/targets/nkx3-1/","tldr":"NKX3-1 (Homeobox protein Nkx-3.1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"nol9","symbol":"NOL9","href":"/targets/nol9/","tldr":"NOL9 (Polynucleotide 5'-hydroxyl-kinase NOL9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"notch1","symbol":"NOTCH1","href":"/targets/notch1/","tldr":"NOTCH1 (Neurogenic locus notch homolog protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Head and neck squamous cell carcinoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"notch2","symbol":"NOTCH2","href":"/targets/notch2/","tldr":"NOTCH2 (Neurogenic locus notch homolog protein 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Breast cancer, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"notch3","symbol":"NOTCH3","href":"/targets/notch3/","tldr":"NOTCH3 (Neurogenic locus notch homolog protein 3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nox4","symbol":"NOX4","href":"/targets/nox4/","tldr":"NOX4 (NADPH oxidase 4) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"nprl2","symbol":"NPRL2","href":"/targets/nprl2/","tldr":"NPRL2 (GATOR1 complex protein NPRL2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nptxr","symbol":"NPTXR","href":"/targets/nptxr/","tldr":"NPTXR (Neuronal pentraxin receptor) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nqo1","symbol":"NQO1","href":"/targets/nqo1/","tldr":"NQO1 (NAD(P)H dehydrogenase [quinone] 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nr2f2","symbol":"NR2F2","href":"/targets/nr2f2/","tldr":"NR2F2 (COUP transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"nr4a2","symbol":"NR4A2","href":"/targets/nr4a2/","tldr":"NR4A2 (Nuclear receptor subfamily 4 group A member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"nr4a3","symbol":"NR4A3","href":"/targets/nr4a3/","tldr":"NR4A3 (Nuclear receptor subfamily 4 group A member 3) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Colorectal cancer, Lung cancer and 1 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"nr5a2","symbol":"NR5A2","href":"/targets/nr5a2/","tldr":"NR5A2 (Nuclear receptor subfamily 5 group A member 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrg1","symbol":"NRG1","href":"/targets/nrg1/","tldr":"NRG1 (Pro-neuregulin-1, membrane-bound isoform) is a protein on the cell surface. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker, a fusion partner and an antigen, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Thyroid cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner","antigen"],"tier":"approved-drug","specificity":"lineage-antigen"},{"id":"nrg2","symbol":"NRG2","href":"/targets/nrg2/","tldr":"NRG2 (Pro-neuregulin-2, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrg3","symbol":"NRG3","href":"/targets/nrg3/","tldr":"NRG3 (Pro-neuregulin-3, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrg4","symbol":"NRG4","href":"/targets/nrg4/","tldr":"NRG4 (Pro-neuregulin-4, membrane-bound isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"nrip1","symbol":"NRIP1","href":"/targets/nrip1/","tldr":"NRIP1 (Nuclear receptor-interacting protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"nrk","symbol":"NRK","href":"/targets/nrk/","tldr":"NRK (Nik-related protein kinase) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nsd1","symbol":"NSD1","href":"/targets/nsd1/","tldr":"NSD1 (Histone-lysine N-methyltransferase, H3 lysine-36 specific) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nsd2","symbol":"NSD2","href":"/targets/nsd2/","tldr":"NSD2 (Histone-lysine N-methyltransferase NSD2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma, Bladder & urothelial cancer, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"nsd3","symbol":"NSD3","href":"/targets/nsd3/","tldr":"NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nt5c2","symbol":"NT5C2","href":"/targets/nt5c2/","tldr":"NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"nt5c3a","symbol":"NT5C3A","href":"/targets/nt5c3a/","tldr":"NT5C3A (Cytosolic 5'-nucleotidase 3A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"cd73-adenosine","symbol":"NT5E","href":"/targets/cd73-adenosine/","tldr":"CD73 is an enzyme on tumour and immune cells that converts AMP into adenosine, which switches off T and natural killer cells through A2A and A2B receptors. Oleclumab (anti-CD73) with durvalumab slowed progression in a phase 2 lung cancer trial and quemliclustat is in phase 3 in pancreatic cancer, but A2A blockers gave only modest signals and several were dropped.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"nthl1","symbol":"NTHL1","href":"/targets/nthl1/","tldr":"NTHL1 (Endonuclease III-like protein 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"nudt15","symbol":"NUDT15","href":"/targets/nudt15/","tldr":"NUDT15 (Nucleotide triphosphate diphosphatase NUDT15) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"numa1","symbol":"NUMA1","href":"/targets/numa1/","tldr":"NUMA1 (Nuclear mitotic apparatus protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"nup214","symbol":"NUP214","href":"/targets/nup214/","tldr":"NUP214 (Nuclear pore complex protein Nup214) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Renal cell carcinoma and 4 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"nup98","symbol":"NUP98","href":"/targets/nup98/","tldr":"NUP98 (Nuclear pore complex protein Nup98-Nup96) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Lung cancer, Leukaemia and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"nutm1","symbol":"NUTM1","href":"/targets/nutm1/","tldr":"NUTM1 (NUT family member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Oesophageal cancer, Ovarian cancer and 4 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"nutm2b","symbol":"NUTM2B","href":"/targets/nutm2b/","tldr":"NUTM2B (NUT family member 2B) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas.","roles":[],"tier":"association-only"},{"id":"nutm2d","symbol":"NUTM2D","href":"/targets/nutm2d/","tldr":"NUTM2D (NUT family member 2D) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nvl","symbol":"NVL","href":"/targets/nvl/","tldr":"NVL (Nuclear valosin-containing protein-like) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"nxf1","symbol":"NXF1","href":"/targets/nxf1/","tldr":"NXF1 (Nuclear RNA export factor 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"oca2","symbol":"OCA2","href":"/targets/oca2/","tldr":"OCA2 (P protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"ogg1","symbol":"OGG1","href":"/targets/ogg1/","tldr":"OGG1 (N-glycosylase/DNA lyase) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"olig2","symbol":"OLIG2","href":"/targets/olig2/","tldr":"OLIG2 (Oligodendrocyte transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"orc1","symbol":"ORC1","href":"/targets/orc1/","tldr":"ORC1 (Origin recognition complex subunit 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"osbpl10","symbol":"OSBPL10","href":"/targets/osbpl10/","tldr":"OSBPL10 (Oxysterol-binding protein-related protein 10) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"otx1","symbol":"OTX1","href":"/targets/otx1/","tldr":"OTX1 (Homeobox protein OTX1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"ovol2","symbol":"OVOL2","href":"/targets/ovol2/","tldr":"OVOL2 (Transcription factor Ovo-like 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"p2ry8","symbol":"P2RY8","href":"/targets/p2ry8/","tldr":"P2RY8 (S-geranylgeranyl-glutathione receptor P2RY8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pabpc1","symbol":"PABPC1","href":"/targets/pabpc1/","tldr":"PABPC1 (Polyadenylate-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Bladder & urothelial cancer and 5 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"palb2","symbol":"PALB2","href":"/targets/palb2/","tldr":"PALB2 (Partner and localizer of BRCA2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer, Colorectal cancer and 5 more.","roles":["drug-target","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"pald1","symbol":"PALD1","href":"/targets/pald1/","tldr":"PALD1 encodes paladin, a protein built like a tyrosine phosphatase that in blood-vessel cells removes a phosphate from a membrane lipid and so tunes VEGF receptor signalling. It is not an established cancer gene: one study ties it to colon cancer spread, and Open Targets records an association with non-Hodgkin lymphoma.","roles":[],"tier":"association-only"},{"id":"pappa2","symbol":"PAPPA2","href":"/targets/pappa2/","tldr":"PAPPA2 (Pappalysin-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"papss1","symbol":"PAPSS1","href":"/targets/papss1/","tldr":"PAPSS1 (Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"parp2","symbol":"PARP2","href":"/targets/parp2/","tldr":"PARP2 (Poly [ADP-ribose] polymerase 2) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Breast cancer and Prostate cancer.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"parp3","symbol":"PARP3","href":"/targets/parp3/","tldr":"PARP3 (Protein mono-ADP-ribosyltransferase PARP3) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer and Prostate cancer.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"parp4","symbol":"PARP4","href":"/targets/parp4/","tldr":"PARP4 (Protein mono-ADP-ribosyltransferase PARP4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Multiple myeloma and Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"patz1","symbol":"PATZ1","href":"/targets/patz1/","tldr":"PATZ1 (POZ-, AT hook-, and zinc finger-containing protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Skin cancer and Colorectal cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pax3","symbol":"PAX3","href":"/targets/pax3/","tldr":"PAX3 (Paired box protein Pax-3) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Rhabdomyosarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pax5","symbol":"PAX5","href":"/targets/pax5/","tldr":"PAX5 (Paired box protein Pax-5) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pax6","symbol":"PAX6","href":"/targets/pax6/","tldr":"PAX6 (Paired box protein Pax-6) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"pax7","symbol":"PAX7","href":"/targets/pax7/","tldr":"PAX7 (Paired box protein Pax-7) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Rhabdomyosarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pax8","symbol":"PAX8","href":"/targets/pax8/","tldr":"PAX8 (Paired box protein Pax-8) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"pax9","symbol":"PAX9","href":"/targets/pax9/","tldr":"PAX9 (Paired box protein Pax-9) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"pbk","symbol":"PBK","href":"/targets/pbk/","tldr":"PBK (Lymphokine-activated killer T-cell-originated protein kinase) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pbld","symbol":"PBLD","href":"/targets/pbld/","tldr":"PBLD (Phenazine biosynthesis-like domain-containing protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"pbrm1","symbol":"PBRM1","href":"/targets/pbrm1/","tldr":"PBRM1 (polybromo 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Skin cancer, Biliary tract cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pbx1","symbol":"PBX1","href":"/targets/pbx1/","tldr":"PBX1 (Pre-B-cell leukaemia transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 3 more.","roles":["fusion-partner"],"tier":"association-only"},{"id":"pcbp1","symbol":"PCBP1","href":"/targets/pcbp1/","tldr":"PCBP1 (Poly(rC)-binding protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pcm1","symbol":"PCM1","href":"/targets/pcm1/","tldr":"PCM1 (Pericentriolar material 1 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"pcmtd1","symbol":"PCMTD1","href":"/targets/pcmtd1/","tldr":"PCMTD1 (Protein-L-isoaspartate O-methyltransferase domain-containing protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"pcna","symbol":"PCNA","href":"/targets/pcna/","tldr":"PCNA (DNA sliding clamp PCNA) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroblastoma.","roles":["biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"pcnx2","symbol":"PCNX2","href":"/targets/pcnx2/","tldr":"PCNX2 (Pecanex-like protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"pd1","symbol":"PDCD1","href":"/targets/pd1/","tldr":"PD-1 is a brake on T cells. Blocking it releases the immune system against the tumour and has cured some previously incurable cancers.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"pdcd1lg2","symbol":"PDCD1LG2","href":"/targets/pdcd1lg2/","tldr":"PDCD1LG2 (Programmed cell death 1 ligand 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and an antigen, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma, Thyroid cancer, Breast cancer and 2 more.","roles":["drug-target","oncogene-driver","biomarker","antigen","immune-checkpoint"],"tier":"approved-drug","specificity":"lineage-antigen"},{"id":"pdcd4","symbol":"PDCD4","href":"/targets/pdcd4/","tldr":"PDCD4 (Programmed cell death protein 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pde3a","symbol":"PDE3A","href":"/targets/pde3a/","tldr":"PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pde3b","symbol":"PDE3B","href":"/targets/pde3b/","tldr":"PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pdgfb","symbol":"PDGFB","href":"/targets/pdgfb/","tldr":"PDGFB (Platelet-derived growth factor subunit B) is a gene. The public catalogues list it as a drug target, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas and Dermatofibrosarcoma protuberans.","roles":["drug-target","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pdgfrl","symbol":"PDGFRL","href":"/targets/pdgfrl/","tldr":"PDGFRL (Platelet-derived growth factor receptor-like protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"pdlim5","symbol":"PDLIM5","href":"/targets/pdlim5/","tldr":"PDLIM5 (PDZ and LIM domain protein 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"pdpk1","symbol":"PDPK1","href":"/targets/pdpk1/","tldr":"PDPK1 (3-phosphoinositide-dependent protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"pdzd2","symbol":"PDZD2","href":"/targets/pdzd2/","tldr":"PDZD2 (PDZ domain-containing protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"peg3","symbol":"PEG3","href":"/targets/peg3/","tldr":"PEG3 (Paternally-expressed gene 3 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"per1","symbol":"PER1","href":"/targets/per1/","tldr":"PER1 (Period circadian protein homolog 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Lung cancer, Gastric & gastro-oesophageal junction cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"per3","symbol":"PER3","href":"/targets/per3/","tldr":"PER3 (Period circadian protein homolog 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"pgap3","symbol":"PGAP3","href":"/targets/pgap3/","tldr":"PGAP3 is an enzyme gene in the HER2 amplicon that remodels the lipid anchors of cell-surface proteins.","roles":["biomarker"],"tier":"association-only"},{"id":"phf6","symbol":"PHF6","href":"/targets/phf6/","tldr":"PHF6 (PHD finger protein 6) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Myeloproliferative neoplasms and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"phlda1","symbol":"PHLDA1","href":"/targets/phlda1/","tldr":"PHLDA1 is a growth-factor-responsive gene involved in cell death; it is high in benign moles and falls as melanoma progresses.","roles":["biomarker"],"tier":"association-only"},{"id":"phlpp2","symbol":"PHLPP2","href":"/targets/phlpp2/","tldr":"PHLPP2 is a phosphatase that switches AKT off; it is lost in most colorectal cancers, which leaves the survival pathway on.","roles":["tumour-suppressor","biomarker"],"tier":"association-only"},{"id":"phox2b","symbol":"PHOX2B","href":"/targets/phox2b/","tldr":"PHOX2B (Paired mesoderm homeobox protein 2B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Colorectal cancer, Lung cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"pi4ka","symbol":"PI4KA","href":"/targets/pi4ka/","tldr":"PI4KA (Phosphatidylinositol 4-kinase alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"picalm","symbol":"PICALM","href":"/targets/picalm/","tldr":"PICALM (Phosphatidylinositol-binding clathrin assembly protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer and Papillary thyroid cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"pik3cb","symbol":"PIK3CB","href":"/targets/pik3cb/","tldr":"PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pik3cg","symbol":"PIK3CG","href":"/targets/pik3cg/","tldr":"PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Acute lymphoblastic leukaemia and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"pik3r1","symbol":"PIK3R1","href":"/targets/pik3r1/","tldr":"PIK3R1 (Phosphatidylinositol 3-kinase regulatory subunit alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Colorectal cancer, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pik3r2","symbol":"PIK3R2","href":"/targets/pik3r2/","tldr":"PIK3R2 (Phosphatidylinositol 3-kinase regulatory subunit beta) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"pik3r3","symbol":"PIK3R3","href":"/targets/pik3r3/","tldr":"PIK3R3 (Phosphatidylinositol 3-kinase regulatory subunit gamma) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"pik3r5","symbol":"PIK3R5","href":"/targets/pik3r5/","tldr":"PIK3R5 (Phosphoinositide 3-kinase regulatory subunit 5) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"pim1","symbol":"PIM1","href":"/targets/pim1/","tldr":"PIM1 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pim2","symbol":"PIM2","href":"/targets/pim2/","tldr":"PIM2 (Serine/threonine-protein kinase pim-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"plag1","symbol":"PLAG1","href":"/targets/plag1/","tldr":"PLAG1 (Zinc finger protein PLAG1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Melanoma and Oral cavity cancer.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"plcg1","symbol":"PLCG1","href":"/targets/plcg1/","tldr":"PLCG1 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas, Renal cell carcinoma, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"plcg2","symbol":"PLCG2","href":"/targets/plcg2/","tldr":"PLCG2 (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chronic lymphocytic leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"plk1","symbol":"PLK1","href":"/targets/plk1/","tldr":"PLK1 (Serine/threonine-protein kinase PLK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"plxnb2","symbol":"PLXNB2","href":"/targets/plxnb2/","tldr":"PLXNB2 (Plexin-B2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"plxnc1","symbol":"PLXNC1","href":"/targets/plxnc1/","tldr":"PLXNC1 (Plexin-C1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Melanoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"pml","symbol":"PML","href":"/targets/pml/","tldr":"PML (PML nuclear body scaffold) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Thyroid cancer, Lung cancer and 3 more.","roles":["drug-target","tumour-suppressor","biomarker","fusion-partner"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pms1","symbol":"PMS1","href":"/targets/pms1/","tldr":"PMS1 (PMS1 protein homolog 1) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"pms2","symbol":"PMS2","href":"/targets/pms2/","tldr":"PMS2 (Mismatch repair endonuclease PMS2) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"pnmt","symbol":"PNMT","href":"/targets/pnmt/","tldr":"PNMT makes adrenaline from noradrenaline in the adrenal gland; in breast cancer it matters only because it lies inside the HER2 amplicon.","roles":["biomarker"],"tier":"association-only"},{"id":"pnpla3","symbol":"PNPLA3","href":"/targets/pnpla3/","tldr":"PNPLA3 (1-acylglycerol-3-phosphate O-acyltransferase PNPLA3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Hepatocellular carcinoma.","roles":[],"tier":"association-only"},{"id":"poglut3","symbol":"POGLUT3","href":"/targets/poglut3/","tldr":"POGLUT3 (Protein O-glucosyltransferase 3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"pola2","symbol":"POLA2","href":"/targets/pola2/","tldr":"POLA2 (DNA polymerase alpha subunit B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pold1","symbol":"POLD1","href":"/targets/pold1/","tldr":"POLD1 (DNA polymerase delta catalytic subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Lung cancer, Breast cancer and 5 more.","roles":["drug-target","tumour-suppressor","biomarker","dna-repair"],"tier":"approved-drug","specificity":"germline-variant"},{"id":"pold2","symbol":"POLD2","href":"/targets/pold2/","tldr":"POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pold3","symbol":"POLD3","href":"/targets/pold3/","tldr":"POLD3 (DNA polymerase delta subunit 3) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pold4","symbol":"POLD4","href":"/targets/pold4/","tldr":"POLD4 (DNA polymerase delta subunit 4) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug"},{"id":"pole","symbol":"POLE","href":"/targets/pole/","tldr":"POLE (DNA polymerase epsilon catalytic subunit A) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Ovarian cancer, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"pole2","symbol":"POLE2","href":"/targets/pole2/","tldr":"POLE2 (DNA polymerase epsilon subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Leukaemia, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pole3","symbol":"POLE3","href":"/targets/pole3/","tldr":"POLE3 (DNA polymerase epsilon subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pole4","symbol":"POLE4","href":"/targets/pole4/","tldr":"POLE4 (DNA polymerase epsilon subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"polk","symbol":"POLK","href":"/targets/polk/","tldr":"POLK (DNA polymerase kappa) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"polq","symbol":"POLQ","href":"/targets/polq/","tldr":"POLQ (DNA polymerase theta) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Endometrial cancer, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"pot1","symbol":"POT1","href":"/targets/pot1/","tldr":"POT1 (Protection of telomeres protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pou2af1","symbol":"POU2AF1","href":"/targets/pou2af1/","tldr":"POU2AF1 (POU domain class 2-associating factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pou2f2","symbol":"POU2F2","href":"/targets/pou2f2/","tldr":"POU2F2 (POU domain, class 2, transcription factor 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pou5f1","symbol":"POU5F1","href":"/targets/pou5f1/","tldr":"POU5F1 (POU domain, class 5, transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer and Lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"pou5f1b","symbol":"POU5F1B","href":"/targets/pou5f1b/","tldr":"POU5F1B (POU domain, class 5, transcription factor 1B) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"pparg","symbol":"PPARG","href":"/targets/pparg/","tldr":"PPARG (Peroxisome proliferator-activated receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Thyroid cancer and Endometrial cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"ppat","symbol":"PPAT","href":"/targets/ppat/","tldr":"PPAT (Amidophosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"ppfibp1","symbol":"PPFIBP1","href":"/targets/ppfibp1/","tldr":"PPFIBP1 (Liprin-beta-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppm1b","symbol":"PPM1B","href":"/targets/ppm1b/","tldr":"PPM1B (Protein phosphatase 1B) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppm1d","symbol":"PPM1D","href":"/targets/ppm1d/","tldr":"PPM1D (Protein phosphatase 1D) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Ovarian cancer, Myeloproliferative neoplasms and 5 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ppp1r14a","symbol":"PPP1R14A","href":"/targets/ppp1r14a/","tldr":"PPP1R14A (Protein phosphatase 1 regulatory subunit 14A) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"ppp1r15a","symbol":"PPP1R15A","href":"/targets/ppp1r15a/","tldr":"PPP1R15A (Protein phosphatase 1 regulatory subunit 15A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ppp2ca","symbol":"PPP2CA","href":"/targets/ppp2ca/","tldr":"PPP2CA (Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ppp2cb","symbol":"PPP2CB","href":"/targets/ppp2cb/","tldr":"PPP2CB (Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform) is an enzyme. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ppp2r1a","symbol":"PPP2R1A","href":"/targets/ppp2r1a/","tldr":"PPP2R1A is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ppp2r1b","symbol":"PPP2R1B","href":"/targets/ppp2r1b/","tldr":"PPP2R1B (Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r2a","symbol":"PPP2R2A","href":"/targets/ppp2r2a/","tldr":"PPP2R2A (Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ppp2r5a","symbol":"PPP2R5A","href":"/targets/ppp2r5a/","tldr":"PPP2R5A (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5b","symbol":"PPP2R5B","href":"/targets/ppp2r5b/","tldr":"PPP2R5B (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5c","symbol":"PPP2R5C","href":"/targets/ppp2r5c/","tldr":"PPP2R5C (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only","specificity":"broadly-expressed"},{"id":"ppp2r5d","symbol":"PPP2R5D","href":"/targets/ppp2r5d/","tldr":"PPP2R5D (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit delta isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp2r5e","symbol":"PPP2R5E","href":"/targets/ppp2r5e/","tldr":"PPP2R5E (Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ppp3ca","symbol":"PPP3CA","href":"/targets/ppp3ca/","tldr":"PPP3CA (Protein phosphatase 3 catalytic subunit alpha) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ppp6c","symbol":"PPP6C","href":"/targets/ppp6c/","tldr":"PPP6C (Serine/threonine-protein phosphatase 6 catalytic subunit) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"prc1","symbol":"PRC1","href":"/targets/prc1/","tldr":"PRC1 (Protein regulator of cytokinesis 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"prcc","symbol":"PRCC","href":"/targets/prcc/","tldr":"PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"prdm1","symbol":"PRDM1","href":"/targets/prdm1/","tldr":"PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Prostate cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"prdm16","symbol":"PRDM16","href":"/targets/prdm16/","tldr":"PRDM16 (Histone-lysine N-methyltransferase PRDM16) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Breast cancer, Neuroendocrine tumours and 4 more.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"prdm2","symbol":"PRDM2","href":"/targets/prdm2/","tldr":"PRDM2 (PR domain zinc finger protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Neuroblastoma and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"prex2","symbol":"PREX2","href":"/targets/prex2/","tldr":"PREX2 is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"prf1","symbol":"PRF1","href":"/targets/prf1/","tldr":"PRF1 (Perforin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.","roles":[],"tier":"association-only"},{"id":"prim1","symbol":"PRIM1","href":"/targets/prim1/","tldr":"PRIM1 (DNA primase small subunit) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"prim2","symbol":"PRIM2","href":"/targets/prim2/","tldr":"PRIM2 (DNA primase large subunit) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"prkaa2","symbol":"PRKAA2","href":"/targets/prkaa2/","tldr":"PRKAA2 (5'-AMP-activated protein kinase catalytic subunit alpha-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prkaca","symbol":"PRKACA","href":"/targets/prkaca/","tldr":"PRKACA (cAMP-dependent protein kinase catalytic subunit alpha) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. In the public catalogues the evidence so far is association rather than a proven role. Tied to Hepatocellular carcinoma.","roles":[],"tier":"association-only"},{"id":"prkar1a","symbol":"PRKAR1A","href":"/targets/prkar1a/","tldr":"PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"prkcb","symbol":"PRKCB","href":"/targets/prkcb/","tldr":"PRKCB (Protein kinase C beta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Head and neck squamous cell carcinoma and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"prkcd","symbol":"PRKCD","href":"/targets/prkcd/","tldr":"PRKCD (Protein kinase C delta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target","tumour-suppressor"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"prkce","symbol":"PRKCE","href":"/targets/prkce/","tldr":"PRKCE (Protein kinase C epsilon type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkcg","symbol":"PRKCG","href":"/targets/prkcg/","tldr":"PRKCG (Protein kinase C gamma type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkch","symbol":"PRKCH","href":"/targets/prkch/","tldr":"PRKCH (PRKCH upstream open reading frame 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"prkci","symbol":"PRKCI","href":"/targets/prkci/","tldr":"PRKCI (Protein kinase C iota type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"prkcq","symbol":"PRKCQ","href":"/targets/prkcq/","tldr":"PRKCQ (Protein kinase C theta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkcz","symbol":"PRKCZ","href":"/targets/prkcz/","tldr":"PRKCZ (Protein kinase C zeta type) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"prkd1","symbol":"PRKD1","href":"/targets/prkd1/","tldr":"PRKD1 (Serine/threonine-protein kinase D1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Colorectal cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"prkd2","symbol":"PRKD2","href":"/targets/prkd2/","tldr":"PRKD2 (Serine/threonine-protein kinase D2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"prkd3","symbol":"PRKD3","href":"/targets/prkd3/","tldr":"PRKD3 (Serine/threonine-protein kinase D3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Systemic mastocytosis and 1 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"prkdc","symbol":"PRKDC","href":"/targets/prkdc/","tldr":"PRKDC (DNA-dependent protein kinase catalytic subunit) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma, Non-small-cell lung cancer and Diffuse large B-cell lymphoma.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"prkn","symbol":"PRKN","href":"/targets/prkn/","tldr":"PRKN (E3 ubiquitin-protein ligase parkin) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer and Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prncr1","symbol":"PRNCR1","href":"/targets/prncr1/","tldr":"PRNCR1 (prostate cancer associated non-coding RNA 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"prom1","symbol":"PROM1","href":"/targets/prom1/","tldr":"PROM1 (Prominin-1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"prps1","symbol":"PRPS1","href":"/targets/prps1/","tldr":"PRPS1 (Ribose-phosphate pyrophosphokinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute lymphoblastic leukaemia.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"prune2","symbol":"PRUNE2","href":"/targets/prune2/","tldr":"PRUNE2 (Protein prune homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Neuroblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"psca","symbol":"PSCA","href":"/targets/psca/","tldr":"PSCA (Prostate stem cell antigen) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"psen2","symbol":"PSEN2","href":"/targets/psen2/","tldr":"PSEN2 (Presenilin-2) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psenen","symbol":"PSENEN","href":"/targets/psenen/","tldr":"PSENEN (Gamma-secretase subunit PEN-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Desmoid tumour.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psip1","symbol":"PSIP1","href":"/targets/psip1/","tldr":"PSIP1 (PC4 and SFRS1-interacting protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Gallbladder cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"psma1","symbol":"PSMA1","href":"/targets/psma1/","tldr":"PSMA1 (Proteasome subunit alpha type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma2","symbol":"PSMA2","href":"/targets/psma2/","tldr":"PSMA2 (Proteasome subunit alpha type-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma3","symbol":"PSMA3","href":"/targets/psma3/","tldr":"PSMA3 (Proteasome subunit alpha type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma4","symbol":"PSMA4","href":"/targets/psma4/","tldr":"PSMA4 (Proteasome subunit alpha type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma5","symbol":"PSMA5","href":"/targets/psma5/","tldr":"PSMA5 (Proteasome subunit alpha type-5) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma6","symbol":"PSMA6","href":"/targets/psma6/","tldr":"PSMA6 (Proteasome subunit alpha type-6) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma7","symbol":"PSMA7","href":"/targets/psma7/","tldr":"PSMA7 (Proteasome subunit alpha type-7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psma8","symbol":"PSMA8","href":"/targets/psma8/","tldr":"PSMA8 (Proteasome subunit alpha-type 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb1","symbol":"PSMB1","href":"/targets/psmb1/","tldr":"PSMB1 (Proteasome subunit beta type-1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb10","symbol":"PSMB10","href":"/targets/psmb10/","tldr":"PSMB10 (Proteasome subunit beta type-10) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb11","symbol":"PSMB11","href":"/targets/psmb11/","tldr":"PSMB11 (Proteasome subunit beta type-11) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmb2","symbol":"PSMB2","href":"/targets/psmb2/","tldr":"PSMB2 (Proteasome subunit beta type-2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb3","symbol":"PSMB3","href":"/targets/psmb3/","tldr":"PSMB3 (Proteasome subunit beta type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb4","symbol":"PSMB4","href":"/targets/psmb4/","tldr":"PSMB4 (Proteasome subunit beta type-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb6","symbol":"PSMB6","href":"/targets/psmb6/","tldr":"PSMB6 (Proteasome subunit beta type-6) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb7","symbol":"PSMB7","href":"/targets/psmb7/","tldr":"PSMB7 (Proteasome subunit beta type-7) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb8","symbol":"PSMB8","href":"/targets/psmb8/","tldr":"PSMB8 (Proteasome subunit beta type-8) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Gastric & gastro-oesophageal junction cancer, Non-Hodgkin lymphoma and 1 more.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmb9","symbol":"PSMB9","href":"/targets/psmb9/","tldr":"PSMB9 (Proteasome subunit beta type-9) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug"},{"id":"psmc1","symbol":"PSMC1","href":"/targets/psmc1/","tldr":"PSMC1 (26S proteasome regulatory subunit 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmc2","symbol":"PSMC2","href":"/targets/psmc2/","tldr":"PSMC2 (26S proteasome regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmc3","symbol":"PSMC3","href":"/targets/psmc3/","tldr":"PSMC3 (26S proteasome regulatory subunit 6A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmc4","symbol":"PSMC4","href":"/targets/psmc4/","tldr":"PSMC4 (26S proteasome regulatory subunit 6B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmc5","symbol":"PSMC5","href":"/targets/psmc5/","tldr":"PSMC5 (26S proteasome regulatory subunit 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmc6","symbol":"PSMC6","href":"/targets/psmc6/","tldr":"PSMC6 (26S proteasome regulatory subunit 10B) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd1","symbol":"PSMD1","href":"/targets/psmd1/","tldr":"PSMD1 (26S proteasome non-ATPase regulatory subunit 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd11","symbol":"PSMD11","href":"/targets/psmd11/","tldr":"PSMD11 (26S proteasome non-ATPase regulatory subunit 11) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd12","symbol":"PSMD12","href":"/targets/psmd12/","tldr":"PSMD12 (26S proteasome non-ATPase regulatory subunit 12) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd13","symbol":"PSMD13","href":"/targets/psmd13/","tldr":"PSMD13 (26S proteasome non-ATPase regulatory subunit 13) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd14","symbol":"PSMD14","href":"/targets/psmd14/","tldr":"PSMD14 (Ubiquitin C-terminal hydrolase PSMD14) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd2","symbol":"PSMD2","href":"/targets/psmd2/","tldr":"PSMD2 (26S proteasome non-ATPase regulatory subunit 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd3","symbol":"PSMD3","href":"/targets/psmd3/","tldr":"PSMD3 (26S proteasome non-ATPase regulatory subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd4","symbol":"PSMD4","href":"/targets/psmd4/","tldr":"PSMD4 (26S proteasome non-ATPase regulatory subunit 4) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Colorectal cancer, Breast cancer and 2 more.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd6","symbol":"PSMD6","href":"/targets/psmd6/","tldr":"PSMD6 (26S proteasome non-ATPase regulatory subunit 6) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd7","symbol":"PSMD7","href":"/targets/psmd7/","tldr":"PSMD7 (26S proteasome non-ATPase regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"psmd8","symbol":"PSMD8","href":"/targets/psmd8/","tldr":"PSMD8 (26S proteasome non-ATPase regulatory subunit 8) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"pspc1","symbol":"PSPC1","href":"/targets/pspc1/","tldr":"PSPC1 (Paraspeckle component 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"pten","symbol":"PTEN","href":"/targets/pten/","tldr":"PTEN is the brake on the PI3K growth pathway; when a tumour loses it the pathway runs unchecked, which is why PTEN loss now selects patients for the AKT inhibitor capivasertib.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ptgs1","symbol":"PTGS1","href":"/targets/ptgs1/","tldr":"PTGS1 (Prostaglandin G/H synthase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"ptma","symbol":"PTMA","href":"/targets/ptma/","tldr":"PTMA (Prothymosin alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Testicular germ cell tumours.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ptp4a3","symbol":"PTP4A3","href":"/targets/ptp4a3/","tldr":"PTP4A3 (Protein tyrosine phosphatase type IVA 3) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ptpn12","symbol":"PTPN12","href":"/targets/ptpn12/","tldr":"PTPN12 (Tyrosine-protein phosphatase non-receptor type 12) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ptpn13","symbol":"PTPN13","href":"/targets/ptpn13/","tldr":"PTPN13 (Tyrosine-protein phosphatase non-receptor type 13) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Pancreatic ductal adenocarcinoma, Endometrial cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptpn14","symbol":"PTPN14","href":"/targets/ptpn14/","tldr":"PTPN14 (Tyrosine-protein phosphatase non-receptor type 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Basal cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptpn22","symbol":"PTPN22","href":"/targets/ptpn22/","tldr":"PTPN22 (Tyrosine-protein phosphatase non-receptor type 22) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ptpn3","symbol":"PTPN3","href":"/targets/ptpn3/","tldr":"PTPN3 (Tyrosine-protein phosphatase non-receptor type 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptpn6","symbol":"PTPN6","href":"/targets/ptpn6/","tldr":"PTPN6 (Tyrosine-protein phosphatase non-receptor type 6) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Diffuse large B-cell lymphoma and Melanoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ptprb","symbol":"PTPRB","href":"/targets/ptprb/","tldr":"PTPRB (Receptor-type tyrosine-protein phosphatase beta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Mesothelioma, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ptprc","symbol":"PTPRC","href":"/targets/ptprc/","tldr":"PTPRC (Receptor-type tyrosine-protein phosphatase C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Anal cancer, Hepatocellular carcinoma, Skin cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptprd","symbol":"PTPRD","href":"/targets/ptprd/","tldr":"PTPRD (Receptor-type tyrosine-protein phosphatase delta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ptprf","symbol":"PTPRF","href":"/targets/ptprf/","tldr":"PTPRF (Receptor-type tyrosine-protein phosphatase F) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ptprk","symbol":"PTPRK","href":"/targets/ptprk/","tldr":"PTPRK (Receptor-type tyrosine-protein phosphatase kappa) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"ptprt","symbol":"PTPRT","href":"/targets/ptprt/","tldr":"PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"pttg1","symbol":"PTTG1","href":"/targets/pttg1/","tldr":"PTTG1 (Securin) is a gene. The public catalogues list it as a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.","roles":["biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"pvr","symbol":"PVR","href":"/targets/pvr/","tldr":"CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.","roles":["immune-checkpoint"]},{"id":"pvrig","symbol":"PVRIG","href":"/targets/pvrig/","tldr":"PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.","roles":["immune-checkpoint"]},{"id":"pwwp2a","symbol":"PWWP2A","href":"/targets/pwwp2a/","tldr":"PWWP2A (PWWP domain-containing protein 2A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"pxdnl","symbol":"PXDNL","href":"/targets/pxdnl/","tldr":"PXDNL (Probable oxidoreductase PXDNL) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"qki","symbol":"QKI","href":"/targets/qki/","tldr":"QKI (KH domain-containing RNA-binding protein QKI) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rabl3","symbol":"RABL3","href":"/targets/rabl3/","tldr":"RABL3 (Rab-like protein 3) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rac1","symbol":"RAC1","href":"/targets/rac1/","tldr":"RAC1 (Ras-related C3 botulinum toxin substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Head and neck squamous cell carcinoma and Melanoma.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rad21","symbol":"RAD21","href":"/targets/rad21/","tldr":"RAD21 (Double-strand-break repair protein rad21 homolog) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Myeloproliferative neoplasms, Lung cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"rad23b","symbol":"RAD23B","href":"/targets/rad23b/","tldr":"RAD23B (Lysine-specific demethylase RAD23B) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Sarcomas.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rad50","symbol":"RAD50","href":"/targets/rad50/","tldr":"RAD50 (DNA repair protein RAD50) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Colorectal cancer and 2 more.","roles":["drug-target","oncogene-driver","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rad51","symbol":"RAD51","href":"/targets/rad51/","tldr":"RAD51 (DNA repair protein RAD51 homolog 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"rad51b","symbol":"RAD51B","href":"/targets/rad51b/","tldr":"RAD51B (DNA repair protein RAD51 homolog 2) is a gene. The public catalogues list it as a drug target, a biomarker, a fusion partner and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Ovarian cancer and 2 more.","roles":["drug-target","biomarker","fusion-partner","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rad51c","symbol":"RAD51C","href":"/targets/rad51c/","tldr":"RAD51C (DNA repair protein RAD51 homolog 3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 2 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"rad51d","symbol":"RAD51D","href":"/targets/rad51d/","tldr":"RAD51D (DNA repair protein RAD51 homolog 4) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 3 more.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"rad54l","symbol":"RAD54L","href":"/targets/rad54l/","tldr":"RAD54L (DNA repair and recombination protein RAD54-like) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence"},{"id":"ranbp2","symbol":"RANBP2","href":"/targets/ranbp2/","tldr":"RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rap1a","symbol":"RAP1A","href":"/targets/rap1a/","tldr":"RAP1A (Ras-related protein Rap-1A) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rap1b","symbol":"RAP1B","href":"/targets/rap1b/","tldr":"RAP1B (Ras-related protein Rap-1b) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rap1gds1","symbol":"RAP1GDS1","href":"/targets/rap1gds1/","tldr":"RAP1GDS1 (Rap1 GTPase-GDP dissociation stimulator 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Breast cancer and 2 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rarb","symbol":"RARB","href":"/targets/rarb/","tldr":"RARB (Retinoic acid receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"rarg","symbol":"RARG","href":"/targets/rarg/","tldr":"RARG (Retinoic acid receptor gamma) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Acute myeloid leukaemia and 1 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"rasa1","symbol":"RASA1","href":"/targets/rasa1/","tldr":"RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rasa2","symbol":"RASA2","href":"/targets/rasa2/","tldr":"RASA2 (Ras GTPase-activating protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rassf6","symbol":"RASSF6","href":"/targets/rassf6/","tldr":"RASSF6 (Ras association domain-containing protein 6) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"rb1","symbol":"RB1","href":"/targets/rb1/","tldr":"RB1 (Retinoblastoma-associated protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Lung cancer, Neuroendocrine tumours and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rbbp7","symbol":"RBBP7","href":"/targets/rbbp7/","tldr":"RBBP7 (Histone-binding protein RBBP7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rbbp8","symbol":"RBBP8","href":"/targets/rbbp8/","tldr":"RBBP8 (DNA endonuclease RBBP8) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"rbfox1","symbol":"RBFOX1","href":"/targets/rbfox1/","tldr":"RBFOX1 (RNA binding protein fox-1 homolog 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rbm10","symbol":"RBM10","href":"/targets/rbm10/","tldr":"RBM10 (Ribosome biogenesis inhibitor MINAS-60) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rbm15","symbol":"RBM15","href":"/targets/rbm15/","tldr":"RBM15 (RNA-binding protein 15) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rbm38","symbol":"RBM38","href":"/targets/rbm38/","tldr":"RBM38 (RNA-binding protein 38) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rbm39","symbol":"RBM39","href":"/targets/rbm39/","tldr":"RBM39 (RNA-binding protein 39) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rbpj","symbol":"RBPJ","href":"/targets/rbpj/","tldr":"RBPJ (Recombining binding protein suppressor of hairless) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rbx1","symbol":"RBX1","href":"/targets/rbx1/","tldr":"RBX1 (E3 ubiquitin-protein ligase RBX1) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"rcc2","symbol":"RCC2","href":"/targets/rcc2/","tldr":"RCC2 (regulator of chromosome condensation 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"recql4","symbol":"RECQL4","href":"/targets/recql4/","tldr":"RECQL4 (ATP-dependent DNA helicase Q4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Gastric & gastro-oesophageal junction cancer, Breast cancer and 5 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rel","symbol":"REL","href":"/targets/rel/","tldr":"REL (Proto-oncogene c-Rel) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"rela","symbol":"RELA","href":"/targets/rela/","tldr":"RELA (Transcription factor p65) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rest","symbol":"REST","href":"/targets/rest/","tldr":"REST (RE1-silencing transcription factor) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Wilms tumour.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rfwd3","symbol":"RFWD3","href":"/targets/rfwd3/","tldr":"RFWD3 (E3 ubiquitin-protein ligase RFWD3) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"rfx7","symbol":"RFX7","href":"/targets/rfx7/","tldr":"RFX7 (DNA-binding protein RFX7) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer and Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rgpd3","symbol":"RGPD3","href":"/targets/rgpd3/","tldr":"RGPD3 (RanBP2-like and GRIP domain-containing protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Non-small-cell lung cancer and Melanoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rgs17","symbol":"RGS17","href":"/targets/rgs17/","tldr":"RGS17 (Regulator of G protein signalling 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"rgs7","symbol":"RGS7","href":"/targets/rgs7/","tldr":"RGS7 (Regulator of G protein signalling 7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Non-small-cell lung cancer and Melanoma.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rheb","symbol":"RHEB","href":"/targets/rheb/","tldr":"RHEB (GTP-binding protein Rheb) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rhoa","symbol":"RHOA","href":"/targets/rhoa/","tldr":"RHOA (Transforming protein RhoA) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Gastric & gastro-oesophageal junction cancer, Bladder & urothelial cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rhobtb2","symbol":"RHOBTB2","href":"/targets/rhobtb2/","tldr":"RHOBTB2 (Rho-related BTB domain-containing protein 2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rhoh","symbol":"RHOH","href":"/targets/rhoh/","tldr":"RHOH (Rho-related GTP-binding protein RhoH) is an enzyme. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"rhpn2","symbol":"RHPN2","href":"/targets/rhpn2/","tldr":"RHPN2 (Rhophilin-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rictor","symbol":"RICTOR","href":"/targets/rictor/","tldr":"RICTOR (Rapamycin-insensitive companion of mTOR) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Lung cancer, Breast cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ripk1","symbol":"RIPK1","href":"/targets/ripk1/","tldr":"RIPK1 (Receptor-interacting serine/threonine-protein kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Chronic lymphocytic leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rit1","symbol":"RIT1","href":"/targets/rit1/","tldr":"RIT1 (GTP-binding protein Rit1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rmi1","symbol":"RMI1","href":"/targets/rmi1/","tldr":"RMI1 (RecQ-mediated genome instability protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"rmi2","symbol":"RMI2","href":"/targets/rmi2/","tldr":"RMI2 (RecQ-mediated genome instability protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Breast cancer, Lung cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"rnasel","symbol":"RNASEL","href":"/targets/rnasel/","tldr":"RNASEL (2-5A-dependent ribonuclease) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"rnaset2","symbol":"RNASET2","href":"/targets/rnaset2/","tldr":"RNASET2 (Ribonuclease T2) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"rnf213","symbol":"RNF213","href":"/targets/rnf213/","tldr":"RNF213 (E3 ubiquitin-protein ligase RNF213) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Bladder & urothelial cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"rnf43","symbol":"RNF43","href":"/targets/rnf43/","tldr":"RNF43 (E3 ubiquitin-protein ligase RNF43) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"rnf6","symbol":"RNF6","href":"/targets/rnf6/","tldr":"RNF6 (E3 ubiquitin-protein ligase RNF6) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Oesophageal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"robo2","symbol":"ROBO2","href":"/targets/robo2/","tldr":"ROBO2 (Roundabout homolog 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Prostate cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"robo4","symbol":"ROBO4","href":"/targets/robo4/","tldr":"ROBO4 (Roundabout homolog 4) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rpl10","symbol":"RPL10","href":"/targets/rpl10/","tldr":"RPL10 (Large ribosomal subunit protein uL16) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target and an oncogene driver, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Leukaemia and 1 more.","roles":["drug-target","oncogene-driver"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rpl22","symbol":"RPL22","href":"/targets/rpl22/","tldr":"RPL22 (Large ribosomal subunit protein eL22) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma, Colorectal cancer and Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rpl5","symbol":"RPL5","href":"/targets/rpl5/","tldr":"RPL5 (Large ribosomal subunit protein uL18) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Skin cancer and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rps19","symbol":"RPS19","href":"/targets/rps19/","tldr":"RPS19 (Small ribosomal subunit protein eS19) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps24","symbol":"RPS24","href":"/targets/rps24/","tldr":"RPS24 (Small ribosomal subunit protein eS24) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps26","symbol":"RPS26","href":"/targets/rps26/","tldr":"RPS26 (Small ribosomal subunit protein eS26) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps27","symbol":"RPS27","href":"/targets/rps27/","tldr":"RPS27 (Small ribosomal subunit protein eS27) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps27a","symbol":"RPS27A","href":"/targets/rps27a/","tldr":"RPS27A (Ubiquitin-ribosomal protein eS31 fusion protein) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps29","symbol":"RPS29","href":"/targets/rps29/","tldr":"RPS29 (Small ribosomal subunit protein uS14) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia and Myeloproliferative neoplasms.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps3a","symbol":"RPS3A","href":"/targets/rps3a/","tldr":"RPS3A (Small ribosomal subunit protein eS1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rps6","symbol":"RPS6","href":"/targets/rps6/","tldr":"RPS6 (Small ribosomal subunit protein eS6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rps6ka3","symbol":"RPS6KA3","href":"/targets/rps6ka3/","tldr":"RPS6KA3 (Ribosomal protein S6 kinase alpha-3) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"rps7","symbol":"RPS7","href":"/targets/rps7/","tldr":"RPS7 (Small ribosomal subunit protein eS7) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rragc","symbol":"RRAGC","href":"/targets/rragc/","tldr":"RRAGC (Ras-related GTP-binding protein C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rras2","symbol":"RRAS2","href":"/targets/rras2/","tldr":"RRAS2 (Ras-related protein R-Ras2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Ovarian cancer and Breast cancer.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"rrm2","symbol":"RRM2","href":"/targets/rrm2/","tldr":"RRM2 (Ribonucleoside-diphosphate reductase subunit M2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Leukaemia, Breast cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"rrm2b","symbol":"RRM2B","href":"/targets/rrm2b/","tldr":"RRM2B (Ribonucleoside-diphosphate reductase subunit M2 B) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 5 more.","roles":["drug-target","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"rrn3","symbol":"RRN3","href":"/targets/rrn3/","tldr":"RRN3 (RNA polymerase I-specific transcription initiation factor RRN3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rsf1","symbol":"RSF1","href":"/targets/rsf1/","tldr":"RSF1 (Remodeling and spacing factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"rspo2","symbol":"RSPO2","href":"/targets/rspo2/","tldr":"RSPO2 (R-spondin-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer and Colorectal cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"rspo3","symbol":"RSPO3","href":"/targets/rspo3/","tldr":"RSPO3 (R-spondin-3) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Breast cancer and Lung cancer.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"rtel1","symbol":"RTEL1","href":"/targets/rtel1/","tldr":"RTEL1 (Regulator of telomere elongation helicase 1) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.","roles":["dna-repair"],"tier":"association-only"},{"id":"runx1","symbol":"RUNX1","href":"/targets/runx1/","tldr":"RUNX1 (Runt-related transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"runx1t1","symbol":"RUNX1T1","href":"/targets/runx1t1/","tldr":"RUNX1T1 (RUNX1 partner transcriptional co-repressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Leukaemia, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"s100b","symbol":"S100B","href":"/targets/s100b/","tldr":"S100B (S100 calcium binding protein B) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"s1pr1","symbol":"S1PR1","href":"/targets/s1pr1/","tldr":"S1PR1 (Sphingosine 1-phosphate receptor 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mantle cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"s1pr2","symbol":"S1PR2","href":"/targets/s1pr2/","tldr":"S1PR2 (Sphingosine 1-phosphate receptor 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"sall4","symbol":"SALL4","href":"/targets/sall4/","tldr":"SALL4 (Sal-like protein 4) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Colorectal cancer, Gastric & gastro-oesophageal junction cancer and 2 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"samd9","symbol":"SAMD9","href":"/targets/samd9/","tldr":"SAMD9 (Sterile alpha motif domain-containing protein 9) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.","roles":[],"tier":"association-only"},{"id":"samd9l","symbol":"SAMD9L","href":"/targets/samd9l/","tldr":"SAMD9L (Sterile alpha motif domain-containing protein 9-like) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms.","roles":[],"tier":"association-only"},{"id":"samhd1","symbol":"SAMHD1","href":"/targets/samhd1/","tldr":"SAMHD1 (Deoxynucleoside triphosphate triphosphohydrolase SAMHD1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["tumour-suppressor","dna-repair"],"tier":"cohort-driver"},{"id":"sbds","symbol":"SBDS","href":"/targets/sbds/","tldr":"SBDS (Ribosome maturation protein SBDS) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.","roles":[],"tier":"association-only"},{"id":"scn10a","symbol":"SCN10A","href":"/targets/scn10a/","tldr":"SCN10A (Sodium channel protein type 10 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn11a","symbol":"SCN11A","href":"/targets/scn11a/","tldr":"SCN11A (Sodium channel protein type 11 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn1a","symbol":"SCN1A","href":"/targets/scn1a/","tldr":"SCN1A (Sodium channel protein type 1 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn2a","symbol":"SCN2A","href":"/targets/scn2a/","tldr":"SCN2A (Sodium channel protein type 2 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn3a","symbol":"SCN3A","href":"/targets/scn3a/","tldr":"SCN3A (Sodium channel protein type 3 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn4a","symbol":"SCN4A","href":"/targets/scn4a/","tldr":"SCN4A (Sodium channel protein type 4 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn5a","symbol":"SCN5A","href":"/targets/scn5a/","tldr":"SCN5A (Sodium channel protein type 5 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn7a","symbol":"SCN7A","href":"/targets/scn7a/","tldr":"SCN7A (Sodium channel protein type 7 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"scn8a","symbol":"SCN8A","href":"/targets/scn8a/","tldr":"SCN8A (Sodium channel protein type 8 subunit alpha) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Non-small-cell lung cancer.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"scn9a","symbol":"SCN9A","href":"/targets/scn9a/","tldr":"SCN9A (Sodium channel protein type 9 subunit alpha) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sdc4","symbol":"SDC4","href":"/targets/sdc4/","tldr":"SDC4 (Syndecan-4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer and Non-small-cell lung cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sdcbp","symbol":"SDCBP","href":"/targets/sdcbp/","tldr":"SDCBP (Syntenin-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Head and neck squamous cell carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"sdccag8","symbol":"SDCCAG8","href":"/targets/sdccag8/","tldr":"SDCCAG8 (Serologically defined colon cancer antigen 8) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"sdha","symbol":"SDHA","href":"/targets/sdha/","tldr":"SDHA (Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Renal cell carcinoma, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sdhaf2","symbol":"SDHAF2","href":"/targets/sdhaf2/","tldr":"SDHAF2 (Succinate dehydrogenase assembly factor 2, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours and Ovarian cancer.","roles":[],"tier":"association-only"},{"id":"sdhb","symbol":"SDHB","href":"/targets/sdhb/","tldr":"SDHB (Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Breast cancer and Gastrointestinal stromal tumour.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"sdhc","symbol":"SDHC","href":"/targets/sdhc/","tldr":"SDHC (Succinate dehydrogenase cytochrome b560 subunit, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours, Breast cancer, Colorectal cancer and 1 more.","roles":[],"tier":"association-only"},{"id":"sdhd","symbol":"SDHD","href":"/targets/sdhd/","tldr":"SDHD (Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.","roles":[],"tier":"association-only"},{"id":"sem1","symbol":"SEM1","href":"/targets/sem1/","tldr":"SEM1 (26S proteasome complex subunit SEM1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"set","symbol":"SET","href":"/targets/set/","tldr":"SET (SET nuclear proto-oncogene) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Leukaemia, Non-Hodgkin lymphoma and Acute lymphoblastic leukaemia.","roles":["fusion-partner"],"tier":"association-only"},{"id":"setbp1","symbol":"SETBP1","href":"/targets/setbp1/","tldr":"SETBP1 (SET-binding protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"setd1b","symbol":"SETD1B","href":"/targets/setd1b/","tldr":"SETD1B (Histone-lysine N-methyltransferase SETD1B) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer, Head and neck squamous cell carcinoma, Ovarian cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"setd2","symbol":"SETD2","href":"/targets/setd2/","tldr":"SETD2 (Histone-lysine N-methyltransferase SETD2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Renal cell carcinoma, Leukaemia, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"setdb1","symbol":"SETDB1","href":"/targets/setdb1/","tldr":"SETDB1 (Histone-lysine N-methyltransferase SETDB1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"sf3b1","symbol":"SF3B1","href":"/targets/sf3b1/","tldr":"SF3B1 (Splicing factor 3B subunit 1) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sfpq","symbol":"SFPQ","href":"/targets/sfpq/","tldr":"SFPQ (Splicing factor, proline- and glutamine-rich) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner and a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["fusion-partner","dna-repair"],"tier":"association-only"},{"id":"sfrp4","symbol":"SFRP4","href":"/targets/sfrp4/","tldr":"SFRP4 (Secreted frizzled-related protein 4) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer and Skin cancer.","roles":[],"tier":"association-only"},{"id":"sgk1","symbol":"SGK1","href":"/targets/sgk1/","tldr":"SGK1 (Serine/threonine-protein kinase Sgk1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 2 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sh2b3","symbol":"SH2B3","href":"/targets/sh2b3/","tldr":"SH2B3 (SH2B adapter protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Myeloproliferative neoplasms, Endometrial cancer and 4 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sh3gl1","symbol":"SH3GL1","href":"/targets/sh3gl1/","tldr":"SH3GL1 (Endophilin-A2) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"shc1","symbol":"SHC1","href":"/targets/shc1/","tldr":"SHC1 (SHC-transforming protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"shtn1","symbol":"SHTN1","href":"/targets/shtn1/","tldr":"SHTN1 (Shootin-1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"sidt1","symbol":"SIDT1","href":"/targets/sidt1/","tldr":"SIDT1 (SID1 transmembrane family member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"siglec10","symbol":"SIGLEC10","href":"/targets/siglec10/","tldr":"Siglec-10 is the receptor on macrophages and other blood cells that reads the CD24 'don't eat me' badge on tumour cells and calls off the attack.","roles":["immune-checkpoint"]},{"id":"sim2","symbol":"SIM2","href":"/targets/sim2/","tldr":"SIM2 (Single-minded homolog 2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"sin3a","symbol":"SIN3A","href":"/targets/sin3a/","tldr":"SIN3A (Paired amphipathic helix protein Sin3a) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Burkitt lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sirpa","symbol":"SIRPA","href":"/targets/sirpa/","tldr":"SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Colorectal cancer, Non-Hodgkin lymphoma and 1 more.","roles":["oncogene-driver","tumour-suppressor","immune-checkpoint"],"tier":"cohort-driver"},{"id":"sirt1","symbol":"SIRT1","href":"/targets/sirt1/","tldr":"SIRT1 (NAD-dependent protein deacetylase sirtuin-1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"six1","symbol":"SIX1","href":"/targets/six1/","tldr":"SIX1 (Homeobox protein SIX1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer and Wilms tumour.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"skil","symbol":"SKIL","href":"/targets/skil/","tldr":"SKIL (Ski-like protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"skp1","symbol":"SKP1","href":"/targets/skp1/","tldr":"SKP1 (S-phase kinase-associated protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"slc12a2","symbol":"SLC12A2","href":"/targets/slc12a2/","tldr":"SLC12A2 (Solute carrier family 12 member 2) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"slc14a1","symbol":"SLC14A1","href":"/targets/slc14a1/","tldr":"SLC14A1 (Urea transporter 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"slc22a3","symbol":"SLC22A3","href":"/targets/slc22a3/","tldr":"SLC22A3 (Solute carrier family 22 member 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"slc24a5","symbol":"SLC24A5","href":"/targets/slc24a5/","tldr":"SLC24A5 (Sodium/potassium/calcium exchanger 5) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"slc25a11","symbol":"SLC25A11","href":"/targets/slc25a11/","tldr":"SLC25A11 (Mitochondrial 2-oxoglutarate/malate carrier protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours.","roles":[],"tier":"association-only"},{"id":"slc29a1","symbol":"SLC29A1","href":"/targets/slc29a1/","tldr":"SLC29A1 (Equilibrative nucleoside transporter 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"slc34a2","symbol":"SLC34A2","href":"/targets/slc34a2/","tldr":"SLC34A2 (Sodium-dependent phosphate transport protein 2B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Colorectal cancer, Non-small-cell lung cancer and 1 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"slc45a2","symbol":"SLC45A2","href":"/targets/slc45a2/","tldr":"SLC45A2 (Membrane-associated transporter protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"slc67a1","symbol":"SLC67A1","href":"/targets/slc67a1/","tldr":"SLC67A1 (Solute carrier family 67 member A1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"slc6a2","symbol":"SLC6A2","href":"/targets/slc6a2/","tldr":"SLC6A2 (Sodium-dependent noradrenaline transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"slc6a3","symbol":"SLC6A3","href":"/targets/slc6a3/","tldr":"SLC6A3 (Sodium-dependent dopamine transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"slc6a4","symbol":"SLC6A4","href":"/targets/slc6a4/","tldr":"SLC6A4 (Sodium-dependent serotonin transporter) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"slco1b1","symbol":"SLCO1B1","href":"/targets/slco1b1/","tldr":"SLCO1B1 (Solute carrier organic anion transporter family member 1B1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"slfn11","symbol":"SLFN11","href":"/targets/slfn11/","tldr":"SLFN11 (Schlafen family member 11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ewing sarcoma and Small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"slx4","symbol":"SLX4","href":"/targets/slx4/","tldr":"SLX4 (Structure-specific endonuclease subunit SLX4) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Myelodysplastic syndromes / neoplasms, Leukaemia, Myeloproliferative neoplasms and 1 more.","roles":["dna-repair"],"tier":"association-only"},{"id":"smad2","symbol":"SMAD2","href":"/targets/smad2/","tldr":"SMAD2 (SMAD family member 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer, Skin cancer, Gastric & gastro-oesophageal junction cancer and 1 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"smad3","symbol":"SMAD3","href":"/targets/smad3/","tldr":"SMAD3 (SMAD family member 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Pancreatic ductal adenocarcinoma, Skin cancer and 4 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"smad4","symbol":"SMAD4","href":"/targets/smad4/","tldr":"SMAD4 (SMAD family member 4) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Oesophageal cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"smad7","symbol":"SMAD7","href":"/targets/smad7/","tldr":"SMAD7 (SMAD family member 7) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"smarca2","symbol":"SMARCA2","href":"/targets/smarca2/","tldr":"SMARCA2 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Salivary gland cancers.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"smarca4","symbol":"SMARCA4","href":"/targets/smarca4/","tldr":"SMARCA4 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"smarcb1","symbol":"SMARCB1","href":"/targets/smarcb1/","tldr":"SMARCB1 is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"smarcd1","symbol":"SMARCD1","href":"/targets/smarcd1/","tldr":"SMARCD1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"smarce1","symbol":"SMARCE1","href":"/targets/smarce1/","tldr":"SMARCE1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Meningioma.","roles":[],"tier":"association-only"},{"id":"smc1a","symbol":"SMC1A","href":"/targets/smc1a/","tldr":"SMC1A (Structural maintenance of chromosomes protein 1A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a DNA repair gene, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver","dna-repair"],"tier":"cohort-driver"},{"id":"snap25","symbol":"SNAP25","href":"/targets/snap25/","tldr":"SNAP25 (Synaptosomal-associated protein 25) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sncaip","symbol":"SNCAIP","href":"/targets/sncaip/","tldr":"SNCAIP (Synphilin-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"snd1","symbol":"SND1","href":"/targets/snd1/","tldr":"SND1 (Staphylococcal nuclease domain-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Cervical cancer, Breast cancer, Lung cancer and 3 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"sntb1","symbol":"SNTB1","href":"/targets/sntb1/","tldr":"SNTB1 (Beta-1-syntrophin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"snw1","symbol":"SNW1","href":"/targets/snw1/","tldr":"SNW1 (SNW domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"snx29","symbol":"SNX29","href":"/targets/snx29/","tldr":"SNX29 (Sorting nexin-29) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer and Small intestine cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"socs1","symbol":"SOCS1","href":"/targets/socs1/","tldr":"SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sorcs3","symbol":"SORCS3","href":"/targets/sorcs3/","tldr":"SORCS3 (VPS10 domain-containing receptor SorCS3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"sos1","symbol":"SOS1","href":"/targets/sos1/","tldr":"SOS1 (Son of sevenless homolog 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Skin cancer, Breast cancer and 1 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sox10","symbol":"SOX10","href":"/targets/sox10/","tldr":"SOX10 (Transcription factor SOX-10) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"sox17","symbol":"SOX17","href":"/targets/sox17/","tldr":"SOX17 (Transcription factor SOX-17) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"sox2","symbol":"SOX2","href":"/targets/sox2/","tldr":"SOX2 (Transcription factor SOX-2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer, Skin cancer and Lung cancer.","roles":[],"tier":"association-only"},{"id":"sox21","symbol":"SOX21","href":"/targets/sox21/","tldr":"SOX21 (Transcription factor SOX-21) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"sox9","symbol":"SOX9","href":"/targets/sox9/","tldr":"SOX9 (Transcription factor SOX-9) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"sp140","symbol":"SP140","href":"/targets/sp140/","tldr":"SP140 (Nuclear body protein SP140) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Mantle cell lymphoma.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"spdl1","symbol":"SPDL1","href":"/targets/spdl1/","tldr":"SPDL1 (spindle apparatus coiled-coil protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"spen","symbol":"SPEN","href":"/targets/spen/","tldr":"SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"sphk1","symbol":"SPHK1","href":"/targets/sphk1/","tldr":"SPHK1 (Sphingosine kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"spop","symbol":"SPOP","href":"/targets/spop/","tldr":"SPOP (Speckle-type POZ protein) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer, Endometrial cancer, Non-Hodgkin lymphoma and 4 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"spry2","symbol":"SPRY2","href":"/targets/spry2/","tldr":"SPRY2 (Protein sprouty homolog 2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"spry4","symbol":"SPRY4","href":"/targets/spry4/","tldr":"SPRY4 is a feedback brake on growth-factor signalling that the MAPK pathway switches on, so its expression is a read-out of how active that pathway is.","roles":["biomarker"],"tier":"association-only"},{"id":"sptbn1","symbol":"SPTBN1","href":"/targets/sptbn1/","tldr":"SPTBN1 (Spectrin beta chain, non-erythrocytic 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"sqstm1","symbol":"SQSTM1","href":"/targets/sqstm1/","tldr":"SQSTM1 (Sequestosome-1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Osteosarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"srd5a1","symbol":"SRD5A1","href":"/targets/srd5a1/","tldr":"SRD5A1 (3-oxo-5-alpha-steroid 4-dehydrogenase 1) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"srd5a3","symbol":"SRD5A3","href":"/targets/srd5a3/","tldr":"SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"srgap1","symbol":"SRGAP1","href":"/targets/srgap1/","tldr":"SRGAP1 (SLIT-ROBO Rho GTPase-activating protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"srgap3","symbol":"SRGAP3","href":"/targets/srgap3/","tldr":"SRGAP3 (SLIT-ROBO Rho GTPase-activating protein 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma and Pleural mesothelioma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"srms","symbol":"SRMS","href":"/targets/srms/","tldr":"SRMS (Tyrosine-protein kinase Srms) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"srsf2","symbol":"SRSF2","href":"/targets/srsf2/","tldr":"SRSF2 (Serine/arginine-rich splicing factor 2) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Myelodysplastic syndromes / neoplasms and 3 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"srsf3","symbol":"SRSF3","href":"/targets/srsf3/","tldr":"SRSF3 (Serine/arginine-rich splicing factor 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ss18","symbol":"SS18","href":"/targets/ss18/","tldr":"SS18 (SS18 subunit of BAF chromatin remodeling complex) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"sstr1","symbol":"SSTR1","href":"/targets/sstr1/","tldr":"SSTR1 (Somatostatin receptor type 1) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sstr3","symbol":"SSTR3","href":"/targets/sstr3/","tldr":"SSTR3 (Somatostatin receptor type 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sstr4","symbol":"SSTR4","href":"/targets/sstr4/","tldr":"SSTR4 (Somatostatin receptor type 4) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"sstr5","symbol":"SSTR5","href":"/targets/sstr5/","tldr":"SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"ssx1","symbol":"SSX1","href":"/targets/ssx1/","tldr":"SSX1 (SSX family member 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"ssx2","symbol":"SSX2","href":"/targets/ssx2/","tldr":"SSX2 (SSX family member 2) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Sarcomas and Synovial sarcoma.","roles":["fusion-partner"],"tier":"association-only"},{"id":"stag2","symbol":"STAG2","href":"/targets/stag2/","tldr":"STAG2 (Cohesin subunit SA-2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Sarcomas, Renal cell carcinoma and 5 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"stag2-as1","symbol":"STAG2-AS1","href":"/targets/stag2-as1/","tldr":"STAG2-AS1 (STAG2 antisense RNA 1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"stag3","symbol":"STAG3","href":"/targets/stag3/","tldr":"STAG3 (Cohesin subunit SA-3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"stard3","symbol":"STARD3","href":"/targets/stard3/","tldr":"STARD3 (MLN64) moves cholesterol between cell compartments and is co-amplified with HER2 in breast cancer.","roles":["biomarker"],"tier":"association-only"},{"id":"stat1","symbol":"STAT1","href":"/targets/stat1/","tldr":"STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"stat3","symbol":"STAT3","href":"/targets/stat3/","tldr":"STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"immune-microenvironment"},{"id":"stat6","symbol":"STAT6","href":"/targets/stat6/","tldr":"STAT6 (Signal transducer and activator of transcription 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"stil","symbol":"STIL","href":"/targets/stil/","tldr":"STIL (SCL-interrupting locus protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Non-Hodgkin lymphoma, Skin cancer and Leukaemia.","roles":[],"tier":"association-only"},{"id":"stk11","symbol":"STK11","href":"/targets/stk11/","tldr":"STK11 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"stmn1","symbol":"STMN1","href":"/targets/stmn1/","tldr":"STMN1 (Stathmin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"stn1","symbol":"STN1","href":"/targets/stn1/","tldr":"STN1 (CST complex subunit STN1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Melanoma.","roles":[],"tier":"association-only"},{"id":"strn","symbol":"STRN","href":"/targets/strn/","tldr":"STRN (Striatin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer and Lung cancer.","roles":[],"tier":"association-only"},{"id":"sufu","symbol":"SUFU","href":"/targets/sufu/","tldr":"SUFU (Suppressor of fused homolog) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Medulloblastoma and 3 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"susd2","symbol":"SUSD2","href":"/targets/susd2/","tldr":"SUSD2 (Sushi domain-containing protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"suz12","symbol":"SUZ12","href":"/targets/suz12/","tldr":"SUZ12 (Polycomb protein SUZ12) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Breast cancer, Prostate cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"syk","symbol":"SYK","href":"/targets/syk/","tldr":"SYK (Tyrosine-protein kinase SYK) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Ovarian cancer, Skin cancer, Lung cancer and 4 more.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"taf15","symbol":"TAF15","href":"/targets/taf15/","tldr":"TAF15 (TATA-binding protein-associated factor 2N) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Mesothelioma and Pleural mesothelioma.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"taf1l","symbol":"TAF1L","href":"/targets/taf1l/","tldr":"TAF1L (Transcription initiation factor TFIID subunit 1-like) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tal1","symbol":"TAL1","href":"/targets/tal1/","tldr":"TAL1 (T-cell acute lymphocytic leukaemia protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Non-Hodgkin lymphoma, Skin cancer and 2 more.","roles":["fusion-partner"],"tier":"cohort-driver"},{"id":"tal2","symbol":"TAL2","href":"/targets/tal2/","tldr":"TAL2 (T-cell acute lymphocytic leukaemia protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"tbk1","symbol":"TBK1","href":"/targets/tbk1/","tldr":"TBK1 (Serine/threonine-protein kinase TBK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"tbl1xr1","symbol":"TBL1XR1","href":"/targets/tbl1xr1/","tldr":"TBL1XR1 (F-box-like/WD repeat-containing protein TBL1XR1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tbpl1","symbol":"TBPL1","href":"/targets/tbpl1/","tldr":"TBPL1 (TATA box-binding protein-like 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tbx1","symbol":"TBX1","href":"/targets/tbx1/","tldr":"TBX1 (T-box transcription factor TBX1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tbx3","symbol":"TBX3","href":"/targets/tbx3/","tldr":"TBX3 (T-box transcription factor TBX3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Colorectal cancer, Skin cancer and 3 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tbxt","symbol":"TBXT","href":"/targets/tbxt/","tldr":"TBXT (T-box transcription factor T) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Chordoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"tcea1","symbol":"TCEA1","href":"/targets/tcea1/","tldr":"TCEA1 (Transcription elongation factor A protein 1) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Oral cavity cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"tcf12","symbol":"TCF12","href":"/targets/tcf12/","tldr":"TCF12 (Transcription factor 12) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tcf19","symbol":"TCF19","href":"/targets/tcf19/","tldr":"TCF19 (Transcription factor 19) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"tcf3","symbol":"TCF3","href":"/targets/tcf3/","tldr":"TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.","roles":["biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tcf4","symbol":"TCF4","href":"/targets/tcf4/","tldr":"TCF4 (Transcription factor 4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma and Paediatric low-grade glioma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tcf7l2","symbol":"TCF7L2","href":"/targets/tcf7l2/","tldr":"TCF7L2 (Transcription factor 7-like 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Prostate cancer and 3 more.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tcl1a","symbol":"TCL1A","href":"/targets/tcl1a/","tldr":"TCL1A (T-cell leukaemia/lymphoma protein 1A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-Hodgkin lymphoma, Skin cancer, Diffuse large B-cell lymphoma and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"tdo2","symbol":"TDO2","href":"/targets/tdo2/","tldr":"TDO2 does the same job as IDO1, breaking down tryptophan into kynurenine, which quietens T cells. It is one reason IDO1 inhibitors alone may not have been enough; no TDO2 drug has reached late trials.","roles":["immune-checkpoint"]},{"id":"tec","symbol":"TEC","href":"/targets/tec/","tldr":"TEC (Tyrosine-protein kinase Tec) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and an oncogene driver, and an approved or late-stage drug is recorded against it. Tied to Oesophageal cancer and Oesophageal squamous cell carcinoma.","roles":["drug-target","oncogene-driver"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tent4a","symbol":"TENT4A","href":"/targets/tent4a/","tldr":"TENT4A (Terminal nucleotidyltransferase 4A) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tent5c","symbol":"TENT5C","href":"/targets/tent5c/","tldr":"TENT5C (Terminal nucleotidyltransferase 5C) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma, Skin cancer, Colorectal cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tert","symbol":"TERT","href":"/targets/tert/","tldr":"TERT (Telomerase reverse transcriptase) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Lung cancer and 5 more.","roles":["drug-target","oncogene-driver","biomarker"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"tet1","symbol":"TET1","href":"/targets/tet1/","tldr":"TET1 (Methylcytosine dioxygenase TET1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Hepatocellular carcinoma, Testicular germ cell tumours and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tf","symbol":"TF","href":"/targets/tf/","tldr":"TF (Serotransferrin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tfap4","symbol":"TFAP4","href":"/targets/tfap4/","tldr":"TFAP4 (Transcription factor AP-4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tfe3","symbol":"TFE3","href":"/targets/tfe3/","tldr":"TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas, Colorectal cancer and 1 more.","roles":["drug-target","fusion-partner"],"tier":"association-only","specificity":"tumour-specific"},{"id":"tfeb","symbol":"TFEB","href":"/targets/tfeb/","tldr":"TFEB (Transcription factor EB) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer and Melanoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tff3","symbol":"TFF3","href":"/targets/tff3/","tldr":"TFF3 (Trefoil factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tfg","symbol":"TFG","href":"/targets/tfg/","tldr":"TFG (trafficking from ER to golgi regulator) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Lung cancer.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"tfrc","symbol":"TFRC","href":"/targets/tfrc/","tldr":"TFRC (Transferrin receptor protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer and Non-small-cell lung cancer.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tg","symbol":"TG","href":"/targets/tg/","tldr":"TG (Thyroglobulin) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Thyroid cancer.","roles":[],"tier":"association-only"},{"id":"tgfa","symbol":"TGFA","href":"/targets/tgfa/","tldr":"TGFA (Protransforming growth factor alpha) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tgfb1","symbol":"TGFB1","href":"/targets/tgfb1/","tldr":"TGFB1 (Transforming growth factor beta-1 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","roles":["drug-target","immune-checkpoint"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tgfb2","symbol":"TGFB2","href":"/targets/tgfb2/","tldr":"TGFB2 (Transforming growth factor beta-2 proprotein) is a gene. The public catalogues list it as a drug target and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","roles":["drug-target","fusion-partner"],"tier":"approved-drug","specificity":"tumour-specific"},{"id":"tgfb3","symbol":"TGFB3","href":"/targets/tgfb3/","tldr":"TGFB3 (Transforming growth factor beta-3 proprotein) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myelodysplastic syndromes / neoplasms.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tgfbr1","symbol":"TGFBR1","href":"/targets/tgfbr1/","tldr":"TGFBR1 (TGF-beta receptor type-1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["drug-target","tumour-suppressor"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tgfbr2","symbol":"TGFBR2","href":"/targets/tgfbr2/","tldr":"TGFBR2 (TGF-beta receptor type-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Oesophageal cancer, Pancreatic ductal adenocarcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tgfbr3","symbol":"TGFBR3","href":"/targets/tgfbr3/","tldr":"TGFBR3 (Transforming growth factor beta receptor type 3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"tgif1","symbol":"TGIF1","href":"/targets/tgif1/","tldr":"TGIF1 (Homeobox protein TGIF1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"tgm3","symbol":"TGM3","href":"/targets/tgm3/","tldr":"TGM3 (Protein-glutamine gamma-glutamyltransferase E) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"thbs2","symbol":"THBS2","href":"/targets/thbs2/","tldr":"THBS2 (Thrombospondin-2) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"thra","symbol":"THRA","href":"/targets/thra/","tldr":"THRA (Thyroid hormone receptor alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer.","roles":["drug-target"],"tier":"approved-drug"},{"id":"thrap3","symbol":"THRAP3","href":"/targets/thrap3/","tldr":"THRAP3 (Thyroid hormone receptor-associated protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"thrb","symbol":"THRB","href":"/targets/thrb/","tldr":"THRB (Thyroid hormone receptor beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Thyroid cancer.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tigit","symbol":"TIGIT","href":"/targets/tigit/","tldr":"TIGIT is an inhibitory receptor on T and natural killer cells that binds PVR (CD155) on tumour cells, so blocking it was expected to amplify PD-1 and PD-L1 inhibitors. Tiragolumab, domvanalimab and others then failed to add benefit in phase 3 lung cancer trials despite encouraging phase 2 signals, and the lack of a TIGIT-specific biomarker remains a weakness.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"timp1","symbol":"TIMP1","href":"/targets/timp1/","tldr":"TIMP1 (Metalloproteinase inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"tlk2","symbol":"TLK2","href":"/targets/tlk2/","tldr":"TLK2 (Serine/threonine-protein kinase tousled-like 2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"tln1","symbol":"TLN1","href":"/targets/tln1/","tldr":"TLN1 (Talin-1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tlx1","symbol":"TLX1","href":"/targets/tlx1/","tldr":"TLX1 (T-cell leukaemia homeobox protein 1) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"tlx3","symbol":"TLX3","href":"/targets/tlx3/","tldr":"TLX3 (T-cell leukaemia homeobox protein 3) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tmem127","symbol":"TMEM127","href":"/targets/tmem127/","tldr":"TMEM127 (Transmembrane protein 127) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Neuroendocrine tumours and Melanoma.","roles":[],"tier":"association-only"},{"id":"tmem17","symbol":"TMEM17","href":"/targets/tmem17/","tldr":"TMEM17 (Transmembrane protein 17) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"tmem238l","symbol":"TMEM238L","href":"/targets/tmem238l/","tldr":"TMEM238L (Transmembrane protein 238-like) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"tmprss2","symbol":"TMPRSS2","href":"/targets/tmprss2/","tldr":"TMPRSS2 (Transmembrane protease serine 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"tmsb4x","symbol":"TMSB4X","href":"/targets/tmsb4x/","tldr":"TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tnc","symbol":"TNC","href":"/targets/tnc/","tldr":"TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tnfaip3","symbol":"TNFAIP3","href":"/targets/tnfaip3/","tldr":"TNFAIP3 (Tumour necrosis factor alpha-induced protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 2 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tnfrsf10b","symbol":"TNFRSF10B","href":"/targets/tnfrsf10b/","tldr":"TNFRSF10B (Tumour necrosis factor receptor superfamily member 10B) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"tnfrsf13b","symbol":"TNFRSF13B","href":"/targets/tnfrsf13b/","tldr":"TNFRSF13B (Tumour necrosis factor receptor superfamily member 13B) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Multiple myeloma.","roles":[],"tier":"association-only"},{"id":"tnfrsf14","symbol":"TNFRSF14","href":"/targets/tnfrsf14/","tldr":"TNFRSF14 (Tumour necrosis factor receptor superfamily member 14) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Skin cancer and 1 more.","roles":["tumour-suppressor","biomarker","immune-checkpoint"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tnfrsf18","symbol":"TNFRSF18","href":"/targets/tnfrsf18/","tldr":"GITR is an accelerator on T cells that agonist antibodies tried to press to boost immunotherapy. Several reached early trials; one programme was dropped for reasons unrelated to safety.","roles":["immune-checkpoint"]},{"id":"tnfrsf4","symbol":"TNFRSF4","href":"/targets/tnfrsf4/","tldr":"OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.","roles":["immune-checkpoint"]},{"id":"cd137","symbol":"TNFRSF9","href":"/targets/cd137/","tldr":"4-1BB is a switch on activated T cells that makes them live longer and kill better. Rather than press it everywhere, new bispecific antibodies press it only on T cells that are already touching a tumour cell marked by PD-L1 or HER2.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"tnfsf10","symbol":"TNFSF10","href":"/targets/tnfsf10/","tldr":"TNFSF10 (Tumour necrosis factor ligand superfamily member 10) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tns1","symbol":"TNS1","href":"/targets/tns1/","tldr":"TNS1 (Tensin-1) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tns3","symbol":"TNS3","href":"/targets/tns3/","tldr":"TNS3 (Tensin-3) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"toe1","symbol":"TOE1","href":"/targets/toe1/","tldr":"TOE1 (Target of EGR1 protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"top2b","symbol":"TOP2B","href":"/targets/top2b/","tldr":"TOP2B (DNA topoisomerase 2-beta) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Neuroendocrine tumours, Breast cancer and 1 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"top3a","symbol":"TOP3A","href":"/targets/top3a/","tldr":"TOP3A (DNA topoisomerase 3-alpha) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tox","symbol":"TOX","href":"/targets/tox/","tldr":"TOX (Thymocyte selection-associated high mobility group box protein TOX) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"tox3","symbol":"TOX3","href":"/targets/tox3/","tldr":"TOX3 (TOX high mobility group box family member 3) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"tp53bp1","symbol":"TP53BP1","href":"/targets/tp53bp1/","tldr":"TP53BP1 (TP53-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, a fusion partner and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.","roles":["biomarker","fusion-partner","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"tp63","symbol":"TP63","href":"/targets/tp63/","tldr":"TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tpcn2","symbol":"TPCN2","href":"/targets/tpcn2/","tldr":"TPCN2 (Two pore channel protein 2) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"tph2","symbol":"TPH2","href":"/targets/tph2/","tldr":"TPH2 (Tryptophan 5-hydroxylase 2) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tpm3","symbol":"TPM3","href":"/targets/tpm3/","tldr":"TPM3 (Tropomyosin alpha-3 chain) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role. Tied to Lung cancer, Colorectal cancer and Non-small-cell lung cancer.","roles":["fusion-partner"],"tier":"association-only"},{"id":"tpm4","symbol":"TPM4","href":"/targets/tpm4/","tldr":"TPM4 (Tropomyosin alpha-4 chain) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"tpr","symbol":"TPR","href":"/targets/tpr/","tldr":"TPR (Nucleoprotein TPR) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Medulloblastoma.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"tpt1","symbol":"TPT1","href":"/targets/tpt1/","tldr":"TPT1 (Translationally-controlled tumour protein) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"traf3","symbol":"TRAF3","href":"/targets/traf3/","tldr":"TRAF3 (TNF receptor-associated factor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Multiple myeloma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"traf7","symbol":"TRAF7","href":"/targets/traf7/","tldr":"TRAF7 (E3 ubiquitin-protein ligase TRAF7) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Mesothelioma, Skin cancer, Pleural mesothelioma and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"trak1","symbol":"TRAK1","href":"/targets/trak1/","tldr":"TRAK1 (Trafficking kinesin-binding protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"trim24","symbol":"TRIM24","href":"/targets/trim24/","tldr":"TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"trim27","symbol":"TRIM27","href":"/targets/trim27/","tldr":"TRIM27 (Zinc finger protein RFP) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"trim28","symbol":"TRIM28","href":"/targets/trim28/","tldr":"TRIM28 (Transcription intermediary factor 1-beta) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Wilms tumour.","roles":[],"tier":"association-only"},{"id":"trim33","symbol":"TRIM33","href":"/targets/trim33/","tldr":"TRIM33 (E3 ubiquitin-protein ligase TRIM33) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Breast cancer, Colorectal cancer and 1 more.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"trim49c","symbol":"TRIM49C","href":"/targets/trim49c/","tldr":"TRIM49C (Tripartite motif-containing protein 49C) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"trip11","symbol":"TRIP11","href":"/targets/trip11/","tldr":"TRIP11 (Thyroid receptor-interacting protein 11) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer.","roles":["tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"trps1","symbol":"TRPS1","href":"/targets/trps1/","tldr":"TRPS1 (Zinc finger transcription factor Trps1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"trrap","symbol":"TRRAP","href":"/targets/trrap/","tldr":"TRRAP (Transformation/transcription domain-associated protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Renal cell carcinoma, Lung cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"tsc1","symbol":"TSC1","href":"/targets/tsc1/","tldr":"TSC1 (Hamartin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.","roles":["drug-target","tumour-suppressor","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tsc2","symbol":"TSC2","href":"/targets/tsc2/","tldr":"TSC2 (Tuberin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Hepatocellular carcinoma, Renal cell carcinoma, Thyroid cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tspyl1","symbol":"TSPYL1","href":"/targets/tspyl1/","tldr":"TSPYL1 (Testis-specific Y-encoded-like protein 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ttf1","symbol":"TTF1","href":"/targets/ttf1/","tldr":"TTF1 (Transcription termination factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"tuba1a","symbol":"TUBA1A","href":"/targets/tuba1a/","tldr":"TUBA1A (Tubulin alpha-1A chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba1b","symbol":"TUBA1B","href":"/targets/tuba1b/","tldr":"TUBA1B (Tubulin alpha-1B chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Prostate cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tuba1c","symbol":"TUBA1C","href":"/targets/tuba1c/","tldr":"TUBA1C (Tubulin alpha-1C chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Breast cancer, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tuba3c","symbol":"TUBA3C","href":"/targets/tuba3c/","tldr":"TUBA3C (Tubulin alpha-3C chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba3e","symbol":"TUBA3E","href":"/targets/tuba3e/","tldr":"TUBA3E (Tubulin alpha-3E chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tuba4a","symbol":"TUBA4A","href":"/targets/tuba4a/","tldr":"TUBA4A (Tubulin alpha-4A chain) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb1","symbol":"TUBB1","href":"/targets/tubb1/","tldr":"TUBB1 (Tubulin beta-1 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb2a","symbol":"TUBB2A","href":"/targets/tubb2a/","tldr":"TUBB2A (Tubulin beta-2A chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb2b","symbol":"TUBB2B","href":"/targets/tubb2b/","tldr":"TUBB2B (Tubulin beta-2B chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Sarcomas and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb3","symbol":"TUBB3","href":"/targets/tubb3/","tldr":"TUBB3 (Tubulin beta-3 chain) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Prostate cancer and 5 more.","roles":["drug-target","biomarker"],"tier":"approved-drug"},{"id":"tubb4a","symbol":"TUBB4A","href":"/targets/tubb4a/","tldr":"TUBB4A (Tubulin beta-4A chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer, Breast cancer, Lung cancer and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tubb4b","symbol":"TUBB4B","href":"/targets/tubb4b/","tldr":"TUBB4B (Tubulin beta-4B chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Breast cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tubb6","symbol":"TUBB6","href":"/targets/tubb6/","tldr":"TUBB6 (Tubulin beta-6 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Breast cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tubb8","symbol":"TUBB8","href":"/targets/tubb8/","tldr":"TUBB8 (Tubulin beta-8 chain) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Non-Hodgkin lymphoma and 5 more.","roles":["drug-target"],"tier":"approved-drug"},{"id":"tyk2","symbol":"TYK2","href":"/targets/tyk2/","tldr":"TYK2 (Non-receptor tyrosine-protein kinase TYK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Malignant peripheral nerve sheath tumour and Polycythaemia vera.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tymp","symbol":"TYMP","href":"/targets/tymp/","tldr":"TYMP (Thymidine phosphorylase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Colorectal cancer.","roles":["drug-target"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"tyr","symbol":"TYR","href":"/targets/tyr/","tldr":"TYR (Tyrosinase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer, Melanoma and Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"tyrp1","symbol":"TYRP1","href":"/targets/tyrp1/","tldr":"TYRP1 (5,6-dihydroxyindole-2-carboxylic acid oxidase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Skin cancer.","roles":[],"tier":"association-only"},{"id":"tyw2","symbol":"TYW2","href":"/targets/tyw2/","tldr":"TYW2 (tRNA wybutosine-synthesising protein 2 homolog) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Salivary gland cancers.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"u2af1","symbol":"U2AF1","href":"/targets/u2af1/","tldr":"U2AF1 (Splicing factor U2AF 35 kDa subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Lung cancer and 5 more.","roles":["oncogene-driver","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"u2af2","symbol":"U2AF2","href":"/targets/u2af2/","tldr":"U2AF2 (Splicing factor U2AF 65 kDa subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"uba52","symbol":"UBA52","href":"/targets/uba52/","tldr":"UBA52 (Ubiquitin-ribosomal protein eL40 fusion protein) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ubb","symbol":"UBB","href":"/targets/ubb/","tldr":"UBB (Polyubiquitin-B) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ubc","symbol":"UBC","href":"/targets/ubc/","tldr":"UBC (Polyubiquitin-C) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ube2a","symbol":"UBE2A","href":"/targets/ube2a/","tldr":"UBE2A (Ubiquitin-conjugating enzyme E2 A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ubr5","symbol":"UBR5","href":"/targets/ubr5/","tldr":"UBR5 (E3 ubiquitin-protein ligase UBR5) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Renal cell carcinoma and 5 more.","roles":["oncogene-driver","tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"ubtf","symbol":"UBTF","href":"/targets/ubtf/","tldr":"UBTF (Nucleolar transcription factor 1) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"ubxn11","symbol":"UBXN11","href":"/targets/ubxn11/","tldr":"UBXN11 (UBX domain-containing protein 11) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Glioma & glioblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"ugt1a","symbol":"UGT1A","href":"/targets/ugt1a/","tldr":"UGT1A (UDP glucuronosyltransferase family 1 member A complex locus) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"ugt1a1","symbol":"UGT1A1","href":"/targets/ugt1a1/","tldr":"UGT1A1 (UDP-glucuronosyltransferase 1A1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"tumour-associated"},{"id":"usp28","symbol":"USP28","href":"/targets/usp28/","tldr":"USP28 (Ubiquitin carboxyl-terminal hydrolase 28) is an enzyme. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"usp6","symbol":"USP6","href":"/targets/usp6/","tldr":"USP6 (Ubiquitin carboxyl-terminal hydrolase 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Breast cancer, Hepatocellular carcinoma and 5 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"usp7","symbol":"USP7","href":"/targets/usp7/","tldr":"USP7 (Ubiquitin C-terminal hydrolase 7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Multiple myeloma and Burkitt lymphoma.","roles":["tumour-suppressor","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"usp8","symbol":"USP8","href":"/targets/usp8/","tldr":"USP8 (Ubiquitin carboxyl-terminal hydrolase 8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma, Multiple myeloma, Breast cancer and 1 more.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"usp9x","symbol":"USP9X","href":"/targets/usp9x/","tldr":"USP9X (Ubiquitin carboxyl-terminal hydrolase 9X) is an enzyme. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Thyroid cancer, Hepatocellular carcinoma, Sarcomas and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"vav1","symbol":"VAV1","href":"/targets/vav1/","tldr":"VAV1 (Proto-oncogene vav) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"vcl","symbol":"VCL","href":"/targets/vcl/","tldr":"VCL (Vinculin) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"vdr","symbol":"VDR","href":"/targets/vdr/","tldr":"VDR (Vitamin D3 receptor) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","roles":["drug-target"],"tier":"clinical-evidence"},{"id":"vegfc","symbol":"VEGFC","href":"/targets/vegfc/","tldr":"VEGFC (Vascular endothelial growth factor C) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"vhl","symbol":"VHL","href":"/targets/vhl/","tldr":"VHL (von Hippel-Lindau disease tumour suppressor) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma, Neuroendocrine tumours, Breast cancer and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"vps37a","symbol":"VPS37A","href":"/targets/vps37a/","tldr":"VPS37A (Vacuolar protein sorting-associated protein 37A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"vps53","symbol":"VPS53","href":"/targets/vps53/","tldr":"VPS53 (Vacuolar protein sorting-associated protein 53 homolog) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Prostate cancer.","roles":[],"tier":"association-only"},{"id":"vista","symbol":"VSIR","href":"/targets/vista/","tldr":"An immune checkpoint on myeloid cells that works at the acidic pH inside tumours and is a suspected escape route after PD-1 therapy; antibodies are in early trials.","roles":["immune-checkpoint"]},{"id":"b7h4","symbol":"VTCN1","href":"/targets/b7h4/","tldr":"B7-H4 is a checkpoint-like protein that many breast, ovarian and endometrial tumours carry on their surface. Antibody-drug conjugates such as puxitatug samrotecan and HS-20089 use it as a docking site to deliver a chemotherapy payload.","roles":["immune-checkpoint"],"specificity":"immune-microenvironment"},{"id":"vti1a","symbol":"VTI1A","href":"/targets/vti1a/","tldr":"VTI1A (Vesicle transport through interaction with t-SNAREs homolog 1A) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"vwf","symbol":"VWF","href":"/targets/vwf/","tldr":"VWF (von Willebrand factor) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"was","symbol":"WAS","href":"/targets/was/","tldr":"WAS (Actin nucleation-promoting factor WAS) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Medulloblastoma and Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"wdcp","symbol":"WDCP","href":"/targets/wdcp/","tldr":"WDCP (WD repeat and coiled-coil-containing protein) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"wdr12","symbol":"WDR12","href":"/targets/wdr12/","tldr":"WDR12 (Ribosome biogenesis protein WDR12) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"wif1","symbol":"WIF1","href":"/targets/wif1/","tldr":"WIF1 (Wnt inhibitory factor 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer and Oral cavity cancer.","roles":[],"tier":"association-only"},{"id":"wnk1","symbol":"WNK1","href":"/targets/wnk1/","tldr":"WNK1 (Serine/threonine-protein kinase WNK1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Burkitt lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"wnk2","symbol":"WNK2","href":"/targets/wnk2/","tldr":"WNK2 (Serine/threonine-protein kinase WNK2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Hepatocellular carcinoma, Mesothelioma and 2 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"wnt1","symbol":"WNT1","href":"/targets/wnt1/","tldr":"WNT1 (Proto-oncogene Wnt-1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Uterine carcinosarcoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"wnt11","symbol":"WNT11","href":"/targets/wnt11/","tldr":"WNT11 (Wnt family member 11) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["biomarker"],"tier":"clinical-evidence"},{"id":"wnt6","symbol":"WNT6","href":"/targets/wnt6/","tldr":"WNT6 (Wnt family member 6) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"wrap53","symbol":"WRAP53","href":"/targets/wrap53/","tldr":"WRAP53 (Telomerase Cajal body protein 1) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"wt1","symbol":"WT1","href":"/targets/wt1/","tldr":"WT1 (Wilms tumour protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Mesothelioma, Myeloproliferative neoplasms and 5 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker","fusion-partner"],"tier":"clinical-evidence","specificity":"tumour-associated"},{"id":"wwox","symbol":"WWOX","href":"/targets/wwox/","tldr":"WWOX (WW domain-containing oxidoreductase) is an enzyme. In the public catalogues the evidence so far is association rather than a proven role. Tied to Oesophageal cancer.","roles":[],"tier":"association-only"},{"id":"wwtr1","symbol":"WWTR1","href":"/targets/wwtr1/","tldr":"WWTR1 (WW domain-containing transcription regulator protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Ovarian cancer, Breast cancer and Skin cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"xpa","symbol":"XPA","href":"/targets/xpa/","tldr":"XPA (DNA repair protein complementing XP-A cells) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Skin cancer, Colorectal cancer and Basal cell carcinoma.","roles":["dna-repair"],"tier":"association-only"},{"id":"xpc","symbol":"XPC","href":"/targets/xpc/","tldr":"XPC (DNA repair protein complementing XP-C cells) is a protein that switches other genes on and off. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role. Tied to Lung cancer and Prostate cancer.","roles":["dna-repair"],"tier":"association-only"},{"id":"xrcc1","symbol":"XRCC1","href":"/targets/xrcc1/","tldr":"XRCC1 (DNA repair protein XRCC1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer and Non-small-cell lung cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"xrcc2","symbol":"XRCC2","href":"/targets/xrcc2/","tldr":"XRCC2 (DNA repair protein XRCC2) is a gene. The public catalogues list it as a DNA repair gene, and the evidence so far is association rather than a proven role.","roles":["dna-repair"],"tier":"association-only"},{"id":"xrcc3","symbol":"XRCC3","href":"/targets/xrcc3/","tldr":"XRCC3 (DNA repair protein XRCC3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Triple-negative breast cancer.","roles":["drug-target","biomarker","dna-repair"],"tier":"clinical-evidence","specificity":"germline-variant"},{"id":"yap1","symbol":"YAP1","href":"/targets/yap1/","tldr":"YAP1 (Transcriptional coactivator YAP1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Oesophageal cancer and Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"yes1","symbol":"YES1","href":"/targets/yes1/","tldr":"YES1 (Tyrosine-protein kinase Yes) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Lung cancer, Leukaemia and 5 more.","roles":["drug-target","biomarker"],"tier":"approved-drug","specificity":"broadly-expressed"},{"id":"ywhab","symbol":"YWHAB","href":"/targets/ywhab/","tldr":"YWHAB (14-3-3 protein beta/alpha) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"ywhae","symbol":"YWHAE","href":"/targets/ywhae/","tldr":"YWHAE (14-3-3 protein epsilon) is a gene. In the public catalogues the evidence so far is association rather than a proven role. Tied to Sarcomas.","roles":[],"tier":"association-only"},{"id":"zbtb10","symbol":"ZBTB10","href":"/targets/zbtb10/","tldr":"ZBTB10 (Zinc finger and BTB domain-containing protein 10) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Basal cell carcinoma.","roles":[],"tier":"association-only"},{"id":"zbtb16","symbol":"ZBTB16","href":"/targets/zbtb16/","tldr":"ZBTB16 (Zinc finger and BTB domain-containing protein 16) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Oesophageal cancer, Skin cancer and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"zbtb20","symbol":"ZBTB20","href":"/targets/zbtb20/","tldr":"ZBTB20 (Zinc finger and BTB domain-containing protein 20) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"zbtb48","symbol":"ZBTB48","href":"/targets/zbtb48/","tldr":"ZBTB48 (Zinc finger and BTB domain-containing protein 48) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Angiosarcoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"zbtb7b","symbol":"ZBTB7B","href":"/targets/zbtb7b/","tldr":"ZBTB7B (Zinc finger and BTB domain-containing protein 7B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Uterine carcinosarcoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"zc3hav1","symbol":"ZC3HAV1","href":"/targets/zc3hav1/","tldr":"ZC3HAV1 (Zinc finger CCCH-type antiviral protein 1) is a gene. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"zcchc8","symbol":"ZCCHC8","href":"/targets/zcchc8/","tldr":"ZCCHC8 (Zinc finger CCHC domain-containing protein 8) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"zcrb1","symbol":"ZCRB1","href":"/targets/zcrb1/","tldr":"ZCRB1 (Zinc finger CCHC-type and RNA-binding motif-containing protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Acute myeloid leukaemia.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"zeb1","symbol":"ZEB1","href":"/targets/zeb1/","tldr":"ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.","roles":["drug-target","oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"zfhx3","symbol":"ZFHX3","href":"/targets/zfhx3/","tldr":"ZFHX3 (Zinc finger homeobox protein 3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Endometrial cancer, Breast cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"zfhx4","symbol":"ZFHX4","href":"/targets/zfhx4/","tldr":"ZFHX4 (Zinc finger homeobox protein 4) is a protein that switches other genes on and off. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.","roles":["fusion-partner"],"tier":"association-only"},{"id":"zfp36l1","symbol":"ZFP36L1","href":"/targets/zfp36l1/","tldr":"ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.","roles":["oncogene-driver","tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"zfpm2","symbol":"ZFPM2","href":"/targets/zfpm2/","tldr":"ZFPM2 (Zinc finger protein ZFPM2) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer.","roles":[],"tier":"association-only"},{"id":"zhx2","symbol":"ZHX2","href":"/targets/zhx2/","tldr":"ZHX2 (Zinc fingers and homeoboxes protein 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Papillary renal cell carcinoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"zmiz1","symbol":"ZMIZ1","href":"/targets/zmiz1/","tldr":"ZMIZ1 (Zinc finger MIZ domain-containing protein 1) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role. Tied to Breast cancer, Prostate cancer and Colorectal cancer.","roles":[],"tier":"association-only"},{"id":"zmym2","symbol":"ZMYM2","href":"/targets/zmym2/","tldr":"ZMYM2 (Zinc finger MYM-type protein 2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Non-Hodgkin lymphoma and 1 more.","roles":["oncogene-driver","fusion-partner"],"tier":"cohort-driver"},{"id":"zmym3","symbol":"ZMYM3","href":"/targets/zmym3/","tldr":"ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"znf208","symbol":"ZNF208","href":"/targets/znf208/","tldr":"ZNF208 (Zinc finger protein 208) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf217","symbol":"ZNF217","href":"/targets/znf217/","tldr":"ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.","roles":["drug-target","biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"znf274","symbol":"ZNF274","href":"/targets/znf274/","tldr":"ZNF274 (Neurotrophin receptor-interacting factor homolog) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Medulloblastoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf292","symbol":"ZNF292","href":"/targets/znf292/","tldr":"ZNF292 (Zinc finger protein 292) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.","roles":["biomarker"],"tier":"clinical-evidence","specificity":"broadly-expressed"},{"id":"znf331","symbol":"ZNF331","href":"/targets/znf331/","tldr":"ZNF331 (Zinc finger protein 331) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma, Skin cancer and Melanoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf395","symbol":"ZNF395","href":"/targets/znf395/","tldr":"ZNF395 (Zinc finger protein 395) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Non-small-cell lung cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf429","symbol":"ZNF429","href":"/targets/znf429/","tldr":"ZNF429 (Zinc finger protein 429) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Hepatocellular carcinoma, Prostate cancer and 1 more.","roles":["oncogene-driver","tumour-suppressor"],"tier":"cohort-driver"},{"id":"znf462","symbol":"ZNF462","href":"/targets/znf462/","tldr":"ZNF462 (Zinc finger protein 462) is a protein that switches other genes on and off. In the public catalogues the evidence so far is association rather than a proven role.","roles":[],"tier":"association-only"},{"id":"znf521","symbol":"ZNF521","href":"/targets/znf521/","tldr":"ZNF521 (Zinc finger protein 521) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Pancreatic ductal adenocarcinoma, Oesophageal cancer, Cervical cancer and 5 more.","roles":["oncogene-driver","tumour-suppressor","fusion-partner"],"tier":"cohort-driver"},{"id":"znf626","symbol":"ZNF626","href":"/targets/znf626/","tldr":"ZNF626 (Zinc finger protein 626) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf680","symbol":"ZNF680","href":"/targets/znf680/","tldr":"ZNF680 (Zinc finger protein 680) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf703","symbol":"ZNF703","href":"/targets/znf703/","tldr":"ZNF703 (Zinc finger protein 703) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.","roles":["drug-target","biomarker"],"tier":"clinical-evidence"},{"id":"znf721","symbol":"ZNF721","href":"/targets/znf721/","tldr":"ZNF721 (Zinc finger protein 721) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf750","symbol":"ZNF750","href":"/targets/znf750/","tldr":"ZNF750 (Zinc finger protein 750) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Oesophageal and junctional adenocarcinoma and Non-small-cell lung cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"znf780a","symbol":"ZNF780A","href":"/targets/znf780a/","tldr":"ZNF780A (Zinc finger protein 780A) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf814","symbol":"ZNF814","href":"/targets/znf814/","tldr":"ZNF814 (Zinc finger protein 814) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Gastric & gastro-oesophageal junction cancer.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf90","symbol":"ZNF90","href":"/targets/znf90/","tldr":"ZNF90 (Zinc finger protein 90) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znf93","symbol":"ZNF93","href":"/targets/znf93/","tldr":"ZNF93 (Zinc finger protein 93) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Nasopharyngeal carcinoma.","roles":["oncogene-driver"],"tier":"cohort-driver"},{"id":"znrf3","symbol":"ZNRF3","href":"/targets/znrf3/","tldr":"ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.","roles":["tumour-suppressor"],"tier":"cohort-driver"},{"id":"zrsr2","symbol":"ZRSR2","href":"/targets/zrsr2/","tldr":"ZRSR2 (U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 2 more.","roles":["tumour-suppressor","biomarker"],"tier":"clinical-evidence","specificity":"tumour-specific"},{"id":"zxdb","symbol":"ZXDB","href":"/targets/zxdb/","tldr":"ZXDB (Zinc finger X-linked protein ZXDB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer.","roles":["tumour-suppressor"],"tier":"cohort-driver"}]